0001554859-22-000014.txt : 20220506 0001554859-22-000014.hdr.sgml : 20220506 20220506164430 ACCESSION NUMBER: 0001554859-22-000014 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 65 CONFORMED PERIOD OF REPORT: 20220331 FILED AS OF DATE: 20220506 DATE AS OF CHANGE: 20220506 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Semler Scientific, Inc. CENTRAL INDEX KEY: 0001554859 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 261367393 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36305 FILM NUMBER: 22901950 BUSINESS ADDRESS: STREET 1: 2340-2348 WALSH AVENUE, SUITE 2344 CITY: SANTA CLARA STATE: CA ZIP: 95051 BUSINESS PHONE: 408-627-4557 MAIL ADDRESS: STREET 1: 2340-2348 WALSH AVENUE, SUITE 2344 CITY: SANTA CLARA STATE: CA ZIP: 95051 10-Q 1 smlr-20220331x10q.htm 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q


	☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2022



	☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ___ to ___

Commission File Number 001-36305

SEMLER SCIENTIFIC, INC.

(Exact name of registrant as specified in its charter)

Delaware	26-1367393
(State or other jurisdiction of	(I.R.S. Employer
incorporation or organization)	Identification No.)

2340-2348 Walsh Avenue, Suite 2344

Santa Clara, CA 95051

(Address of principal executive offices) (Zip Code)

(877) 774-4211

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act: None.

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		SMLR		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

Large Accelerated Filer	☐	Accelerated Filer	☐

Non-Accelerated Filer	☒	Smaller Reporting Company	☒

Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of April 29, 2022, there were 6,792,753 shares of the issuer’s common stock, $0.001 par value per share, outstanding.

Table of Contents

TABLE OF CONTENTS

		Page
Part I.	Financial Information	1

Item 1.	Financial Statements	1
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	15
Item 3.	Quantitative and Qualitative Disclosures about Market Risk	18
Item 4.	Controls and Procedures	18

Part II.	Other Information	19

Item 1.	Legal Proceedings	19
Item 1A.	Risk Factors	19
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	19
Item 3.	Defaults upon Senior Securities	19
Item 4.	Mine Safety Disclosures	19
Item 5.	Other Information	19
Item 6.	Exhibits	20

Signatures		21

In this report, unless otherwise stated or as the context otherwise requires, references to “Semler Scientific,” “the Company,” “we,” “us,” “our” and similar references refer to Semler Scientific, Inc. The Semler Scientific logo, QuantaFlo and other trademarks or service marks of Semler Scientific, Inc. appearing in this report are the property of Semler Scientific, Inc. This report also contains registered marks, trademarks and trade names of other companies. All other trademarks, registered marks and trade names appearing in this report are the property of their respective holders.

Table of Contents

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This quarterly report on Form 10-Q contains forward-looking statements. Such forward-looking statements include those that express plans, anticipation, intent, contingency, goals, targets or future development and/or otherwise are not statements of historical fact. In some cases, you can identify forward-looking statements by terminology, such as “expects,” “anticipates,” “intends,” “estimates,” “plans,” “believes,” “seeks,” “may,” “should,” “continue,” “could” or the negative of such terms or other similar expressions. Any forward-looking statements are qualified in their entirety by reference to the factors discussed throughout this report. These forward-looking statements are based on our current expectations and projections about future events and they are subject to risks and uncertainties known and unknown that could cause actual results and developments to differ materially from those expressed or implied in such statements, including risks associated with:

●

implementation of our business strategy and the fact that we actively market only two FDA-cleared products and may not benefit from our recent investments in other companies developing complementary products or the extension of QuantaFlo to test for other diseases;

●

the failure of physicians and other customers to widely adopt our products, or to determine that our product provides a safe and effective alternative to existing ankle brachial index, or ABI, devices;

●

the fact that our testing product is generally but not specifically approved for reimbursement under any third-party payor codes;

●

our reliance on the talents of a small number of key personnel, and a small direct sales force;

●

not requiring customers to enter into long-term licenses;

●

concentration of our revenues and accounts receivable with a limited number of customers;

●

our reliance on a small number of independent suppliers and facilities for the manufacturing of our product;

●

our business being subject to many laws and government regulations, including governing the manufacture and sale of medical devices, patient data, and others;

●

our ability to protect our intellectual property;

●

impacts of the ongoing Covid-19 pandemic and macroeconomic factors that could impact our business, such as the effects of the Russian invasion of Ukraine on the global economy and supply chain; and

●

the other factors set forth under the caption “Risk Factors” in our annual report on Form 10-K filed with the Securities and Exchange Commission, or SEC, on March 4, 2022.

Because the risks and uncertainties referred to above and in our SEC reports could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements made by us or on our behalf, you should not place undue reliance on any forward-looking statements.

You should read this quarterly report and the documents that we reference herein and therein and have filed as exhibits to this report and our other filings with the SEC. You should assume that the information appearing in this quarterly report is accurate as of the date of this quarterly report only. Further, any forward-looking statement speaks only as of the date on which it is made, and we undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events. New factors emerge from time to time, and it is not possible for us to predict which factors will arise. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. We qualify all of the information presented in this quarterly report, and particularly our forward-looking statements, by these cautionary statements.

Table of Contents

PART I—FINANCIAL INFORMATION

Item 1. Financial Statements.

Semler Scientific, Inc.

Condensed Statements of Income

Unaudited

(In thousands of U.S. Dollars, except share and per share data)


	For the three months ended March 31,
		2022		2021

Revenues	$	14,016	$	13,183
Operating expenses:
Cost of revenues		970		1,579
Engineering and product development		1,126		693
Sales and marketing		4,676		2,816
General and administrative		3,302		2,076
Total operating expenses		10,074		7,164
Income from operations		3,942		6,019
Interest income		1		3
Other expenses		—		(2)
Other income		1		1
Pre-tax net income		3,943		6,020
Income tax provision		583		1,143
Net income	$	3,360	$	4,877
Net income per share, basic	$	0.50	$	0.73
Weighted average number of shares used in computing basic income per share		6,777,950		6,710,990
Net income per share, diluted	$	0.41	$	0.60
Weighted average number of shares used in computing diluted income per share		8,116,456		8,169,375

See accompanying notes to unaudited condensed financial statements.

Table of Contents

Semler Scientific, Inc.

Condensed Balance Sheets

(In thousands of U.S. Dollars, except share and per share data)


	March 31,		December 31,
	2022		2021
		Unaudited
Assets
Current Assets:
Cash and cash equivalents	$	38,426	$	37,323
Trade accounts receivable, net of allowance for doubtful accounts of $71 and $61, respectively		5,416		3,619
Inventory		595		550
Prepaid expenses and other current assets		6,033		4,044
Total current assets		50,470		45,536
Assets for lease, net		1,594		1,643
Property and equipment, net		470		394
Other non-current assets		313		332
Long-term investments		821		821
Long-term deferred tax assets		1,767		1,946
Total assets	$	55,435	$	50,672

Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$	375	$	443
Accrued expenses		4,383		3,436
Deferred revenue		980		921
Other short-term liabilities		81		80
Total current liabilities		5,819		4,880

Long-term liabilities:
Other long-term liabilities		224		245
Total long-term liabilities		224		245
Commitments and contingencies (Note 10)
Stockholders’ equity:
Common stock, $0.001 par value; 50,000,000 shares authorized; 6,855,168, and 6,824,380 shares issued, and 6,787,216 and 6,758,458 shares outstanding (treasury shares of 67,952 and 65,922, respectively)		7		7
Additional paid-in capital		21,130		20,645
Retained earnings		28,255		24,895

Total stockholders’ equity		49,392		45,547

Total liabilities and stockholders’ equity	$	55,435	$	50,672

See accompanying notes to unaudited condensed financial statements.

Table of Contents

Semler Scientific, Inc.

Statements of Stockholders’ Equity

Unaudited

(In thousands of U.S. Dollars, except share and per share data)


	For the Three Months Ended March 31, 2021
	Common Stock			Treasury Stock			Additional
		Common Stock					Paid-In		Retained Earnings		Total Stockholders'
	Shares Issued	Amount		Shares	Amount		Capital				Equity
Balance at December 31, 2020	6,725,422	$	7	(25,000)	$	—	$	22,113	$	7,673	$	29,793
Employee stock grants	5,400		—	—		—		537		—		537
Stock option exercises	14,984		—	—		—		9		—		9
Stock-based compensation	—		—	—		—		52		—		52
Net income	—		—	—		—		—		4,877		4,877
Balance at March 31, 2021	6,745,806	$	7	(25,000)	$	—	$	22,711	$	12,550	$	35,268


	For the Three Months Ended March 31, 2022
	Common Stock			Treasury Stock			Additional
		Common Stock					Paid-In		Retained Earnings		Total Stockholders'
	Shares Issued	Amount		Shares	Amount		Capital				Equity
Balance at December 31, 2021	6,824,380	$	7	(65,922)	$	—	$	20,645	$	24,895	$	45,547
Treasury stock acquired	—		—	(2,030)		—		(99)		—		(99)
Employee stock grant	8,406		—	—		—		628		—		628
Taxes paid related to net share settlement of equity awards	(1,418)		—	—		—		(106)		—		(106)
Stock option exercises	23,800		—	—		—		62		—		62
Net income	—		—	—		—		—		3,360		3,360
Balance at March 31, 2022	6,855,168	$	7	(67,952)	$	—	$	21,130	$	28,255	$	49,392

See accompanying notes to unaudited condensed financial statements

Table of Contents

Semler Scientific, Inc.

Condensed Statements of Cash Flows

Unaudited

(In thousands of U.S. Dollars)


	For the three months ended March 31
	2022		2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$	3,360	$	4,877

Reconciliation of Net Income to Net Cash Provided by Operating Activities:
Depreciation		155		155
Deferred tax expense		179		626
Loss on disposal of assets for lease		74		83
Allowance for doubtful accounts		21		5
Stock-based compensation expense		628		589
Changes in Operating Assets and Liabilities:
Trade accounts receivable		(1,818)		(1,595)
Inventory		(45)		(299)
Prepaid expenses and other current assets		(1,988)		(393)
Other non-current assets		19		26
Accounts payable		(68)		(207)
Accrued expenses		946		679
Other current and non-current liabilities		(20)		(26)
Deferred revenue		59		86
Net Cash Provided by Operating Activities		1,502		4,606

CASH FLOWS FROM INVESTING ACTIVITIES:
Additions to property and equipment		(122)		(133)
Purchase of assets for lease		(134)		(83)
Net Cash Used in Investing Activities		(256)		(216)

CASH FLOWS FROM FINANCING ACTIVITIES:
Taxes paid related to net settlement of equity awards		(106)		-
Treasury stock acquired		(99)		-
Proceeds from exercise of stock options		62		9
Net Cash (Used in) Provided by Financing Activities		(143)		9
INCREASE IN CASH		1,103		4,399
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD		37,323		22,079
CASH AND CASH EQUIVALENTS, END OF PERIOD	$	38,426	$	26,478

See accompanying notes to unaudited condensed financial statements

Table of Contents

Semler Scientific, Inc.

Notes to Condensed Financial Statements

Unaudited

(In thousands of U.S. Dollars, except share and per share data)

1. Basis of Presentation

Semler Scientific, Inc., a Delaware corporation (“Semler” or “the Company”), prepared the unaudited interim financial statements included in this report in accordance with United States generally accepted accounting principles (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. As such, the information included in this quarterly report on Form 10-Q should be read in conjunction with the audited financial statements and notes thereto included in the Company’s annual report on Form 10-K for the year ended December 31, 2021 filed with the SEC on March 4, 2022 (the “Annual Report”). In the opinion of management, these financial statements include all adjustments (consisting of normal recurring adjustments) necessary for a fair statement of the financial position, results of operations and cash flows for the periods presented. The results of operations for the interim periods shown in this report are not necessarily indicative of the results that may be expected for any future period, including the full year.

COVID-19

In 2021, variable fee license revenues (fee-per-test), which grew strongly in the first half of 2021, decreased subsequently in the second half of 2021. The Company believes this new pattern in the home-testing market is due to a COVID-19 related timing change in the behavior of insurance plans when ordering QuantaFlo testing from its health risk assessment customers.

The first quarter results of 2022 support this pattern of testing earlier in the year, as the home-testing market had higher volume of sequential revenues, which grew 67% compared to the fourth quarter of 2021. However, the Company does not know if this newly observed pattern will continue in 2022 or in future years.

The Company believes that the relatively slower growth in the period-over-period comparison, was due to the COVID-19 pandemic. The Company's staff and many of its customers and prospects experienced a higher-than-normal rate of employee absence due to illness, which can have a slowing effect on its sales cycle.

The extent and duration of the pandemic is unknown, and the future effects on the Company’s business are uncertain and difficult to predict. The Company is continuing to monitor the events and circumstances surrounding the COVID-19 pandemic, which may require adjustments to the Company’s estimates and assumptions in the future.

Recently Issued Accounting Pronouncements

Accounting Pronouncements Recently Adopted

In May 2021, the financial Accounting Standards Board(“FASB”) issued Accounting Standards Update (“ASU”) No. 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40) Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. This update provides guidance for a modification or an exchange of a freestanding equity-classified written call option that is not within the scope of another Topic. This update is effective for the Company’s fiscal years beginning after December 15, 2021. The Company adopted this ASU prospectively effective January 1, 2022 and determined that the adoption of this new accounting standard did not have a material impact on its financial statements.

In July 2021, the FASB issued ASU No. 2021-05, Leases (Topic 842): Lessors—Certain Leases with Variable Lease Payments. This update addresses stakeholders’ concerns by amending the lease classification requirements for lessors to align them with practice under Topic 840. Lessors should classify and account for a lease with variable lease payments that do not depend on a reference index or a rate as an operating lease if both of the following criteria are met: i) The lease would have been classified as a sales-type lease or a direct financing lease in accordance with the classification criteria in paragraphs 842-10-25-2 through 25-3, ii) the lessor would have otherwise recognized a day-one loss. This update is effective for the Company’s fiscal years beginning after

Table of Contents

Semler Scientific, Inc.
Notes to Condensed Financial Statements

Unaudited

(In thousands of U.S. Dollars, except share and per share data)

December 15, 2021. The Company adopted this ASU prospectively to the leases that commence or modified on or after January 1, 2022 and determined that the adoption of this new accounting standard did not have a material impact on its financial statements.

In November 2021, the FASB issued ASU No. 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance. This ASU increases the transparency of government assistance to include the disclosure of (1) the types of assistance, (2) an entity's accounting for the assistance, and (3) the effect of the assistance on an entity's financial statements. The guidance in ASU 2021-10 is effective for financial statements of all entities, including private companies, for annual periods beginning after December 15, 2021, with early application permitted. Entities are required to provide the new disclosures prospectively for all transactions with a government entity that are accounted for under either a grant or a contribution accounting model and are reflected in the financial statements at the date of initially applying the new amendments, and to new transactions entered into after that date. The Company adopted ASU No. 2021-10 prospectively to the government assistance received after January 1, 2022 and determined that the adoption of this new accounting standard did not have a material impact on its financial statements.

Accounting Pronouncements Not Yet Adopted

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“Topic 326”). This ASU requires timelier recording of credit losses on loans and other financial instruments held. Instead of reserves based on a current probability analysis, Topic 326 requires the measurement of all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. All organizations will now use forward-looking information to better inform their credit loss estimates. Topic 326 requires enhanced disclosures regarding significant estimates and judgments used in estimating credit losses, as well as the credit quality and underwriting standards of an organization’s portfolio. These disclosures include qualitative and quantitative requirements that provide information about the amounts recorded in the financial statements. In addition, Topic 326 amends the accounting for credit losses on available-for-sale debt securities and purchased financial assets with credit deterioration. In April 2019, the FASB issued ASU No. 2019-04, Codification Improvements to Topic 326 Financial Instruments—Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments, to introduce amendments which will affect the recognition and measurement of financial instruments, including derivatives and hedging. In May 2019, the FASB issued ASU No. 2019-05, Financial Instruments – Credit Losses (Topic 326); Targeted Transition Relief. The amendments in this ASU provide entities that have certain instruments within the scope of Subtopic 326-20 with an option to irrevocably elect the fair value option in Subtopic 825-10, applied on an instrument-by-instrument basis for eligible instruments upon adoption of Topic 326. This standard and related amendments are effective for the Company’s fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The Company will adopt the new standard in the first quarter of fiscal year 2023. The Company is evaluating the effect of adopting this new accounting guidance but does not expect adoption will have a material impact on the Company's financial statements.

In March 2020, FASB issued ASU No. 2020-03, Codification Improvements to Financial Instruments. This ASU improves and clarifies various financial instruments topics, including the current expected credit losses standard issued in 2016 (ASU No. 2016-13). The ASU includes seven different issues that describe the areas of improvement and the related amendments to GAAP, intended to make the standards easier to understand and apply by eliminating inconsistencies and providing clarifications. The amendments have different effective dates. The issues 1-5 are conforming amendments, which are effective upon issuance of this final update. The Company determined that issues 1-5 have no impact on its financials. The amendments related to issue 6 and 7 effect ASU No. 2016-13, Financial instruments – credit losses (Topic 326): measurement of credit losses on financial statements. Effective dates of issue 6 and 7 are the same as the effective date of ASU No. 2016-13. The Company will adopt the new standard in the first quarter of fiscal year 2023.The Company is evaluating the effect of adopting this new accounting guidance, but does not expect adoption will have a material impact on the Company's financial statements.

In October 2021, the FASB issued ASU No.2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. This ASU improves the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in practice and inconsistency related to recognition of an acquired contract liability and payment terms and their effect on subsequent revenue recognized by the acquirer. For public business entities,

Table of Contents

Semler Scientific, Inc.
Notes to Condensed Financial Statements

Unaudited

(In thousands of U.S. Dollars, except share and per share data)

this guidance will be effective for fiscal years beginning after December 15, 2022 and for interim periods within those fiscal years. For all other entities, this guidance is effective for fiscal years beginning after December 15, 2023 and for interim periods within those fiscal years. This ASU should be applied prospectively to all business combinations in the year of adoption. The Company will adopt the new standard in the first quarter of fiscal year 2023. The Company does not expect the adoption of this standard will have a material impact on its financial statements.

2.Variably-Priced Revenue

The Company recognizes variable-fee licenses (i.e., fee per test) and sales of hardware equipment and accessories in accordance with ASC 606. Total fees from variable-fee licenses represent approximately $5,842 and $5,658 for the three months ended March 31, 2022 and 2021, respectively. Total sales of hardware and equipment accessories represent approximately $285 and $331 of revenues for the three months ended March 31, 2022 and 2021, respectively. The remainder of the revenue is earned from leasing the Company's testing product for a fixed fee, which is not subject to Topic 606.

3. Inventory

Inventory, which is made up of finished goods, is recorded at the lower of cost or net realizable value. Cost is determined on the first-in, first-out method. The Company periodically analyzes its inventory levels to identify inventory that has a cost basis in excess of its estimated realizable value, and writes down such inventory as appropriate. Inventory balance was $595 and $550 as of March 31, 2022 and December 31, 2021, respectively.

4. Assets for Lease, net

The Company enters into contracts with customers for the Company’s QuantaFlo product. The Company has determined these contracts meet the definition of a lease under Topic 842. Operating leases are short-term in nature (monthly, quarterly or one year), and all of which have renewal options. The assets that may be associated with these leasing arrangements are identified below as assets for lease. Upon shipment under operating leases, assets for lease are depreciated. Upon shipment under variable-fee license contracts, these assets for lease are sold to the customers, and the asset is recognized as cost of revenue under Accounting Standards Codification or ASC 606, Revenue from Contracts with Customers. During the three months ended March 31, 2022 and 2021, the Company recognized approximately $7,889 and $7,194, respectively, in lease revenues related to these arrangements.

Assets for lease consist of the following:


	March 31,		December 31,
	2022		2021
Assets for lease	$	3,210	$	3,241
Less: accumulated depreciation		(1,616)		(1,598)
Assets for lease, net	$	1,594	$	1,643

Depreciation expense amounted to $108 and $113 for the three months ended March 31, 2022 and 2021, respectively. Reduction to accumulated depreciation for returned items was $90 and $141 for the three months ended March 31, 2022 and 2021, respectively. The Company recognized a loss on disposal of assets for lease in the amount of $74 and $83 for the three months ended March 31, 2022 and 2021, respectively.

Table of Contents

Semler Scientific, Inc.
Notes to Condensed Financial Statements

Unaudited

(In thousands of U.S. Dollars, except share and per share data)

5. Property and Equipment, net

Capital assets consist of the following:


	March 31,		December 31,
	2022		2021
Capital assets	$	1,005	$	882
Less: accumulated depreciation		(535)		(488)
Capital assets, net	$	470	$	394

Depreciation expense amounted to $46 and $43 for the three months ended March 31, 2022 and 2021, respectively.

6.Long-Term Investments

Long term investments consist of the following for the periods presented:


	March 31,		December 31,
	2022		2021
Investments in SYNAPS Dx	$	512	$	512
Investments in Mellitus Health Inc.		309		309
Total	$	821	$	821

In September 2020, the Company acquired a promissory note from NeuroDiagnostics Inc., which is doing business as SYNAPS Dx, in the principal amount of $500. Subsequently, in December 2020, the Company agreed to convert the promissory note, together with all accrued interest thereon, into shares of preferred stock of SYNAPS Dx as repayment in full of the promissory note. The value of the note exchanged for the shares of preferred stock of SYNAPS Dx held by the Company as of March 31, 2022 and December 31, 2021 was approximately $512.

In October 2020, the Company acquired from a seller a convertible promissory note previously issued by Mellitus Health Inc., (“Mellitus”) to such seller for a purchase price of $59, which represented the $50 principal amount of the note and all accrued and unpaid interest thereon.

Subsequently, in October 2020, the Company purchased $250 of shares of preferred stock of Mellitus, and in connection with such transaction, the convertible promissory note, together with all accrued interest thereon, also converted pursuant to its terms into shares of preferred stock of Mellitus as repayment in full of such convertible promissory note. The value of consideration exchanged for the shares of preferred stock of Mellitus held by the Company as of March 31, 2022 and December 31, 2021 was approximately $309.

In April 2021, the Company entered into an agreement with Mellitus to exclusively market and distribute its product line in the United States, including Puerto Rico, except for selected accounts. The Company is currently developing a marketing plan. Under this distribution agreement, the Company agreed to purchase $2,000 of product licenses and prepaid $2,000 for the license purchases. This prepayment is included in ‘Prepaid expenses and other current assets’ in the balance sheet. Unless terminated early in accordance with its terms, the exclusive distribution agreement will remain in full force and effect until April 1, 2026, and thereafter there is an option for this agreement to be automatically renewed for additional one-year terms. Revenue from these product licenses will be recognized in accordance with ASC 606, Revenue from Contracts with Customers. Revenue from these product licenses during the three months ended March 31, 2022 was not significant.

The investments in SYNAPS Dx and Mellitus securities that were retained by the Company as of March 31, 2022 were recorded in accordance with ASC 321, Investments – equity securities, which provides that investments in equity securities in privately-held companies without readily determinable fair values are generally recorded at cost, plus or minus subsequent observable price changes in orderly transactions for identical or similar investments, less impairments. The Company elected the practical

Table of Contents

Semler Scientific, Inc.
Notes to Condensed Financial Statements

Unaudited

(In thousands of U.S. Dollars, except share and per share data)

expedient permitted by ASC 321 and recorded the above investments on a cost basis. As a part of the assessment for impairment indicators, the Company considers significant deterioration in the earnings performance and overall business prospects of the investee as well as significant adverse changes in the external environment these investments operate. If qualitative assessment indicates the investments are impaired, the fair value of these equity securities would be estimated, which would involve a significant degree of judgement and subjectivity. In accordance with ASC 321, the Company assessed qualitatively for impairment and determined that there was no impairment for these investments as of March 31, 2022 and December 31, 2021.

7. Accrued Expenses

Accrued expenses consist of the following:


	March 31,		December 31,
	2022		2021
Compensation	$	2,522	$	1,754
Accrued Taxes		1,339		1,159
Miscellaneous Accruals		522		523
Total Accrued Expenses	$	4,383	$	3,436

8. Concentration of Credit Risk

Credit risk is the risk of loss from amounts owed by the financial counterparties. Credit risk can occur at multiple levels; as a result of broad economic conditions, challenges within specific sectors of the economy, or from issues affecting individual companies. Financial instruments that potentially subject the Company to credit risk consist of cash and accounts receivable.

The Company maintains cash with major financial institutions. The Company’s cash and cash equivalents consist of bank deposits and money market funds held with banks that, at times, exceed federally insured limits. The Company limits its credit risk by dealing with counterparties that are considered to be of high credit quality and by performing periodic evaluations of the relative credit standing of these financial institutions.

Management periodically monitors the creditworthiness of its customers and believes that it has adequately provided for any exposure to potential credit loss. For the three months ended March 31, 2022, two customers accounted for 35.4% and 31.7% of the Company’s revenues, respectively. For the three months ended March 31, 2021, two customers accounted for 38.3% and 30.4% of the Company’s revenues. As of March 31, 2022, three customers accounted for 30.2%, 26.8%, and 22.5% of the Company’s accounts receivable, respectively. As of December 31, 2021, three customers accounted for 21.9%, 20.1%, and 16.6% of the Company’s accounts receivable, respectively. The Company’s largest customer in terms of both revenues and accounts receivable in the three months ended March 31, 2022 is a U.S. diversified healthcare company and its affiliated plans.

As of March 31, 2022, three vendors accounted for 18.0%, 17.1% and 10.6% of the Company’s accounts payable, respectively. As of December 31, 2021, one vendor accounted for 14.0% of the Company’s accounts payable, respectively.

9. Leases

On July 31, 2020, the Company entered into a 61-month lease agreement for office space to use, as necessary, for office administration, lab space and assembly and storage purposes, located in Santa Clara, California. The Company took possession of the leased office space in September 2020, and the lease is effective through September 30, 2025.

As of March 31, 2022, the remaining lease term is three years and six months with no options to renew. The Company recognized facilities lease expenses of $22 and $44 for the three months ended March 31, 2022 and 2021, respectively.

Table of Contents

Semler Scientific, Inc.
Notes to Condensed Financial Statements

Unaudited

(In thousands of U.S. Dollars, except share and per share data)

The following table summarizes the future minimum rental payments required under operating leases that had initial or remaining non-cancelable lease terms greater than one year as of March 31, 2022:


	Total
2022 Remaining period	$	66
2023		90
2024		93
2025		71
Thereafter		—
Total undiscounted future minimum lease payments		320
Less: present value discount		(15)
Total lease liabilities		305
Lease expense in excess cash payment		(11)
Total ROU asset	$	294

As of March 31, 2022, the Company’s right-of-use (“ROU”) asset was $294, which was recorded on the Company’s balance sheet as other noncurrent assets, and the Company’s current and noncurrent lease liabilities were $81 and $224, respectively, which were recorded on the Company’s balance sheet as other short-term liabilities and other long-term liabilities, respectively. As of December 31, 2021, the Company’s ROU asset was $314, which was recorded on the Company’s balance sheet as other noncurrent assets, and the Company’s current and noncurrent lease liabilities were $80 and $245, respectively, which were recorded on the Company’s balance sheet as other short-term liabilities and other long-term liabilities, respectively.

Lease Arrangements

The Company enters into contracts with customers for the Company’s QuantaFlo product. The Company has determined these contracts meet the definition of a lease under Topic 842. The lease portfolio primarily consists of operating leases that are short-term in nature (monthly, quarterly or one year, all of which have renewal options). The Company allocates the consideration in a bundled contract with its customers based on relative standalone selling prices of the lease and non-lease components. The Company made an accounting policy election to apply the practical expedient to not separate lease and eligible non-lease components. The lease component is the predominant component and consists of fees charged for use of the equipment over the period of the arrangement. The nature of the eligible non-lease component is primarily software support. The assets associated with these leasing arrangements are separately identified in the Balance Sheet as Assets for Lease and separately disclosed in Note 4 to the Unaudited Condensed Financial Statements.

10. Commitments and Contingencies

Facilities Leases

Indemnification Obligations

The Company enters into agreements with customers, partners, lenders, consultants, lessors, contractors, sales representatives and parties to certain transactions in the ordinary course of the Company’s business. These agreements may require the Company to indemnify the other party against third party claims alleging that its product infringes a patent or copyright. Certain of these agreements require the Company to indemnify the other party against losses arising from: a breach of representations or covenants, claims relating to property damage, personal injury or acts or omissions of the Company, its employees, agents or representatives. The Company has also agreed to indemnify the directors and certain of the officers and employees in accordance with the by-laws of the

Table of Contents

Semler Scientific, Inc.
Notes to Condensed Financial Statements

Unaudited

(In thousands of U.S. Dollars, except share and per share data)

Company. These indemnification provisions will vary based upon the nature and terms of the agreements. In many cases, these indemnification provisions do not contain limits on the Company’s liability, and the occurrence of contingent events that will trigger payment under these indemnities is difficult to predict. As a result, the Company cannot estimate its potential liability under these indemnities. The Company believes that the likelihood of conditions arising that would trigger these indemnities is remote and, historically, the Company has not made any significant payment under such indemnification provisions. Accordingly, the Company has not recorded any liabilities relating to these agreements. In certain cases, the Company has recourse against third parties with respect to the aforesaid indemnities, and the Company believes it maintains adequate levels of insurance coverage to protect the Company with respect to potential claims arising from such agreements.

401(K) Plan

Effective January 1, 2022, the Company started to match 50% of employee’s 401(k) deferral up to a maximum of 6% of the employee’s eligible earnings.

Other

The Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) provides for an employee retention payroll tax credit for certain employers, which is a refundable tax credit against certain employment taxes equal to 50% of the qualified wages an eligible employer pays to employees after March 12, 2020 and before December 31, 2021. For each employee, wages (including health plan costs) up to $10,000 can be counted to determine the amount of the 50% credit. The Company started claiming this credit on its July 2020 payroll until mid-April 2021 when it determined that it no longer qualified given the change in government restrictions on travel that had impacted its sales activities. The Company’s determination that it qualified to claim the employee retention payroll tax credit is subjective and subject to audit by the Internal Revenue Service (“IRS”). If the IRS were to disagree with the Company’s tax position, it could be required to pay the retention credit claimed, along with penalties. As of December 31, 2021, the Company has claimed $1.24 million in this retention credit.

Litigation

From time to time in the normal course of business, the Company is subject to various legal matters such as threatened or pending claims or litigation. Although the results of claims and litigation cannot be predicted with certainty, the Company does not believe it is a party to any claim or litigation the outcome of which, if determined adversely to it, would individually or in the aggregate be reasonably expected to have a material adverse effect on its results of operations or financial condition.

11. Stock Incentive Plan

The Company’s stock-based compensation program is designed to attract and retain employees while also aligning employees’ interests with the interests of its stockholders. Stock options have been granted to employees under the stockholder-approved 2007 Key Person Stock Option Plan (“2007 Plan”) and stock options and restricted stock have been granted to employees under the stockholder-approved 2014 Stock Incentive Plan (“2014 Plan”). Stockholder approval of the 2014 Plan became effective in September 2014. The 2014 Plan originally provided that the aggregate number of shares of common stock that may be issued pursuant to awards granted under the 2014 Plan may not exceed 450,000 shares (the “Share Reserve”), however in October 2015, the stockholders approved a 1,500,000 increase to the Share Reserve. In addition, the Share Reserve automatically increases on January 1st of each year, for a period of not more than 10 years, beginning on January 1st of the year following the year in which the 2014 Plan became effective and ending on (and including) January 1, 2024, in an amount equal to 4% of the total number of shares of common stock outstanding on December 31st of the preceding calendar year. The Company’s Board of Directors may act prior to January 1st of a given year to provide that there will be no January 1st increase in the Share Reserve for such year or that the increase in the Share Reserve for such year will be a lesser number of shares of common stock than would otherwise occur. In the fourth quarter of 2020, the Board of Directors agreed not to increase the Share Reserve, and accordingly, the Share Reserve did not increase on January 1, 2021. On January 1, 2022, the Share Reserve increased by 270,338. The Share Reserve is currently 3,315,203 shares as of March 31, 2022.

Table of Contents

Semler Scientific, Inc.
Notes to Condensed Financial Statements

Unaudited

(In thousands of U.S. Dollars, except share and per share data)

In light of stockholder approval of the 2014 Plan, the Company no longer grants equity awards under the 2007 Plan. As of March 31, 2022, there were no shares available for future stock-based compensation grants under the 2007 Plan and 1,479,103 shares of an aggregate total of 3,315,203 shares were available for future stock-based compensation grants under the 2014 Plan.

Treasury Stock Acquired

On March 14, 2022, the Company’s Board of Directors authorized a share repurchase program under which it may repurchase up to $20.0 million of its outstanding common stock. Under this program the Company may purchase shares on a discretionary basis from time to time through open market purchases, privately negotiated transactions or other means, including through Rule 10b5-1 trading plans or through the use of other techniques such as accelerated share repurchases. The timing and amount of any transactions will be subject to the discretion of the Company based upon market conditions and other opportunities that it may have for the use or investment of its cash balances. The repurchase program has no expiration date, does not require the purchase of any minimum number of shares and may be suspended, modified or discontinued at any time without prior notice. The Company purchased 2,030 shares at a cost of approximately $99 during the three months ended March 31, 2022.

Stock Awards

The Company granted fully vested stock awards of 8,406 shares of common stock to the non-employee members of the board of directors, employees and one non-employee as compensation during the three months ended March 31, 2022. Net shares issued after deducting taxes paid on these grants were 6,988. Fair value of these stock awards on grant date was $628. The Company granted fully vested stock awards of 5,400 shares of common stock to the non-employee members of the board of directors, employees and one non-employee as compensation during the three months ended March 31, 2021. Fair value of these stock awards on grant date was $537.

Stock Options

Aggregate intrinsic value represents the difference between the closing market value as of March 31, 2022 of the underlying common stock and the exercise price of outstanding, in-the-money options. A summary of the Company’s stock option activity and related information for the three months ended March 31, 2022 is as follows:


	Options Outstanding
				Weighted
				Average
	Number of	Weighted		Remaining	Aggregate
	Stock Options	Average		Contractual	Intrinsic Value
	Outstanding	Exercise Price		Term (In Years)	(In Thousands)
Balance, December 31, 2021	1,356,245	$	3.30	3.97	$	119,830
Options exercised	(23,800)		2.58	—		—
Balance, March 31, 2022	1,332,445	$	3.31	3.73	$	61,627
Exercisable as of March 31, 2022	1,332,445	$	3.31	3.73	$	61,627

There were no options granted during the three months ended March 31, 2022 or 2021.

Table of Contents

Semler Scientific, Inc.
Notes to Condensed Financial Statements

Unaudited

(In thousands of U.S. Dollars, except share and per share data)

The Company has recorded an expense of $628 and $589 as it relates to stock-based compensation for the three months ended March 31, 2022 and 2021, respectively:


	Three months ended March 31,
	2022		2021
Cost of Revenues	$	—	$	—
Engineering and Product Development		45		32
Sales and Marketing		172		105
General and Administrative		411		452
Total	$	628	$	589

12. Income Taxes

The Company’s income tax provision for the three months ended March 31, 2022 and March 31, 2021 was $583 and $1,143, respectively. The income tax provision reflects its estimate of the effective tax rates expected to be applicable for the full year, adjusted for any discrete events that are recorded in the period in which they occurred. The estimates are re-evaluated each quarter based on the estimated tax expense for the full year.

For uncertain tax positions that meet a “more likely than not” threshold, the Company recognizes the benefit of uncertain tax positions in the financial statements. The Company’s practice is to recognize interest and penalties, if any, related to uncertain tax positions in income tax expense in the statements of operations.

The effective tax rate for the three months ended March 31, 2022 was 14.79%, compared to 18.99% for the three months ended March 31, 2021. The decrease in the effective tax rate for the three months ended March 31, 2022 is primarily related to tax benefits associated with employee share-based compensation plans and federal and state research and development credits net of reserves for uncertain tax positions related to these credits.

The effective tax rate for the three months ended March 31, 2022 differed from the U.S. federal statutory rate of 21% primarily due to state income taxes (net of federal benefit) partially offset by tax benefits associated with employee share-based compensation plans and federal and state research and development (“R&D”) credit benefit. The difference between the U.S. Federal statutory rate of 21% and the Company’s effective tax rate of 18.99% for the three months ended March 31, 2021 was state income taxes (net of federal benefit) partially offset by tax benefit associated with employee share-based compensation plans and federal and state R&D credit benefit.

As of March 31, 2022, and December 31, 2021, the Company had $419 and $476, respectively of unrecognized tax benefits, excluding interest and penalties. The Company’s practice is to recognize interest and penalty expenses related to uncertain tax positions in income tax expense, which was zero for the year ended December 31, 2021 and three months ended March 31, 2022.

Table of Contents

Semler Scientific, Inc.
Notes to Condensed Financial Statements

Unaudited

(In thousands of U.S. Dollars, except share and per share data)

13. Net Income Per Share, Basic and Diluted

Basic earnings per share (“EPS”) represent net income attributable to common stockholders divided by the weighted average number of common shares outstanding during the measurement period. Diluted EPS represents net income attributable to common stockholders divided by the weighted average number of common shares outstanding during the measurement period while also giving effect to all potentially dilutive common shares that were outstanding during the period using the treasury stock method.

Basic and diluted EPS is calculated as follows:


	Three months ended March 31,
	2022					2021
	Shares	Net Income		EPS		Shares	Net Income		EPS
Basic	6,777,950	$	3,360	$	0.50	6,710,990	$	4,877	$	0.73
Common stock warrants	71,839		—			73,497		—
Common stock options	1,266,667		—			1,384,888		—
Diluted	8,116,456	$	3,360	$	0.41	8,169,375	$	4,877	$	0.60

The were no weighted average shares outstanding of common stock equivalents excluded from the computation of diluted net income per share for the three months ended March 31, 2022 and 2021.

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The following discussion and analysis should be read together with our condensed unaudited financial statements and the related notes appearing elsewhere in this quarterly report on Form 10-Q and with the audited financial statements and notes for the fiscal year ended December 31, 2021, and the information under the headings “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K filed with the SEC on March 4, 2022, or the Annual Report. This discussion contains forward-looking statements reflecting our current expectations that involve risks and uncertainties. See “Cautionary Note Regarding Forward-Looking Statements” for a discussion of the uncertainties, risks and assumptions associated with these statements. Actual results and the timing of events could differ materially from those discussed in our forward-looking statements as a result of many factors, including those set forth under “Risk Factors” in the Annual Report.

Overview

We are a company providing technology solutions to improve the clinical effectiveness and efficiency of healthcare providers. Our mission is to develop, manufacture and market innovative products and services that assist our customers in evaluating and treating chronic diseases. In 2011, we began commercializing our first patented and U.S. Food and Drug Administration, or FDA, cleared product, which measured arterial blood flow in the extremities to aid in the diagnosis of peripheral arterial disease, or PAD. In March 2015, we received FDA 510(k) clearance for the next generation version of our product, QuantaFlo, which we began commercializing in August 2015.

In April 2021, we entered into an agreement with a private company to exclusively market and distribute Insulin Insights, an FDA-cleared software product that recommends optimal insulin dosing for diabetic patients in the United States, including Puerto Rico, except for selected accounts. We made investments in this private software company and in another private company whose product, Discern is a test for early Alzheimer’s disease. We continue to develop additional complementary, innovative products in-house, and seek out other arrangements for additional products and services that we believe will bring value to our customers and to our company. We believe our current products and services, and any future products or services that we may offer, position us to provide valuable information to our customer base, which in turn permits them to better guide patient care.

In the three months ended March 31, 2022, we had total revenues of $14.0 million and net income of $3.4 million, compared to total revenues of $13.2 million and net income of $4.9 million in the same period in 2021.

Recent Developments

In 2021, variable fee license revenues (fee-per-test), which grew strongly in the first half of 2021, decreased subsequently in the second half of 2021. We believe this new pattern in the home-testing market is due to a COVID-19 related timing change in the behavior of insurance plans when ordering QuantaFlo testing from our health risk assessment customers.

The first quarter results of 2022 support this pattern of testing earlier in the year, as the home-testing market had higher volume of sequential revenues, which grew 67% compared to the fourth quarter of 2021. However, we do not know if this newly observed pattern will continue in 2022 or in future years.

We believe that the relatively slower growth in the period-over-period comparison, was due to the COVID-19 pandemic. Our staff and many of our customers and prospects experienced a higher-than-normal rate of employee absence due to illness, which can have a slowing effect on its sales cycle.

As we look forward into 2022, there is continued uncertainty as recent outbreaks of new variants have occurred and vaccination rates lag in certain jurisdictions. New, additional or different restrictions could be imposed, which could impact the usage of our product by our customers, or further impact the timing of demand for our products. Other customers who have fixed-fee licenses could decide to cancel their licenses if they are not able to use our device as frequently as they had anticipated in light of such restrictions.

Common Stock Repurchase

Table of Contents

time through open market purchases, privately negotiated transactions or other means, including through Rule 10b5-1 trading plans or through the use of other techniques such as accelerated share repurchases. The timing and amount of any transactions will be subject to our discretion and based upon market conditions and other opportunities that we may have for the use or investment of our cash balances. The repurchase program has no expiration date, does not require the purchase of any minimum number of shares and may be suspended, modified or discontinued at any time without prior notice. We purchased 2,030 shares of our common stock for approximately $0.1 million during the three months ended March 31, 2022.

Results of Operations

Three Months Ended March 31, 2022 Compared to Three Months Ended March 31, 2021

Revenues

We had revenues of $14.0 million for the three months ended March 31, 2022, an increase of $0.8 million, or 6%, compared to $13.2 million in the same period in 2021. Our revenues are primarily from fees charged to customers for use of our vascular testing products and from sale of accessories used with these products. We recognized revenues of $13.7 million from fees for our vascular testing products for the three months ended March 31, 2022, consisting of $7.9 million from fixed-fee licenses and $5.8 million from variable-fee licenses compared to $12.9 million in the same period of the prior year, consisting of $7.2 million from fixed-fee licenses and $5.7 million from variable-fee licenses. The remainder was from sales of other products, which were $0.3 million in both the periods.

Revenues from fees for vascular testing products are recognized monthly for each unit installed with a customer, usually billed as a fixed monthly fee, or as a variable monthly fee dependent on usage. The primary reason for the increase in revenues was growth in the number of installed units from both new customers and established customers, which we believe is the result of our sales and marketing efforts.

Operating expenses

We had total operating expenses of $10.0 million for the three months ended March 31, 2022, an increase of $2.9 million or 41%, compared to $7.1 million in the same period in the prior year. The primary reasons for this change were increased expenses associated with our expanding business, such as increased personnel expense. As a percentage of revenues, operating expenses increased to 72% in the first quarter of 2022 as compared to 54% in the prior year period. The changes in the various components of our operating expenses are described below.

Cost of revenues

We had cost of revenues of $1.0 million for the three months ended March 31, 2022, a decrease of $0.6 million, or 39%, compared to $1.6 million in the same period of the prior year. The primary reason for this change was that the prior year period included a non-recurring inventory adjustment for supplies.

Engineering and product development expense

We had engineering and product development expense of $1.1 million for the three months ended March 31, 2022, an increase of $0.4 million, or 62%, compared to $0.7 million in the same period of the prior year. The increase was primarily due to increased headcount and annual pay increases in line with our business expansion, expiry of COVID-19 related payroll tax credits received in the prior year and consulting costs associated with ongoing projects to extend QuantaFlo to additional cardiovascular diseases. As a percentage of revenues, engineering and product development expense was 8% in the first quarter of 2022, as compared to 5% in the prior year period.

Sales and marketing expense

We had sales and marketing expense of $4.7 million for the three months ended March 31, 2022, an increase of $1.9 million, or 66%, compared to $2.8 million in the same period of the prior year. The increase was primarily due to increased headcount and annual salary increases, ceasing to claim COVID-19 related payroll tax credits received in the prior year period and associated

Table of Contents

expense to serve a continued expansion of customer activities. As a percentage of revenues, sales and marketing expense increased to 33% in the first quarter of 2022, as compared to 21% in the prior year period.

General and administrative expense

We had general and administrative expense of $3.3 million for the three months ended March 31, 2022, an increase of $1.2 million, or 59%, compared to $2.1 million in the same period of the prior year. The increase was primarily due to the growth in our business, which led to increased expenses including insurance, compensation due to annual salary increases, ceasing to claim COVID-19 related payroll tax credits received in the prior year period, information technology related subscriptions, legal, and other professional fees. As a percentage of revenues, general and administrative expense increased to 24% in the first quarter of 2022, as compared to 16% in the prior year period.

Other income

We had total other income of $1.0 thousand for each of the three months ended March 31, 2022 and 2021, which remained flat even though interest income decreased by $2.0 thousand from the prior year period due to a gain on sale of old equipment of $1.0 thousand, which was partially offset by credit card merchant fees. In the prior year period interest income was also partially offset by credit card merchant fees.

Net income

We had net income of $3.4 million, or $0.50 per basic share and $0.41 per diluted share, for the three months ended March 31, 2022, a decrease of $1.5 million, or 31%, compared to a net income of $4.9 million, or $0.73 per basic share and $0.60 per diluted share, for the same period of the prior year.

Liquidity and Capital Resources

We had cash and cash equivalents of $38.4 million on March 31, 2022 compared to $37.3 million at December 31, 2021, and total current liabilities of $5.8 million at March 31, 2022 compared to $4.9 million at December 31, 2021. As of March 31, 2022, we had working capital of approximately $44.7 million.

Our cash and cash equivalents are held in a variety of interest and non-interest bearing bank and money market accounts. All cash is readily available and there were no restrictions on cash. We may also hold interest-bearing instruments subject to investment guidelines allowing for holdings in U.S. government and agency securities, corporate securities, taxable municipal bonds, commercial paper and money market accounts. In addition, we may also choose to invest some of our cash resources in other entities that may have complementary technologies or product offerings, such as prepayment for product licenses for distribution in the United States, including Puerto Rico, of Insulin Insights, as well as make minority investments in other privately-held companies in new product areas similar to our investments in Mellitus Health Inc. and Neurodiagnostics Inc.

Operating activities

We generated $1.5 million of net cash from operating activities for the three months ended March 31, 2022, compared to $4.6 million of net cash from operating activities for the same period of the prior year. The change was primarily due to lower net income, and higher trade receivables, as well as higher prepaid expenses during the first quarter of 2022, which increased our working capital requirements as compared to the prior year period. Non-cash adjustments to reconcile net income to net cash from operating activities provided net cash of $1.1 million and were primarily due to stock-based compensation expense of $0.6 million, depreciation of $0.2 million, deferred tax assets of $0.2 million and loss on disposal of assets for lease of $0.1 million. Changes in operating assets and liabilities used $2.9 million of net cash. These changes in operating assets and liabilities included cash used by trade accounts receivable of $1.8 million, prepaid and other expenses of $2.0 million, partially offset by cash provided by accrued expenses of $0.9 million.

Investing activities

We used $0.3 million of net cash in investing activities for the three months ended March 31, 2022, which reflects funding of purchases of assets for lease of $0.2 million and fixed asset purchases of $0.1 million to support our growing business.

Table of Contents

We used $0.2 million of net cash in investing activities for the three months ended March 31, 2021, which reflects funding of purchases of assets for lease of $0.1 million and fixed asset purchases $0.1 million to support our growing business.

Financing activities

We used $0.1 million in net cash from financing activities during the three months ended March 31, 2022, which reflects payment of taxes withheld for stock grants of $0.1 and $0.1 million for the treasury stock acquisition, under our recently announced share purchase program, partially offset by proceeds from exercise of stock options of $0.1 million.

We generated $9,000 in net cash from financing activities during the three months ended March 31, 2021, due to proceeds from exercise of stock options.

Critical Accounting Policies and Estimates

The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities, revenues and expenses, and related disclosures in the financial statements. Critical accounting policies are those accounting policies that may be material due to the levels of subjectivity and judgment necessary to account for highly uncertain matters or the susceptibility of such matters to change, and that have a material impact on financial condition or operating performance. While we base our estimates and judgments on our experience and on various other factors that we believe to be reasonable under the circumstances, actual results may differ from these estimates under different assumptions or conditions. For a discussion of our critical accounting policies and estimates, see “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and notes to the financial statements in our Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC on March 4, 2022. There have been no material changes to these critical accounting policies and estimates through March 31, 2022 from those discussed in our Annual Report on Form 10-K for the year ended December 31, 2021.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

Not applicable.

Item 4. Controls and Procedures.

Disclosure Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure material information required to be disclosed in our reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer, our Senior Vice President, Finance and Accounting and our Vice President, Finance, as appropriate, to allow timely decisions regarding required financial disclosure. In designing and evaluating the disclosure controls and procedures, we recognized that a control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected. Management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

Under the supervision of and with the participation of our management, including our Chief Executive Officer, our Senior Vice President, Finance and Accounting and our Vice President, Finance, we evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of March 31, 2022. Based upon that evaluation, our Chief Executive Officer, our Senior Vice President, Finance and Accounting and our Vice President, Finance concluded that our disclosure controls and procedures were effective.

Changes in Internal Control over Financial Reporting

There have been no changes in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting during our first fiscal quarter ended March 31, 2022.

Table of Contents

PART II—OTHER INFORMATION

Item 1. Legal Proceedings.

None.

Item 1A. Risk Factors.

Not applicable.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

(a) Recent Sales of Unregistered Securities

None.

(b) Use of Proceeds

Not Applicable.

(c) Issuer Purchases of Equity Securities.

The following table reflects the share repurchase of our common stock.


	(a)	(b)		(c)	(d)
Period	Total number of shares (or units) purchased	Average price paid per share (or unit)		Total number of shares (or units) purchased as part of publicly announced plans or programs	Maximum number (or approximate dollar value) of shares (or units) that may yet be purchased under the plans or programs
March 15, 2022 to March 31, 2022	2,030	$	48.45	2,030	$	19,901,359

On March 14, 2022, our Board of Directors authorized a share repurchase program under which we may repurchase up to $20.0 million of our outstanding common stock. Under this program we may purchase shares on a discretionary basis from time to time through open market purchases, privately negotiated transactions or other means, including through Rule 10b5-1 trading plans or through the use of other techniques such as accelerated share repurchases. The timing and amount of any transactions will be subject to our discretion based upon market conditions and other opportunities that we may have for the use or investment of our cash balances. The repurchase program has no expiration date, does not require the purchase of any minimum number of shares and may be suspended, modified or discontinued at any time without prior notice.

Item 3. Defaults upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

None.

Table of Contents

Item 6. Exhibits.

Exh. No.		Exhibit Name
3.1		Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 of our Form 8-K filed with the Securities and Exchange Commission on November 2, 2015).
3.2		Second Amended and Restated Bylaws (incorporated by reference to Exhibit 3.1 of our Form 8-K filed with the Securities and Exchange Commission on October 26, 2021).
31.1		Rule 13a-14(a) Certification of Principal Executive Officer of Registrant
31.2		Rule 13a-14(a) Certification of Principal Financial Officer of Registrant
32.1*		Section 1350 Certification

101.INS		XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH		Inline XBRL Taxonomy Extension Schema
101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase
101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase
101.LAB		Inline XBRL Taxonomy Extension Label Linkbase
101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase
104		The cover page from Semler Scientific's Quarterly Report on Form 10-Q for the three months ended March 31, 2022 is formatted in Inline XBRL and it is contained in Exhibit 101

* These certifications are furnished to the SEC pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and are deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

May 6, 2022	SEMLER SCIENTIFIC, INC.

	By:	/s/ Douglas Murphy-Chutorian, M.D.
		Douglas Murphy-Chutorian, M.D.
		Chief Executive Officer

	By:	/s/ Andrew B. Weinstein
		Andrew B. Weinstein
		Senior Vice President, Finance and Accounting

EX-31.1 2 smlr-20220331ex311902d5a.htm EX-31.1

Exhibit 31.1

RULE 13A-14(A) CERTIFICATION

I, Douglas Murphy-Chutorian, M.D., certify that:

1. I have reviewed this quarterly report on Form 10-Q of Semler Scientific, Inc., a Delaware corporation;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a–15(e) and 15d–15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a–15(f) and 15d–15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


Dated: May 6, 2022
	/s/ Douglas Murphy-Chutorian, M.D.
	Douglas Murphy-Chutorian, M.D.
	Chief Executive Officer (Principal Executive Officer)

EX-31.2 3 smlr-20220331ex312490167.htm EX-31.2

Exhibit 31.2

RULE 13A-14(A) CERTIFICATION

I, Andrew B. Weinstein, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Semler Scientific, Inc., a Delaware corporation;

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


Dated: May 6, 2022

	/s/ Andrew B. Weinstein
	Andrew B. Weinstein Senior Vice President, Finance and Accounting
	(Principal Financial Officer)

EX-32.1 4 smlr-20220331ex3216095a4.htm EX-32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Each of the undersigned, Douglas Murphy-Chutorian, M.D., Chief Executive Officer of Semler Scientific, Inc., a Delaware corporation (the “Company”), and Andrew B. Weinstein, Senior Vice President, Finance and Accounting of the Company, does hereby certify, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of his knowledge (1) the quarterly report on Form 10-Q of the Company for the period ended March 31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and (2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


		/s/ Douglas Murphy-Chutorian, M.D.
		Name: Douglas Murphy-Chutorian, M.D.
		Title: Chief Executive Officer
		(Principal Executive Officer)
		Dated: May 6, 2022

		/s/ Andrew B. Weinstein
		Name: Andrew B. Weinstein
		Title: Senior Vice President, Finance and Accounting
		(Principal Financial Officer)
		Dated: May 6, 2022

This certification accompanies and is being “furnished” with this Report, shall not be deemed “filed” by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability under that Section and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Report, irrespective of any general incorporation language contained in such filing. A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

EX-101.SCH 5 smlr-20220331.xsd EX-101.SCH 99900 - Disclosure - Standard And Custom Axis Domain Defaults link:presentationLink link:calculationLink link:definitionLink 00100 - Statement - Condensed Statements of Income link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - Condensed Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00400 - Statement - Condensed Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 40401 - Disclosure - Assets for Lease, net (Details) link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - Property and Equipment, net (Details) link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 40901 - Disclosure - Leases - Future minimum rental payments (Details) link:presentationLink link:calculationLink link:definitionLink 40901 - Disclosure - Leases - future minimum rental payments (Details) - calc 2 link:presentationLink link:calculationLink link:definitionLink 41301 - Disclosure - Net Income Per Share, Basic and Diluted (Details) link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - Statements of Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - Inventory (Details) link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - Long-Term Investments (Details) link:presentationLink link:calculationLink link:definitionLink 40602 - Disclosure - Long-Term Investments - Investments in SYNAPS Dx (Details) link:presentationLink link:calculationLink link:definitionLink 40603 - Disclosure - Long-Term Investments - Investments in Mellitus Health Inc., (Details) link:presentationLink link:calculationLink link:definitionLink 40801 - Disclosure - Concentration of Credit Risk (Details) link:presentationLink link:calculationLink link:definitionLink 40902 - Disclosure - Leases - Lessee Arrangements (Details) link:presentationLink link:calculationLink link:definitionLink 41001 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 41101 - Disclosure - Stock Incentive Plan - Additional information (Details) link:presentationLink link:calculationLink link:definitionLink 41104 - Disclosure - Stock Incentive Plan - Stock-based compensation - Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 41302 - Disclosure - Net Income Per Share, Basic and Diluted - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00205 - Statement - Condensed Balance Sheets (Parentheticals) link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - Variably-Priced Revenue link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - Inventory link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - Assets for Lease, net link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - Property and Equipment, net link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - Long-Term Investments link:presentationLink link:calculationLink link:definitionLink 10701 - Disclosure - Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 10801 - Disclosure - Concentration of Credit Risk link:presentationLink link:calculationLink link:definitionLink 10901 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 11001 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 11101 - Disclosure - Stock Incentive Plan link:presentationLink link:calculationLink link:definitionLink 11201 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 11301 - Disclosure - Net Income Per Share, Basic and Diluted link:presentationLink link:calculationLink link:definitionLink 20102 - Disclosure - Basis of Presentation (Policies) link:presentationLink link:calculationLink link:definitionLink 30403 - Disclosure - Assets for Lease, net (Tables) link:presentationLink link:calculationLink link:definitionLink 30503 - Disclosure - Property and Equipment, net (Tables) link:presentationLink link:calculationLink link:definitionLink 30603 - Disclosure - Long-Term Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 30703 - Disclosure - Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 30903 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 31103 - Disclosure - Stock Incentive Plan (Tables) link:presentationLink link:calculationLink link:definitionLink 31303 - Disclosure - Net Income Per Share, Basic and Diluted (Tables) link:presentationLink link:calculationLink link:definitionLink 40101 - Disclosure - Basis of Presentation (Details) link:presentationLink link:calculationLink link:definitionLink 40201 - Disclosure - Variably-Priced Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 40402 - Disclosure - Assets for Lease, net - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 40502 - Disclosure - Property and Equipment, net - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 41102 - Disclosure - Stock Incentive Plan - Common Stock Repurchase (Details) link:presentationLink link:calculationLink link:definitionLink 41103 - Disclosure - Stock Incentive Plan - Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 41201 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 smlr-20220331_cal.xml EX-101.CAL EX-101.DEF 7 smlr-20220331_def.xml EX-101.DEF EX-101.LAB 8 smlr-20220331_lab.xml EX-101.LAB Document and Entity Information Document Type Document Quarterly Report Document Period End Date Document Transition Report Entity File Number Entity Registrant Name Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Address, Address Line One Entity Address, City or Town Entity Address, State or Province Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security Trading Symbol Security Exchange Name Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Shell Company Entity Common Stock, Shares Outstanding Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Period Focus Entity Central Index Key Amendment Flag Condensed Statements of Income Revenues Revenues Operating Expenses [Abstract] Operating expenses: Cost of Revenue Cost of revenues Operating Expenses Engineering and product development Selling and Marketing Expense Sales and marketing General and Administrative Expense General and administrative Costs and Expenses Total operating expenses Operating Income (Loss) Income from operations Interest Income (Expense), Net Interest income Other Nonoperating Income (Expense) Other expenses Nonoperating Income (Expense) Other income Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Pre-tax net income Income Tax Expense (Benefit) Income tax provision Net Income (Loss) Attributable to Parent Net income Net income Earnings Per Share, Basic Net income per share, basic Basic EPS (in dollars per share) Weighted Average Number of Shares Outstanding, Basic Weighted average number of shares used in computing basic income per share Basic shares (in shares) Earnings Per Share, Diluted Net income per share, diluted Diluted EPS (in dollars per share) Weighted Average Number of Shares Outstanding, Diluted Weighted average number of shares used in computing diluted income per share Diluted shares (in shares) Condensed Balance Sheets Assets [Abstract] Assets Assets, Current [Abstract] Current Assets: Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Accounts Receivable, Net, Current Trade accounts receivable, net of allowance for doubtful accounts of $71 and $61, respectively Inventory, Net Inventory Inventory balance Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Assets, Current Total current assets Property, Plant, and Equipment, Lessor Asset under Operating Lease, after Accumulated Depreciation Assets for lease, net Property, Plant, and Equipment, Excluding Lessor Asset under Operating Lease, after Accumulated Depreciation Property and equipment, net Capital assets, net Other Assets, Noncurrent Other non-current assets Long-term Investments Long-term investments Deferred Income Tax Assets, Net Long-term deferred tax assets Assets Total assets Liabilities and Equity [Abstract] Liabilities and Stockholders' Equity Liabilities, Current [Abstract] Current liabilities: Accounts Payable, Current Accounts payable Accrued Liabilities, Current Accrued expenses Total Accrued Expenses Deferred Revenue, Current Deferred revenue Other Liabilities, Current Other short-term liabilities Liabilities, Current Total current liabilities Liabilities, Noncurrent [Abstract] Long-term liabilities: Other Liabilities, Noncurrent Other long-term liabilities Liabilities, Noncurrent Total long-term liabilities Commitments and Contingencies Commitments and contingencies (Note 10) Stockholders' Equity Attributable to Parent [Abstract] Stockholders' equity: Common Stock, Value, Issued Common stock, $0.001 par value; 50,000,000 shares authorized; 6,855,168, and 6,824,380 shares issued, and 6,787,216 and 6,758,458 shares outstanding (treasury shares of 67,952 and 65,922, respectively) Additional Paid in Capital Additional paid-in capital Retained Earnings (Accumulated Deficit) Retained earnings Stockholders' Equity Attributable to Parent Balance Balance Total stockholders' equity Liabilities and Equity Total liabilities and stockholders' equity Allowance for Doubtful Accounts Receivable, Current Allowance for doubtful accounts on trade accounts receivable (in dollars) Common Stock, Par or Stated Value Per Share Common stock, par value (in dollars per share) Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Outstanding Common stock, shares outstanding Treasury Stock, Shares Treasury stock, shares Statements of Stockholders' Equity Statement [Table] Equity Components [Axis] Equity Component [Domain] Common Stock Treasury Stock Additional Paid-In Capital Retained Earnings Statement [Line Items] Increase (Decrease) in Stockholders' Equity [Roll Forward] Shares, Issued Balance (in shares) Balance (in shares) Stock Repurchased During Period, Value Treasury stock acquired Stock Repurchased During Period, Shares Treasury stock acquired (Shares) Number of share repurchased Stock Issued During Period, Value, Employee Stock Ownership Plan Employee stock grants Stock Issued During Period, Shares, Employee Stock Ownership Plan Employee stock grants (in shares) Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net Taxes paid related to net share settlement of equity awards Number of shares impact from taxes paid related to net share settlement of equity awards. Taxes Paid related to Net Share Settlement of Equity Awards, Shares Taxes paid related to net share settlement of equity awards, shares Stock Issued During Period, Value, Stock Options Exercised Stock option exercises Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Options exercised Stock option exercises (in shares) Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Stock-based compensation Condensed Statements of Cash Flows Net Cash Provided by (Used in) Operating Activities [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net income Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Reconciliation of Net Income to Net Cash Provided by Operating Activities: Depreciation, Depletion and Amortization, Nonproduction Depreciation Deferred Income Tax Expense (Benefit) Deferred tax expense Gain (Loss) on Sale of Leased Assets, Net, Operating Leases Loss on disposal of assets for lease Loss on disposal of assets for lease Provision for Doubtful Accounts Allowance for doubtful accounts Share-based Compensation Stock-based compensation expense Increase (Decrease) in Operating Capital [Abstract] Changes in Operating Assets and Liabilities: Increase (Decrease) in Accounts Receivable Trade accounts receivable Increase (Decrease) in Inventories Inventory Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other current assets Increase (Decrease) in Other Noncurrent Assets Other non-current assets Increase (Decrease) in Accounts Payable Accounts payable Increase (Decrease) in Accrued Liabilities Accrued expenses Increase (Decrease) in Other Operating Liabilities Other current and non-current liabilities Increase (Decrease) in Contract with Customer, Liability Deferred revenue Net Cash Provided by (Used in) Operating Activities Net Cash Provided by Operating Activities Net Cash Provided by (Used in) Investing Activities [Abstract] CASH FLOWS FROM INVESTING ACTIVITIES: Payments to Acquire Property, Plant, and Equipment Additions to property and equipment Payments to Acquire Equipment on Lease Purchase of assets for lease Net Cash Provided by (Used in) Investing Activities Net Cash Used in Investing Activities Net Cash Provided by (Used in) Financing Activities [Abstract] CASH FLOWS FROM FINANCING ACTIVITIES: Payment, Tax Withholding, Share-based Payment Arrangement Taxes paid related to net settlement of equity awards Taxes paid on stock awards Payments for Repurchase of Common Stock Treasury stock acquired Cost of share repurchased Proceeds from Stock Options Exercised Proceeds from exercise of stock options Net Cash Provided by (Used in) Financing Activities Net Cash (Used in) Provided by Financing Activities Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect INCREASE IN CASH Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents CASH AND CASH EQUIVALENTS, END OF PERIOD CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD Summary of Significant Accounting Policies and Estimates Basis of Accounting [Text Block] Basis of Presentation Variably-Priced Revenue Revenue from Contract with Customer [Text Block] Variably-Priced Revenue Inventory Inventory Disclosure [Text Block] Inventory Assets for Lease, net Lessee, Finance Leases [Text Block] Assets for Lease, net Property and Equipment, net Property, Plant and Equipment Disclosure [Text Block] Property and Equipment, net Long-Term Investments. Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Long-Term Investments Accrued Expenses Accrued Liabilities Disclosure [Text Block] Accrued Expenses Concentration of Credit Risk Concentration Risk Disclosure [Text Block] Concentration of Credit Risk Leases The entire disclosure of information about leases. Lease Disclosure [Text Block] Leases Commitments and Contingencies. Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Stock Option Plan Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Stock Option Plan Income Taxes Income Tax Disclosure [Text Block] Income Taxes Net Income Per Share, Basic and Diluted Earnings Per Share [Text Block] Net Income Per Share, Basic and Diluted Basis of Accounting, Policy [Policy Text Block] Basis of Presentation Disclosure of the policy for an event or transaction that is unusual in nature or infrequent in occurrence, or both. Unusual or Infrequent Items Disclosure [Policy Text Block] COVID-19 New Accounting Pronouncements, Policy [Policy Text Block] Recently Issued Accounting Pronouncements Tabular disclosure of assets for lease. Schedule of Assets for Lease [Table Text Block] Schedule of assets for lease Property, Plant and Equipment [Table Text Block] Schedule of capital assets Equity Securities without Readily Determinable Fair Value [Table Text Block] Schedule of long term investments Schedule of Accrued Liabilities [Table Text Block] Schedule of accrued expenses Lessee, Operating Lease, Liability, Maturity [Table Text Block] Schedule of future minimum rental payments required under operating leases Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Schedule of stock option activity Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block] Schedule of stock-based compensation expense Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of basic and diluted EPS Percentage of Revenue Growth. Percentage of Revenue Growth Percentage of Revenue Growth It represents as a revenue recognition from variable license fee contracts. Revenue Recognition From Variable License Fee Contracts Revenue from variable-fee licenses It represents as a revenue recognition from sales of hardware and equipment accessories. Revenue Recognition From Sales of Hardware and Equipment Accessories Revenue from sales of hardware and equipment accessories Inventory, Current [Table] Inventory [Line Items] Inventory Finance Lease, Right-of-Use Asset, before Accumulated Amortization Assets for lease Finance Lease, Right-of-Use Asset, Accumulated Amortization Less: accumulated depreciation Finance Lease, Right-of-Use Asset, after Accumulated Amortization Assets for lease, net Revenue from Contract with Customer, Excluding Assessed Tax Lease revenue Depreciation, Nonproduction Depreciation expense This element represents reduction in accumulated depreciation for returned items. Accumulated Depreciation Reduction For Returned Items Reduction to accumulated depreciation for returned items No definition available. Property and Equipment, net. Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Property, Plant, and Equipment, Excluding Lessor Asset under Operating Lease, before Accumulated Depreciation Capital assets Property, Plant, and Equipment, Excluding Lessor Asset under Operating Lease, Accumulated Depreciation Less: accumulated depreciation Depreciation Depreciation expense Equity Securities without Readily Determinable Fair Value [Table] Investment Type [Axis] Investments [Domain] EX-101.PRE 9 smlr-20220331_pre.xml EX-101.PRE XML 10 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2022	Apr. 29, 2022
Document and Entity Information
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2022
Document Transition Report	false
Entity File Number	001-36305
Entity Registrant Name	SEMLER SCIENTIFIC, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	26-1367393
Entity Address, Address Line One	2340-2348 Walsh Avenue, Suite 2344
Entity Address, City or Town	Santa Clara
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	95051
City Area Code	877
Local Phone Number	774-4211
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	SMLR
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		6,792,753
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q1
Entity Central Index Key	0001554859
Amendment Flag	false

XML 11 R2.htm IDEA: XBRL DOCUMENT

Condensed Statements of Income - USD ($) $ in Thousands	3 Months Ended
Condensed Statements of Income - USD ($) $ in Thousands	Mar. 31, 2022	Mar. 31, 2021
Condensed Statements of Income
Revenues	$ 14,016	$ 13,183
Operating expenses:
Cost of revenues	970	1,579
Engineering and product development	1,126	693
Sales and marketing	4,676	2,816
General and administrative	3,302	2,076
Total operating expenses	10,074	7,164
Income from operations	3,942	6,019
Interest income	1	3
Other expenses		(2)
Other income	1	1
Pre-tax net income	3,943	6,020
Income tax provision	583	1,143
Net income	$ 3,360	$ 4,877
Net income per share, basic	$ 0.50	$ 0.73
Weighted average number of shares used in computing basic income per share	6,777,950	6,710,990
Net income per share, diluted	$ 0.41	$ 0.60
Weighted average number of shares used in computing diluted income per share	8,116,456	8,169,375

XML 12 R3.htm IDEA: XBRL DOCUMENT

Condensed Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Current Assets:
Cash and cash equivalents	$ 38,426	$ 37,323
Trade accounts receivable, net of allowance for doubtful accounts of $71 and $61, respectively	5,416	3,619
Inventory	595	550
Prepaid expenses and other current assets	6,033	4,044
Total current assets	50,470	45,536
Assets for lease, net	1,594	1,643
Property and equipment, net	470	394
Other non-current assets	313	332
Long-term investments	821	821
Long-term deferred tax assets	1,767	1,946
Total assets	55,435	50,672
Current liabilities:
Accounts payable	375	443
Accrued expenses	4,383	3,436
Deferred revenue	980	921
Other short-term liabilities	81	80
Total current liabilities	5,819	4,880
Long-term liabilities:
Other long-term liabilities	224	245
Total long-term liabilities	224	245
Commitments and contingencies (Note 10)
Stockholders' equity:
Common stock, $0.001 par value; 50,000,000 shares authorized; 6,855,168, and 6,824,380 shares issued, and 6,787,216 and 6,758,458 shares outstanding (treasury shares of 67,952 and 65,922, respectively)	7	7
Additional paid-in capital	21,130	20,645
Retained earnings	28,255	24,895
Total stockholders' equity	49,392	45,547
Total liabilities and stockholders' equity	$ 55,435	$ 50,672

XML 13 R4.htm IDEA: XBRL DOCUMENT

Condensed Balance Sheets (Parentheticals) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Condensed Balance Sheets
Allowance for doubtful accounts on trade accounts receivable (in dollars)	$ 71	$ 61
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	6,855,168	6,824,380
Common stock, shares outstanding	6,787,216	6,758,458
Treasury stock, shares	67,952	65,922

XML 14 R5.htm IDEA: XBRL DOCUMENT

Statements of Stockholders' Equity - USD ($) $ in Thousands	Common Stock	Treasury Stock	Additional Paid-In Capital	Retained Earnings	Total
Balance at Dec. 31, 2020	$ 7		$ 22,113	$ 7,673	$ 29,793
Balance (in shares) at Dec. 31, 2020	6,725,422	(25,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Employee stock grants			537		537
Employee stock grants (in shares)	5,400
Stock option exercises			9		9
Stock option exercises (in shares)	14,984
Stock-based compensation			52		52
Net income				4,877	4,877
Balance at Mar. 31, 2021	$ 7		22,711	12,550	35,268
Balance (in shares) at Mar. 31, 2021	6,745,806	(25,000)
Balance at Dec. 31, 2021	$ 7		20,645	24,895	45,547
Balance (in shares) at Dec. 31, 2021	6,824,380	(65,922)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Treasury stock acquired			(99)		$ (99)
Treasury stock acquired (Shares)		(2,030)			(2,030)
Employee stock grants			628		$ 628
Employee stock grants (in shares)	8,406
Taxes paid related to net share settlement of equity awards			(106)		(106)
Taxes paid related to net share settlement of equity awards, shares	(1,418)
Stock option exercises			62		$ 62
Stock option exercises (in shares)	23,800				23,800
Net income				3,360	$ 3,360
Balance at Mar. 31, 2022	$ 7		$ 21,130	$ 28,255	$ 49,392
Balance (in shares) at Mar. 31, 2022	6,855,168	(67,952)

XML 15 R6.htm IDEA: XBRL DOCUMENT

Condensed Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
Condensed Statements of Cash Flows - USD ($) $ in Thousands	Mar. 31, 2022	Mar. 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$ 3,360	$ 4,877
Reconciliation of Net Income to Net Cash Provided by Operating Activities:
Depreciation	155	155
Deferred tax expense	179	626
Loss on disposal of assets for lease	74	83
Allowance for doubtful accounts	21	5
Stock-based compensation expense	628	589
Changes in Operating Assets and Liabilities:
Trade accounts receivable	(1,818)	(1,595)
Inventory	(45)	(299)
Prepaid expenses and other current assets	(1,988)	(393)
Other non-current assets	19	26
Accounts payable	(68)	(207)
Accrued expenses	946	679
Other current and non-current liabilities	(20)	(26)
Deferred revenue	59	86
Net Cash Provided by Operating Activities	1,502	4,606
CASH FLOWS FROM INVESTING ACTIVITIES:
Additions to property and equipment	(122)	(133)
Purchase of assets for lease	(134)	(83)
Net Cash Used in Investing Activities	(256)	(216)
CASH FLOWS FROM FINANCING ACTIVITIES:
Taxes paid related to net settlement of equity awards	(106)
Treasury stock acquired	(99)
Proceeds from exercise of stock options	62	9
Net Cash (Used in) Provided by Financing Activities	(143)	9
INCREASE IN CASH	1,103	4,399
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	37,323	22,079
CASH AND CASH EQUIVALENTS, END OF PERIOD	$ 38,426	$ 26,478

XML 16 R7.htm IDEA: XBRL DOCUMENT

Basis of Presentation

3 Months Ended

Mar. 31, 2022

Summary of Significant Accounting Policies and Estimates

Basis of Presentation

1. Basis of Presentation

COVID-19

Recently Issued Accounting Pronouncements

Accounting Pronouncements Recently Adopted

Accounting Pronouncements Not Yet Adopted

XML 17 R8.htm IDEA: XBRL DOCUMENT

Variably-Priced Revenue

3 Months Ended

Mar. 31, 2022

Variably-Priced Revenue

Variably-Priced Revenue

2.Variably-Priced Revenue

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI http://asc.fasb.org/topic&trid=49130388

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045

+ Details

XML 18 R9.htm IDEA: XBRL DOCUMENT

Inventory

3 Months Ended

Mar. 31, 2022

Inventory

Inventory

3. Inventory

XML 19 R10.htm IDEA: XBRL DOCUMENT

Assets for Lease, net

3 Months Ended

Mar. 31, 2022

Assets for Lease, net

Assets for Lease, net

4. Assets for Lease, net

Assets for lease consist of the following:


	March 31,		December 31,
	2022		2021
Assets for lease	$	3,210	$	3,241
Less: accumulated depreciation		(1,616)		(1,598)
Assets for lease, net	$	1,594	$	1,643

XML 20 R11.htm IDEA: XBRL DOCUMENT

Property and Equipment, net

3 Months Ended

Mar. 31, 2022

Property and Equipment, net

Property and Equipment, net

5. Property and Equipment, net

Capital assets consist of the following:


	March 31,		December 31,
	2022		2021
Capital assets	$	1,005	$	882
Less: accumulated depreciation		(535)		(488)
Capital assets, net	$	470	$	394

Depreciation expense amounted to $46 and $43 for the three months ended March 31, 2022 and 2021, respectively.

XML 21 R12.htm IDEA: XBRL DOCUMENT

Long-Term Investments

3 Months Ended

Mar. 31, 2022

Long-Term Investments.

Long-Term Investments

6.Long-Term Investments

Long term investments consist of the following for the periods presented:


	March 31,		December 31,
	2022		2021
Investments in SYNAPS Dx	$	512	$	512
Investments in Mellitus Health Inc.		309		309
Total	$	821	$	821

XML 22 R13.htm IDEA: XBRL DOCUMENT

Accrued Expenses

3 Months Ended

Mar. 31, 2022

Accrued Expenses

Accrued Expenses

7. Accrued Expenses

Accrued expenses consist of the following:


	March 31,		December 31,
	2022		2021
Compensation	$	2,522	$	1,754
Accrued Taxes		1,339		1,159
Miscellaneous Accruals		522		523
Total Accrued Expenses	$	4,383	$	3,436

XML 23 R14.htm IDEA: XBRL DOCUMENT

Concentration of Credit Risk

3 Months Ended

Mar. 31, 2022

Concentration of Credit Risk

Concentration of Credit Risk

8. Concentration of Credit Risk

XML 24 R15.htm IDEA: XBRL DOCUMENT

Leases

3 Months Ended

Mar. 31, 2022

Leases

Leases

9. Leases

The following table summarizes the future minimum rental payments required under operating leases that had initial or remaining non-cancelable lease terms greater than one year as of March 31, 2022:


	Total
2022 Remaining period	$	66
2023		90
2024		93
2025		71
Thereafter		—
Total undiscounted future minimum lease payments		320
Less: present value discount		(15)
Total lease liabilities		305
Lease expense in excess cash payment		(11)
Total ROU asset	$	294

Lease Arrangements

The Company enters into contracts with customers for the Company’s QuantaFlo product. The Company has determined these contracts meet the definition of a lease under Topic 842. The lease portfolio primarily consists of operating leases that are short-term in nature (monthly, quarterly or one year, all of which have renewal options). The Company allocates the consideration in a bundled contract with its customers based on relative standalone selling prices of the lease and non-lease components. The Company made an accounting policy election to apply the practical expedient to not separate lease and eligible non-lease components. The lease component is the predominant component and consists of fees charged for use of the equipment over the period of the arrangement. The nature of the eligible non-lease component is primarily software support. The assets associated with these leasing arrangements are separately identified in the Balance Sheet as Assets for Lease and separately disclosed in Note 4 to the Unaudited Condensed Financial Statements.

XML 25 R16.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

3 Months Ended

Mar. 31, 2022

Commitments and Contingencies.

Commitments and Contingencies

10. Commitments and Contingencies

Facilities Leases

Indemnification Obligations

401(K) Plan

Effective January 1, 2022, the Company started to match 50% of employee’s 401(k) deferral up to a maximum of 6% of the employee’s eligible earnings.

Other

Litigation

XML 26 R17.htm IDEA: XBRL DOCUMENT

Stock Incentive Plan

3 Months Ended

Mar. 31, 2022

Stock Option Plan

Stock Option Plan

11. Stock Incentive Plan

Treasury Stock Acquired

Stock Awards

Stock Options


	Options Outstanding
				Weighted
				Average
	Number of	Weighted		Remaining	Aggregate
	Stock Options	Average		Contractual	Intrinsic Value
	Outstanding	Exercise Price		Term (In Years)	(In Thousands)
Balance, December 31, 2021	1,356,245	$	3.30	3.97	$	119,830
Options exercised	(23,800)		2.58	—		—
Balance, March 31, 2022	1,332,445	$	3.31	3.73	$	61,627
Exercisable as of March 31, 2022	1,332,445	$	3.31	3.73	$	61,627

There were no options granted during the three months ended March 31, 2022 or 2021.

The Company has recorded an expense of $628 and $589 as it relates to stock-based compensation for the three months ended March 31, 2022 and 2021, respectively:


	Three months ended March 31,
	2022		2021
Cost of Revenues	$	—	$	—
Engineering and Product Development		45		32
Sales and Marketing		172		105
General and Administrative		411		452
Total	$	628	$	589

XML 27 R18.htm IDEA: XBRL DOCUMENT

Income Taxes

3 Months Ended

Mar. 31, 2022

Income Taxes

Income Taxes

12. Income Taxes

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI http://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

XML 28 R19.htm IDEA: XBRL DOCUMENT

Net Income Per Share, Basic and Diluted

3 Months Ended

Mar. 31, 2022

Net Income Per Share, Basic and Diluted

Net Income Per Share, Basic and Diluted

13. Net Income Per Share, Basic and Diluted

Basic and diluted EPS is calculated as follows:


	Three months ended March 31,
	2022					2021
	Shares	Net Income		EPS		Shares	Net Income		EPS
Basic	6,777,950	$	3,360	$	0.50	6,710,990	$	4,877	$	0.73
Common stock warrants	71,839		—			73,497		—
Common stock options	1,266,667		—			1,384,888		—
Diluted	8,116,456	$	3,360	$	0.41	8,169,375	$	4,877	$	0.60

The were no weighted average shares outstanding of common stock equivalents excluded from the computation of diluted net income per share for the three months ended March 31, 2022 and 2021.

XML 29 R20.htm IDEA: XBRL DOCUMENT

Basis of Presentation (Policies)	3 Months Ended
Basis of Presentation (Policies)	Mar. 31, 2022
Summary of Significant Accounting Policies and Estimates
Basis of Presentation	Semler Scientific, Inc., a Delaware corporation (“Semler” or “the Company”), prepared the unaudited interim financial statements included in this report in accordance with United States generally accepted accounting principles (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. As such, the information included in this quarterly report on Form 10-Q should be read in conjunction with the audited financial statements and notes thereto included in the Company’s annual report on Form 10-K for the year ended December 31, 2021 filed with the SEC on March 4, 2022 (the “Annual Report”). In the opinion of management, these financial statements include all adjustments (consisting of normal recurring adjustments) necessary for a fair statement of the financial position, results of operations and cash flows for the periods presented. The results of operations for the interim periods shown in this report are not necessarily indicative of the results that may be expected for any future period, including the full year.
COVID-19	COVID-19 In 2021, variable fee license revenues (fee-per-test), which grew strongly in the first half of 2021, decreased subsequently in the second half of 2021. The Company believes this new pattern in the home-testing market is due to a COVID-19 related timing change in the behavior of insurance plans when ordering QuantaFlo testing from its health risk assessment customers. The first quarter results of 2022 support this pattern of testing earlier in the year, as the home-testing market had higher volume of sequential revenues, which grew 67% compared to the fourth quarter of 2021. However, the Company does not know if this newly observed pattern will continue in 2022 or in future years. The Company believes that the relatively slower growth in the period-over-period comparison, was due to the COVID-19 pandemic. The Company's staff and many of its customers and prospects experienced a higher-than-normal rate of employee absence due to illness, which can have a slowing effect on its sales cycle. The extent and duration of the pandemic is unknown, and the future effects on the Company’s business are uncertain and difficult to predict. The Company is continuing to monitor the events and circumstances surrounding the COVID-19 pandemic, which may require adjustments to the Company’s estimates and assumptions in the future.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements Accounting Pronouncements Recently Adopted In May 2021, the financial Accounting Standards Board(“FASB”) issued Accounting Standards Update (“ASU”) No. 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40) Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. This update provides guidance for a modification or an exchange of a freestanding equity-classified written call option that is not within the scope of another Topic. This update is effective for the Company’s fiscal years beginning after December 15, 2021. The Company adopted this ASU prospectively effective January 1, 2022 and determined that the adoption of this new accounting standard did not have a material impact on its financial statements. In July 2021, the FASB issued ASU No. 2021-05, Leases (Topic 842): Lessors—Certain Leases with Variable Lease Payments. This update addresses stakeholders’ concerns by amending the lease classification requirements for lessors to align them with practice under Topic 840. Lessors should classify and account for a lease with variable lease payments that do not depend on a reference index or a rate as an operating lease if both of the following criteria are met: i) The lease would have been classified as a sales-type lease or a direct financing lease in accordance with the classification criteria in paragraphs 842-10-25-2 through 25-3, ii) the lessor would have otherwise recognized a day-one loss. This update is effective for the Company’s fiscal years beginning after December 15, 2021. The Company adopted this ASU prospectively to the leases that commence or modified on or after January 1, 2022 and determined that the adoption of this new accounting standard did not have a material impact on its financial statements. In November 2021, the FASB issued ASU No. 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance. This ASU increases the transparency of government assistance to include the disclosure of (1) the types of assistance, (2) an entity's accounting for the assistance, and (3) the effect of the assistance on an entity's financial statements. The guidance in ASU 2021-10 is effective for financial statements of all entities, including private companies, for annual periods beginning after December 15, 2021, with early application permitted. Entities are required to provide the new disclosures prospectively for all transactions with a government entity that are accounted for under either a grant or a contribution accounting model and are reflected in the financial statements at the date of initially applying the new amendments, and to new transactions entered into after that date. The Company adopted ASU No. 2021-10 prospectively to the government assistance received after January 1, 2022 and determined that the adoption of this new accounting standard did not have a material impact on its financial statements. Accounting Pronouncements Not Yet Adopted In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“Topic 326”). This ASU requires timelier recording of credit losses on loans and other financial instruments held. Instead of reserves based on a current probability analysis, Topic 326 requires the measurement of all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. All organizations will now use forward-looking information to better inform their credit loss estimates. Topic 326 requires enhanced disclosures regarding significant estimates and judgments used in estimating credit losses, as well as the credit quality and underwriting standards of an organization’s portfolio. These disclosures include qualitative and quantitative requirements that provide information about the amounts recorded in the financial statements. In addition, Topic 326 amends the accounting for credit losses on available-for-sale debt securities and purchased financial assets with credit deterioration. In April 2019, the FASB issued ASU No. 2019-04, Codification Improvements to Topic 326 Financial Instruments—Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments, to introduce amendments which will affect the recognition and measurement of financial instruments, including derivatives and hedging. In May 2019, the FASB issued ASU No. 2019-05, Financial Instruments – Credit Losses (Topic 326); Targeted Transition Relief. The amendments in this ASU provide entities that have certain instruments within the scope of Subtopic 326-20 with an option to irrevocably elect the fair value option in Subtopic 825-10, applied on an instrument-by-instrument basis for eligible instruments upon adoption of Topic 326. This standard and related amendments are effective for the Company’s fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The Company will adopt the new standard in the first quarter of fiscal year 2023. The Company is evaluating the effect of adopting this new accounting guidance but does not expect adoption will have a material impact on the Company's financial statements. In March 2020, FASB issued ASU No. 2020-03, Codification Improvements to Financial Instruments. This ASU improves and clarifies various financial instruments topics, including the current expected credit losses standard issued in 2016 (ASU No. 2016-13). The ASU includes seven different issues that describe the areas of improvement and the related amendments to GAAP, intended to make the standards easier to understand and apply by eliminating inconsistencies and providing clarifications. The amendments have different effective dates. The issues 1-5 are conforming amendments, which are effective upon issuance of this final update. The Company determined that issues 1-5 have no impact on its financials. The amendments related to issue 6 and 7 effect ASU No. 2016-13, Financial instruments – credit losses (Topic 326): measurement of credit losses on financial statements. Effective dates of issue 6 and 7 are the same as the effective date of ASU No. 2016-13. The Company will adopt the new standard in the first quarter of fiscal year 2023.The Company is evaluating the effect of adopting this new accounting guidance, but does not expect adoption will have a material impact on the Company's financial statements. In October 2021, the FASB issued ASU No.2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. This ASU improves the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in practice and inconsistency related to recognition of an acquired contract liability and payment terms and their effect on subsequent revenue recognized by the acquirer. For public business entities, this guidance will be effective for fiscal years beginning after December 15, 2022 and for interim periods within those fiscal years. For all other entities, this guidance is effective for fiscal years beginning after December 15, 2023 and for interim periods within those fiscal years. This ASU should be applied prospectively to all business combinations in the year of adoption. The Company will adopt the new standard in the first quarter of fiscal year 2023. The Company does not expect the adoption of this standard will have a material impact on its financial statements.

XML 30 R21.htm IDEA: XBRL DOCUMENT

Assets for Lease, net (Tables)

3 Months Ended

Mar. 31, 2022

Assets for Lease, net

Schedule of assets for lease


	March 31,		December 31,
	2022		2021
Assets for lease	$	3,210	$	3,241
Less: accumulated depreciation		(1,616)		(1,598)
Assets for lease, net	$	1,594	$	1,643

XML 31 R22.htm IDEA: XBRL DOCUMENT

Property and Equipment, net (Tables)

3 Months Ended

Mar. 31, 2022

Property and Equipment, net

Schedule of capital assets


	March 31,		December 31,
	2022		2021
Capital assets	$	1,005	$	882
Less: accumulated depreciation		(535)		(488)
Capital assets, net	$	470	$	394

XML 32 R23.htm IDEA: XBRL DOCUMENT

Long-Term Investments (Tables)

3 Months Ended

Mar. 31, 2022

Long-Term Investments.

Schedule of long term investments


	March 31,		December 31,
	2022		2021
Investments in SYNAPS Dx	$	512	$	512
Investments in Mellitus Health Inc.		309		309
Total	$	821	$	821

XML 33 R24.htm IDEA: XBRL DOCUMENT

Accrued Expenses (Tables)

3 Months Ended

Mar. 31, 2022

Accrued Expenses

Schedule of accrued expenses


	March 31,		December 31,
	2022		2021
Compensation	$	2,522	$	1,754
Accrued Taxes		1,339		1,159
Miscellaneous Accruals		522		523
Total Accrued Expenses	$	4,383	$	3,436

XML 34 R25.htm IDEA: XBRL DOCUMENT

Leases (Tables)

3 Months Ended

Mar. 31, 2022

Leases

Schedule of future minimum rental payments required under operating leases


	Total
2022 Remaining period	$	66
2023		90
2024		93
2025		71
Thereafter		—
Total undiscounted future minimum lease payments		320
Less: present value discount		(15)
Total lease liabilities		305
Lease expense in excess cash payment		(11)
Total ROU asset	$	294

XML 35 R26.htm IDEA: XBRL DOCUMENT

Stock Incentive Plan (Tables)

3 Months Ended

Mar. 31, 2022

Stock Option Plan

Schedule of stock option activity


	Options Outstanding
				Weighted
				Average
	Number of	Weighted		Remaining	Aggregate
	Stock Options	Average		Contractual	Intrinsic Value
	Outstanding	Exercise Price		Term (In Years)	(In Thousands)
Balance, December 31, 2021	1,356,245	$	3.30	3.97	$	119,830
Options exercised	(23,800)		2.58	—		—
Balance, March 31, 2022	1,332,445	$	3.31	3.73	$	61,627
Exercisable as of March 31, 2022	1,332,445	$	3.31	3.73	$	61,627

Schedule of stock-based compensation expense


	Three months ended March 31,
	2022		2021
Cost of Revenues	$	—	$	—
Engineering and Product Development		45		32
Sales and Marketing		172		105
General and Administrative		411		452
Total	$	628	$	589

XML 36 R27.htm IDEA: XBRL DOCUMENT

Net Income Per Share, Basic and Diluted (Tables)

3 Months Ended

Mar. 31, 2022

Net Income Per Share, Basic and Diluted

Schedule of basic and diluted EPS


	Three months ended March 31,
	2022					2021
	Shares	Net Income		EPS		Shares	Net Income		EPS
Basic	6,777,950	$	3,360	$	0.50	6,710,990	$	4,877	$	0.73
Common stock warrants	71,839		—			73,497		—
Common stock options	1,266,667		—			1,384,888		—
Diluted	8,116,456	$	3,360	$	0.41	8,169,375	$	4,877	$	0.60

XML 37 R28.htm IDEA: XBRL DOCUMENT

Basis of Presentation (Details)	3 Months Ended
Basis of Presentation (Details)	Mar. 31, 2022
Summary of Significant Accounting Policies and Estimates
Percentage of Revenue Growth	67.00%

XML 38 R29.htm IDEA: XBRL DOCUMENT

Variably-Priced Revenue (Details) - USD ($) $ in Thousands	3 Months Ended
Variably-Priced Revenue (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Mar. 31, 2021
Variably-Priced Revenue
Revenue from variable-fee licenses	$ 5,842	$ 5,658
Revenue from sales of hardware and equipment accessories	$ 285	$ 331

XML 39 R30.htm IDEA: XBRL DOCUMENT

Inventory (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Inventory
Inventory balance	$ 595	$ 550

XML 40 R31.htm IDEA: XBRL DOCUMENT

Assets for Lease, net (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Assets for Lease, net
Assets for lease	$ 3,210	$ 3,241
Less: accumulated depreciation	(1,616)	(1,598)
Assets for lease, net	$ 1,594	$ 1,643

XML 41 R32.htm IDEA: XBRL DOCUMENT

Assets for Lease, net - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Assets for Lease, net
Lease revenue	$ 7,889	$ 7,194
Depreciation expense	108	113
Reduction to accumulated depreciation for returned items	90	141
Loss on disposal of assets for lease	$ (74)	$ (83)

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

XML 42 R33.htm IDEA: XBRL DOCUMENT

Property and Equipment, net (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Property and Equipment, net.
Capital assets	$ 1,005	$ 882
Less: accumulated depreciation	(535)	(488)
Capital assets, net	$ 470	$ 394

XML 43 R34.htm IDEA: XBRL DOCUMENT

Property and Equipment, net - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Property and Equipment, net
Depreciation expense	$ 46	$ 43

XML 44 R35.htm IDEA: XBRL DOCUMENT

Long-Term Investments (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Equity Securities without Readily Determinable Fair Value [Line Items]
Long-term investments	$ 821	$ 821
Investments in SYNAPS Dx
Equity Securities without Readily Determinable Fair Value [Line Items]
Long-term investments	512	512
Investments in Mellitus Health Inc.
Equity Securities without Readily Determinable Fair Value [Line Items]
Long-term investments	$ 309	$ 309

XML 45 R36.htm IDEA: XBRL DOCUMENT

Long-Term Investments - Investments in SYNAPS Dx (Details) - Promissory note from SYNAPS Dx - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2020
Equity Securities without Readily Determinable Fair Value [Line Items]
Principal amount			$ 500
Conversion value	$ 512	$ 512

XML 46 R37.htm IDEA: XBRL DOCUMENT

Long-Term Investments - Investments in Mellitus Health Inc., (Details) - USD ($) $ in Thousands	1 Months Ended		3 Months Ended	12 Months Ended
	Apr. 30, 2021	Oct. 31, 2020	Mar. 31, 2022	Dec. 31, 2021
Equity Securities without Readily Determinable Fair Value [Line Items]
Impairment			$ 0	$ 0
Mellitus
Equity Securities without Readily Determinable Fair Value [Line Items]
Purchase of product licenses	$ 2,000
Renewal term of purchase agreement (in years)	1 year
Mellitus \| Prepaid expenses and other current assets
Equity Securities without Readily Determinable Fair Value [Line Items]
Prepaid license purchases	$ 2,000
Investments in Mellitus Health Inc.
Equity Securities without Readily Determinable Fair Value [Line Items]
Shares purchased		250
First Promissory note from Mellitus
Equity Securities without Readily Determinable Fair Value [Line Items]
Purchase price		$ 59
Principal amount		$ 50
Conversion value			$ 309	$ 309

XML 47 R38.htm IDEA: XBRL DOCUMENT

Accrued Expenses (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Accrued Expenses
Compensation	$ 2,522	$ 1,754
Accrued Taxes	1,339	1,159
Miscellaneous Accruals	522	523
Total Accrued Expenses	$ 4,383	$ 3,436

XML 48 R39.htm IDEA: XBRL DOCUMENT

Concentration of Credit Risk (Details)	3 Months Ended		12 Months Ended
Concentration of Credit Risk (Details)	Mar. 31, 2022 customer item	Mar. 31, 2021 customer	Dec. 31, 2021 customer item
Customer concentration risk \| Revenue
Concentration of Credit Risk
Number of customers	2	2
Customer concentration risk \| Revenue \| Customer one
Concentration of Credit Risk
Concentration risk percentage	35.40%	38.30%
Customer concentration risk \| Revenue \| Customer two
Concentration of Credit Risk
Concentration risk percentage	31.70%	30.40%
Customer concentration risk \| Accounts receivable
Concentration of Credit Risk
Number of customers	3		3
Customer concentration risk \| Accounts receivable \| Customer one
Concentration of Credit Risk
Concentration risk percentage	30.20%		21.90%
Customer concentration risk \| Accounts receivable \| Customer two
Concentration of Credit Risk
Concentration risk percentage	26.80%		20.10%
Customer concentration risk \| Accounts receivable \| Customer three
Concentration of Credit Risk
Concentration risk percentage	22.50%		16.60%
Vendor concentration risk \| Accounts payable
Concentration of Credit Risk
Number of vendors \| item	3		1
Vendor concentration risk \| Accounts payable \| Vendor one
Concentration of Credit Risk
Concentration risk percentage	18.00%		14.00%
Vendor concentration risk \| Accounts payable \| Vendor two
Concentration of Credit Risk
Concentration risk percentage	17.10%
Vendor concentration risk \| Accounts payable \| Vendor three
Concentration of Credit Risk
Concentration risk percentage	10.60%

XML 49 R40.htm IDEA: XBRL DOCUMENT

Leases - Future minimum rental payments (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Leases
2022 Remaining period	$ 66
2023	90
2024	93
2025	71
Total undiscounted future minimum lease payments	320
Less: present value discount	(15)
Total lease liabilities	305
Lease expense in excess cash payment	(11)
Total ROU asset	$ 294	$ 314

XML 50 R41.htm IDEA: XBRL DOCUMENT

Leases - Lessee Arrangements (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Jul. 31, 2020
Leases
Lease agreement term				61 months
Remaining lease term	3 years 6 months
Options to renew	false
Lease expenses	$ 22	$ 44
ROU asset	$ 294		$ 314
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]	Other Assets, Noncurrent		Other Assets, Noncurrent
Current lease liabilities	$ 81		$ 80
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]	Other Liabilities, Current		Other Liabilities, Current
Noncurrent lease liabilities	$ 224		$ 245
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]	Other Liabilities, Noncurrent		Other Liabilities, Noncurrent

XML 51 R42.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Details) - USD ($) $ in Thousands	Jan. 01, 2022	Dec. 31, 2021	Jul. 31, 2020
Defined Contribution Plan Disclosure [Line Items]
Lease agreement term			61 months
Income Taxes Receivable, Cares Act		$ 1,240
Employer matching contribution	50.00%
Maximum
Defined Contribution Plan Disclosure [Line Items]
Maximum contribution of percentage of employee's eligible earnings	6.00%

XML 52 R43.htm IDEA: XBRL DOCUMENT

Stock Incentive Plan - Additional information (Details) $ in Thousands	1 Months Ended	3 Months Ended
	Oct. 31, 2015 shares	Mar. 31, 2022 USD ($) item shares	Mar. 31, 2021 USD ($) item shares	Jan. 01, 2022 shares	Sep. 30, 2014 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense \| $		$ 628	$ 589
Number of stock option granted		0	0
Aggregate of shares granted fully vested stock awards		8,406	5,400
Number of non-employees \| item		1	1
Fair value of stock awards on grant date \| $		$ 628	$ 537
Taxes paid on stock awards \| $		$ 106
Net shares issued after deducting taxes paid on granted shares		6,988
2014 Stock Incentive Plan \| Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares available for future stock-based compensation grants		1,479,103
Maximum number of shares issued pursuant to awards granted under plan		3,315,203			450,000
Maximum term of stock option grants		10 years
Number of share reserve approved	1,500,000
Number of shares increase in Share Reserve				270,338
Percentage of shares reserve increased	4.00%
Total number of unvested shares		3,315,203
2007 Key Person Stock Option Plan \| Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares available for future stock-based compensation grants		0

XML 53 R44.htm IDEA: XBRL DOCUMENT

Stock Incentive Plan - Common Stock Repurchase (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 14, 2022
Stock Option Plan
Shares authorized under Share Repurchase Program		$ 20,000
Number of share repurchased	2,030
Cost of share repurchased	$ 99

XML 54 R45.htm IDEA: XBRL DOCUMENT

Stock Incentive Plan - Stock Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Number of Stock Options Outstanding
Balance, Beginning	1,356,245
Options exercised	(23,800)
Balance, Ending	1,332,445	1,356,245
Exercisable, Ending	1,332,445
Weighted Average Exercise Price
Balance, Beginning	$ 3.30
Options exercised	2.58
Balance, Ending	3.31	$ 3.30
Exercisable, Ending	$ 3.31
Weighted Average Remaining Contractual Term, Options Outstanding (in years)	3 years 8 months 23 days	3 years 11 months 19 days
Weighted Average Remaining Contractual Term, Options Exercisable (in years)	3 years 8 months 23 days
Aggregate Intrinsic Value, Options Outstanding	$ 61,627	$ 119,830
Aggregate Intrinsic Value, Options Exercisable	$ 61,627

XML 55 R46.htm IDEA: XBRL DOCUMENT

Stock Incentive Plan - Stock-based compensation - Expenses (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 628	$ 589
Engineering and Product Development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	45	32
Sales and Marketing
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	172	105
General and Administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 411	$ 452

XML 56 R47.htm IDEA: XBRL DOCUMENT

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
Income Taxes (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Income Taxes
Income tax provision	$ 583	$ 1,143
Effective income tax rate	14.79%	18.99%
Federal statutory rate	21.00%
Unrecognized tax benefits	$ 419		$ 476
Interest and penalty expenses related to uncertain tax positions	$ 0		$ 0

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References + Details

XML 57 R48.htm IDEA: XBRL DOCUMENT

Net Income Per Share, Basic and Diluted (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Net Income Per Share, Basic and Diluted
Basic shares (in shares)	6,777,950	6,710,990
Common stock warrants (in shares)	71,839	73,497
Common stock options (in shares)	1,266,667	1,384,888
Diluted shares (in shares)	8,116,456	8,169,375
Net Income - Basic EPS	$ 3,360	$ 4,877
Net Income - Common stock warrants	0	0
Net Income - Common stock options	0	0
Net Income - Diluted EPS	$ 3,360	$ 4,877
Basic EPS (in dollars per share)	$ 0.50	$ 0.73
Diluted EPS (in dollars per share)	$ 0.41	$ 0.60

XML 58 R49.htm IDEA: XBRL DOCUMENT

Net Income Per Share, Basic and Diluted - Additional Information (Details) - shares	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Net Income Per Share, Basic and Diluted
Weighted average shares outstanding excluded from the computation of diluted net income per share	0	0

XML 59 smlr-20220331x10q_htm.xml IDEA: XBRL DOCUMENT 0001554859 2022-03-14 0001554859 us-gaap:TreasuryStockMember 2022-01-01 2022-03-31 0001554859 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001554859 us-gaap:RetainedEarningsMember 2022-03-31 0001554859 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001554859 us-gaap:RetainedEarningsMember 2021-12-31 0001554859 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001554859 us-gaap:RetainedEarningsMember 2021-03-31 0001554859 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001554859 us-gaap:RetainedEarningsMember 2020-12-31 0001554859 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001554859 us-gaap:TreasuryStockMember 2022-03-31 0001554859 us-gaap:CommonStockMember 2022-03-31 0001554859 us-gaap:TreasuryStockMember 2021-12-31 0001554859 us-gaap:CommonStockMember 2021-12-31 0001554859 us-gaap:TreasuryStockMember 2021-03-31 0001554859 us-gaap:CommonStockMember 2021-03-31 0001554859 us-gaap:TreasuryStockMember 2020-12-31 0001554859 us-gaap:CommonStockMember 2020-12-31 0001554859 us-gaap:EmployeeStockOptionMember smlr:KeyPersonStockOptionPlan2007Member 2022-03-31 0001554859 us-gaap:EmployeeStockOptionMember smlr:StockIncentivePlan2014Member 2022-03-31 0001554859 us-gaap:EmployeeStockOptionMember smlr:StockIncentivePlan2014Member 2014-09-30 0001554859 us-gaap:EmployeeStockOptionMember smlr:StockIncentivePlan2014Member 2022-01-01 2022-03-31 0001554859 smlr:PrivateCompanyThreeMember 2021-04-30 0001554859 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001554859 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001554859 smlr:InvestmentInPrivateCompanyTwoMember 2022-03-31 0001554859 smlr:InvestmentInPrivateCompanyThreeMember 2022-03-31 0001554859 smlr:InvestmentInPrivateCompanyTwoMember 2021-12-31 0001554859 smlr:InvestmentInPrivateCompanyThreeMember 2021-12-31 0001554859 2020-07-31 0001554859 2021-01-01 2021-12-31 0001554859 2022-01-01 2022-01-01 0001554859 srt:MaximumMember 2022-01-01 2022-01-01 0001554859 smlr:PromissoryNoteFromPrivateCompanyTwoMember 2020-09-30 0001554859 smlr:PromissoryNoteFromPrivateCompanyTwoMember 2022-01-01 2022-03-31 0001554859 smlr:ConvertiblePromissoryNoteOneFromPrivateCompanyThreeMember 2022-01-01 2022-03-31 0001554859 smlr:PromissoryNoteFromPrivateCompanyTwoMember 2021-01-01 2021-12-31 0001554859 smlr:ConvertiblePromissoryNoteOneFromPrivateCompanyThreeMember 2021-01-01 2021-12-31 0001554859 smlr:VendorTwoMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2022-01-01 2022-03-31 0001554859 smlr:VendorThreeMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2022-01-01 2022-03-31 0001554859 smlr:VendorOneMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2022-01-01 2022-03-31 0001554859 smlr:CustomerTwoConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-03-31 0001554859 smlr:CustomerTwoConcentrationRiskMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-03-31 0001554859 smlr:CustomerThreeConcentrationRiskMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-03-31 0001554859 smlr:CustomerOneConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-03-31 0001554859 smlr:CustomerOneConcentrationRiskMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-03-31 0001554859 smlr:VendorOneMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2021-01-01 2021-12-31 0001554859 smlr:CustomerTwoConcentrationRiskMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001554859 smlr:CustomerThreeConcentrationRiskMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001554859 smlr:CustomerOneConcentrationRiskMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001554859 smlr:CustomerTwoConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-03-31 0001554859 smlr:CustomerOneConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-03-31 0001554859 us-gaap:EmployeeStockOptionMember smlr:StockIncentivePlan2014Member 2022-01-01 0001554859 2021-03-31 0001554859 2020-12-31 0001554859 us-gaap:SellingAndMarketingExpenseMember 2022-01-01 2022-03-31 0001554859 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-03-31 0001554859 smlr:EngineeringAndProductDevelopmentMember 2022-01-01 2022-03-31 0001554859 us-gaap:SellingAndMarketingExpenseMember 2021-01-01 2021-03-31 0001554859 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-03-31 0001554859 smlr:EngineeringAndProductDevelopmentMember 2021-01-01 2021-03-31 0001554859 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001554859 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001554859 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001554859 smlr:PrivateCompanyThreeMember 2021-04-01 2021-04-30 0001554859 smlr:PrivateCompanyThreeMember us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2021-04-30 0001554859 us-gaap:EmployeeStockOptionMember smlr:StockIncentivePlan2014Member 2015-10-01 2015-10-31 0001554859 2022-03-31 0001554859 smlr:InvestmentInPrivateCompanyThreeMember 2020-10-01 2020-10-31 0001554859 2021-12-31 0001554859 smlr:ConvertiblePromissoryNoteOneFromPrivateCompanyThreeMember 2020-10-31 0001554859 us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2022-01-01 2022-03-31 0001554859 us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2021-01-01 2021-12-31 0001554859 us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-03-31 0001554859 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-03-31 0001554859 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001554859 us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-03-31 0001554859 2021-01-01 2021-03-31 0001554859 2022-04-29 0001554859 2022-01-01 2022-03-31 shares iso4217:USD smlr:customer smlr:item pure iso4217:USD shares

0001554859 --12-31 2022 Q1 false

P61M

http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent

http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent

http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent

http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent

http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent

http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent

P3Y6M

10-Q true 2022-03-31 false 001-36305 SEMLER SCIENTIFIC, INC. DE 26-1367393 2340-2348 Walsh Avenue, Suite 2344 Santa Clara CA 95051 877 774-4211 Common Stock, par value $0.001 per share SMLR NASDAQ Yes Yes Non-accelerated Filer true false false 6792753

14016000

13183000

970000

1579000

1126000

693000

4676000

2816000

3302000

2076000

10074000

7164000

3942000

6019000

1000

3000

-2000

1000

3943000

6020000

583000

1143000

3360000

4877000

0.50

0.73

6777950

6710990

0.41

0.60

8116456

8169375

38426000

37323000

71000

61000

5416000

3619000

595000

550000

6033000

4044000

50470000

45536000

1594000

1643000

470000

394000

313000

332000

821000

1767000

1946000

55435000

50672000

375000

443000

4383000

3436000

980000

921000

81000

80000

5819000

4880000

224000

245000

224000

245000

0.001

50000000

6855168

6824380

6787216

6758458

67952

65922

7000

21130000

20645000

28255000

24895000

49392000

45547000

55435000

50672000

6725422

7000

-25000

22113000

7673000

29793000

5400

537000

14984

9000

52000

4877000

6745806

7000

-25000

22711000

12550000

35268000

6824380

7000

-65922

20645000

24895000

45547000

2030

99000

8406

628000

-1418

-106000

23800

62000

3360000

6855168

7000

-67952

21130000

28255000

49392000

3360000

4877000

155000

179000

626000

-74000

-83000

21000

5000

628000

589000

1818000

1595000

45000

299000

1988000

393000

-19000

-26000

-68000

-207000

946000

679000

-20000

-26000

59000

86000

1502000

4606000

122000

133000

134000

83000

-256000

-216000

106000

99000

62000

9000

-143000

9000

1103000

4399000

37323000

22079000

38426000

26478000

1. Basis of PresentationSemler Scientific, Inc., a Delaware corporation (“Semler” or “the Company”), prepared the unaudited interim financial statements included in this report in accordance with United States generally accepted accounting principles (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. As such, the information included in this quarterly report on Form 10-Q should be read in conjunction with the audited financial statements and notes thereto included in the Company’s annual report on Form 10-K for the year ended December 31, 2021 filed with the SEC on March 4, 2022 (the “Annual Report”). In the opinion of management, these financial statements include all adjustments (consisting of normal recurring adjustments) necessary for a fair statement of the financial position, results of operations and cash flows for the periods presented. The results of operations for the interim periods shown in this report are not necessarily indicative of the results that may be expected for any future period, including the full year. COVID-19In 2021, variable fee license revenues (fee-per-test), which grew strongly in the first half of 2021, decreased subsequently in the second half of 2021. The Company believes this new pattern in the home-testing market is due to a COVID-19 related timing change in the behavior of insurance plans when ordering QuantaFlo testing from its health risk assessment customers.The first quarter results of 2022 support this pattern of testing earlier in the year, as the home-testing market had higher volume of sequential revenues, which grew 67% compared to the fourth quarter of 2021. However, the Company does not know if this newly observed pattern will continue in 2022 or in future years.The Company believes that the relatively slower growth in the period-over-period comparison, was due to the COVID-19 pandemic. The Company's staff and many of its customers and prospects experienced a higher-than-normal rate of employee absence due to illness, which can have a slowing effect on its sales cycle.The extent and duration of the pandemic is unknown, and the future effects on the Company’s business are uncertain and difficult to predict. The Company is continuing to monitor the events and circumstances surrounding the COVID-19 pandemic, which may require adjustments to the Company’s estimates and assumptions in the future.Recently Issued Accounting PronouncementsAccounting Pronouncements Recently AdoptedIn May 2021, the financial Accounting Standards Board(“FASB”) issued Accounting Standards Update (“ASU”) No. 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40) Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. This update provides guidance for a modification or an exchange of a freestanding equity-classified written call option that is not within the scope of another Topic. This update is effective for the Company’s fiscal years beginning after December 15, 2021. The Company adopted this ASU prospectively effective January 1, 2022 and determined that the adoption of this new accounting standard did not have a material impact on its financial statements.In July 2021, the FASB issued ASU No. 2021-05, Leases (Topic 842): Lessors—Certain Leases with Variable Lease Payments. This update addresses stakeholders’ concerns by amending the lease classification requirements for lessors to align them with practice under Topic 840. Lessors should classify and account for a lease with variable lease payments that do not depend on a reference index or a rate as an operating lease if both of the following criteria are met: i) The lease would have been classified as a sales-type lease or a direct financing lease in accordance with the classification criteria in paragraphs 842-10-25-2 through 25-3, ii) the lessor would have otherwise recognized a day-one loss. This update is effective for the Company’s fiscal years beginning after December 15, 2021. The Company adopted this ASU prospectively to the leases that commence or modified on or after January 1, 2022 and determined that the adoption of this new accounting standard did not have a material impact on its financial statements. In November 2021, the FASB issued ASU No. 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance. This ASU increases the transparency of government assistance to include the disclosure of (1) the types of assistance, (2) an entity's accounting for the assistance, and (3) the effect of the assistance on an entity's financial statements. The guidance in ASU 2021-10 is effective for financial statements of all entities, including private companies, for annual periods beginning after December 15, 2021, with early application permitted. Entities are required to provide the new disclosures prospectively for all transactions with a government entity that are accounted for under either a grant or a contribution accounting model and are reflected in the financial statements at the date of initially applying the new amendments, and to new transactions entered into after that date. The Company adopted ASU No. 2021-10 prospectively to the government assistance received after January 1, 2022 and determined that the adoption of this new accounting standard did not have a material impact on its financial statements.Accounting Pronouncements Not Yet AdoptedIn June 2016, the FASB issued ASU No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“Topic 326”). This ASU requires timelier recording of credit losses on loans and other financial instruments held. Instead of reserves based on a current probability analysis, Topic 326 requires the measurement of all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. All organizations will now use forward-looking information to better inform their credit loss estimates. Topic 326 requires enhanced disclosures regarding significant estimates and judgments used in estimating credit losses, as well as the credit quality and underwriting standards of an organization’s portfolio. These disclosures include qualitative and quantitative requirements that provide information about the amounts recorded in the financial statements. In addition, Topic 326 amends the accounting for credit losses on available-for-sale debt securities and purchased financial assets with credit deterioration. In April 2019, the FASB issued ASU No. 2019-04, Codification Improvements to Topic 326 Financial Instruments—Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments, to introduce amendments which will affect the recognition and measurement of financial instruments, including derivatives and hedging. In May 2019, the FASB issued ASU No. 2019-05, Financial Instruments – Credit Losses (Topic 326); Targeted Transition Relief. The amendments in this ASU provide entities that have certain instruments within the scope of Subtopic 326-20 with an option to irrevocably elect the fair value option in Subtopic 825-10, applied on an instrument-by-instrument basis for eligible instruments upon adoption of Topic 326. This standard and related amendments are effective for the Company’s fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The Company will adopt the new standard in the first quarter of fiscal year 2023. The Company is evaluating the effect of adopting this new accounting guidance but does not expect adoption will have a material impact on the Company's financial statements.In March 2020, FASB issued ASU No. 2020-03, Codification Improvements to Financial Instruments. This ASU improves and clarifies various financial instruments topics, including the current expected credit losses standard issued in 2016 (ASU No. 2016-13). The ASU includes seven different issues that describe the areas of improvement and the related amendments to GAAP, intended to make the standards easier to understand and apply by eliminating inconsistencies and providing clarifications. The amendments have different effective dates. The issues 1-5 are conforming amendments, which are effective upon issuance of this final update. The Company determined that issues 1-5 have no impact on its financials. The amendments related to issue 6 and 7 effect ASU No. 2016-13, Financial instruments – credit losses (Topic 326): measurement of credit losses on financial statements. Effective dates of issue 6 and 7 are the same as the effective date of ASU No. 2016-13. The Company will adopt the new standard in the first quarter of fiscal year 2023.The Company is evaluating the effect of adopting this new accounting guidance, but does not expect adoption will have a material impact on the Company's financial statements.In October 2021, the FASB issued ASU No.2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. This ASU improves the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in practice and inconsistency related to recognition of an acquired contract liability and payment terms and their effect on subsequent revenue recognized by the acquirer. For public business entities, this guidance will be effective for fiscal years beginning after December 15, 2022 and for interim periods within those fiscal years. For all other entities, this guidance is effective for fiscal years beginning after December 15, 2023 and for interim periods within those fiscal years. This ASU should be applied prospectively to all business combinations in the year of adoption. The Company will adopt the new standard in the first quarter of fiscal year 2023. The Company does not expect the adoption of this standard will have a material impact on its financial statements.

Semler Scientific, Inc., a Delaware corporation (“Semler” or “the Company”), prepared the unaudited interim financial statements included in this report in accordance with United States generally accepted accounting principles (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. As such, the information included in this quarterly report on Form 10-Q should be read in conjunction with the audited financial statements and notes thereto included in the Company’s annual report on Form 10-K for the year ended December 31, 2021 filed with the SEC on March 4, 2022 (the “Annual Report”). In the opinion of management, these financial statements include all adjustments (consisting of normal recurring adjustments) necessary for a fair statement of the financial position, results of operations and cash flows for the periods presented. The results of operations for the interim periods shown in this report are not necessarily indicative of the results that may be expected for any future period, including the full year.

COVID-19In 2021, variable fee license revenues (fee-per-test), which grew strongly in the first half of 2021, decreased subsequently in the second half of 2021. The Company believes this new pattern in the home-testing market is due to a COVID-19 related timing change in the behavior of insurance plans when ordering QuantaFlo testing from its health risk assessment customers.The first quarter results of 2022 support this pattern of testing earlier in the year, as the home-testing market had higher volume of sequential revenues, which grew 67% compared to the fourth quarter of 2021. However, the Company does not know if this newly observed pattern will continue in 2022 or in future years.The Company believes that the relatively slower growth in the period-over-period comparison, was due to the COVID-19 pandemic. The Company's staff and many of its customers and prospects experienced a higher-than-normal rate of employee absence due to illness, which can have a slowing effect on its sales cycle.The extent and duration of the pandemic is unknown, and the future effects on the Company’s business are uncertain and difficult to predict. The Company is continuing to monitor the events and circumstances surrounding the COVID-19 pandemic, which may require adjustments to the Company’s estimates and assumptions in the future. 0.67

Recently Issued Accounting PronouncementsAccounting Pronouncements Recently AdoptedIn May 2021, the financial Accounting Standards Board(“FASB”) issued Accounting Standards Update (“ASU”) No. 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40) Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. This update provides guidance for a modification or an exchange of a freestanding equity-classified written call option that is not within the scope of another Topic. This update is effective for the Company’s fiscal years beginning after December 15, 2021. The Company adopted this ASU prospectively effective January 1, 2022 and determined that the adoption of this new accounting standard did not have a material impact on its financial statements.In July 2021, the FASB issued ASU No. 2021-05, Leases (Topic 842): Lessors—Certain Leases with Variable Lease Payments. This update addresses stakeholders’ concerns by amending the lease classification requirements for lessors to align them with practice under Topic 840. Lessors should classify and account for a lease with variable lease payments that do not depend on a reference index or a rate as an operating lease if both of the following criteria are met: i) The lease would have been classified as a sales-type lease or a direct financing lease in accordance with the classification criteria in paragraphs 842-10-25-2 through 25-3, ii) the lessor would have otherwise recognized a day-one loss. This update is effective for the Company’s fiscal years beginning after December 15, 2021. The Company adopted this ASU prospectively to the leases that commence or modified on or after January 1, 2022 and determined that the adoption of this new accounting standard did not have a material impact on its financial statements. In November 2021, the FASB issued ASU No. 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance. This ASU increases the transparency of government assistance to include the disclosure of (1) the types of assistance, (2) an entity's accounting for the assistance, and (3) the effect of the assistance on an entity's financial statements. The guidance in ASU 2021-10 is effective for financial statements of all entities, including private companies, for annual periods beginning after December 15, 2021, with early application permitted. Entities are required to provide the new disclosures prospectively for all transactions with a government entity that are accounted for under either a grant or a contribution accounting model and are reflected in the financial statements at the date of initially applying the new amendments, and to new transactions entered into after that date. The Company adopted ASU No. 2021-10 prospectively to the government assistance received after January 1, 2022 and determined that the adoption of this new accounting standard did not have a material impact on its financial statements.Accounting Pronouncements Not Yet AdoptedIn June 2016, the FASB issued ASU No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“Topic 326”). This ASU requires timelier recording of credit losses on loans and other financial instruments held. Instead of reserves based on a current probability analysis, Topic 326 requires the measurement of all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. All organizations will now use forward-looking information to better inform their credit loss estimates. Topic 326 requires enhanced disclosures regarding significant estimates and judgments used in estimating credit losses, as well as the credit quality and underwriting standards of an organization’s portfolio. These disclosures include qualitative and quantitative requirements that provide information about the amounts recorded in the financial statements. In addition, Topic 326 amends the accounting for credit losses on available-for-sale debt securities and purchased financial assets with credit deterioration. In April 2019, the FASB issued ASU No. 2019-04, Codification Improvements to Topic 326 Financial Instruments—Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments, to introduce amendments which will affect the recognition and measurement of financial instruments, including derivatives and hedging. In May 2019, the FASB issued ASU No. 2019-05, Financial Instruments – Credit Losses (Topic 326); Targeted Transition Relief. The amendments in this ASU provide entities that have certain instruments within the scope of Subtopic 326-20 with an option to irrevocably elect the fair value option in Subtopic 825-10, applied on an instrument-by-instrument basis for eligible instruments upon adoption of Topic 326. This standard and related amendments are effective for the Company’s fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The Company will adopt the new standard in the first quarter of fiscal year 2023. The Company is evaluating the effect of adopting this new accounting guidance but does not expect adoption will have a material impact on the Company's financial statements.In March 2020, FASB issued ASU No. 2020-03, Codification Improvements to Financial Instruments. This ASU improves and clarifies various financial instruments topics, including the current expected credit losses standard issued in 2016 (ASU No. 2016-13). The ASU includes seven different issues that describe the areas of improvement and the related amendments to GAAP, intended to make the standards easier to understand and apply by eliminating inconsistencies and providing clarifications. The amendments have different effective dates. The issues 1-5 are conforming amendments, which are effective upon issuance of this final update. The Company determined that issues 1-5 have no impact on its financials. The amendments related to issue 6 and 7 effect ASU No. 2016-13, Financial instruments – credit losses (Topic 326): measurement of credit losses on financial statements. Effective dates of issue 6 and 7 are the same as the effective date of ASU No. 2016-13. The Company will adopt the new standard in the first quarter of fiscal year 2023.The Company is evaluating the effect of adopting this new accounting guidance, but does not expect adoption will have a material impact on the Company's financial statements.In October 2021, the FASB issued ASU No.2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. This ASU improves the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in practice and inconsistency related to recognition of an acquired contract liability and payment terms and their effect on subsequent revenue recognized by the acquirer. For public business entities, this guidance will be effective for fiscal years beginning after December 15, 2022 and for interim periods within those fiscal years. For all other entities, this guidance is effective for fiscal years beginning after December 15, 2023 and for interim periods within those fiscal years. This ASU should be applied prospectively to all business combinations in the year of adoption. The Company will adopt the new standard in the first quarter of fiscal year 2023. The Company does not expect the adoption of this standard will have a material impact on its financial statements.

2.Variably-Priced RevenueThe Company recognizes variable-fee licenses (i.e., fee per test) and sales of hardware equipment and accessories in accordance with ASC 606. Total fees from variable-fee licenses represent approximately $5,842 and $5,658 for the three months ended March 31, 2022 and 2021, respectively. Total sales of hardware and equipment accessories represent approximately $285 and $331 of revenues for the three months ended March 31, 2022 and 2021, respectively. The remainder of the revenue is earned from leasing the Company's testing product for a fixed fee, which is not subject to Topic 606.

5842000 5658000 285000 331000

3. InventoryInventory, which is made up of finished goods, is recorded at the lower of cost or net realizable value. Cost is determined on the first-in, first-out method. The Company periodically analyzes its inventory levels to identify inventory that has a cost basis in excess of its estimated realizable value, and writes down such inventory as appropriate. Inventory balance was $595 and $550 as of March 31, 2022 and December 31, 2021, respectively.

595000

550000

4. Assets for Lease, netThe Company enters into contracts with customers for the Company’s QuantaFlo product. The Company has determined these contracts meet the definition of a lease under Topic 842. Operating leases are short-term in nature (monthly, quarterly or one year), and all of which have renewal options. The assets that may be associated with these leasing arrangements are identified below as assets for lease. Upon shipment under operating leases, assets for lease are depreciated. Upon shipment under variable-fee license contracts, these assets for lease are sold to the customers, and the asset is recognized as cost of revenue under Accounting Standards Codification or ASC 606, Revenue from Contracts with Customers. During the three months ended March 31, 2022 and 2021, the Company recognized approximately $7,889 and $7,194, respectively, in lease revenues related to these arrangements. Assets for lease consist of the following:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.31%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.8%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;">March 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;margin:0pt;padding:0pt;">December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:72.31%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.8%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #231f20;margin:0pt;padding:0pt;">2022</td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:1px solid #231f20;margin:0pt;padding:0pt;">2021</td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:72.31%;background:#cceeff;margin:0pt;padding:0pt;">Assets for lease </td><td style="vertical-align:bottom;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;background:#cceeff;margin:0pt;padding:0pt;"> 3,210</td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"> 3,241</td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:72.31%;margin:0pt;padding:0pt;">Less: accumulated depreciation </td><td style="vertical-align:bottom;width:1.8%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (1,616)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (1,598)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:72.31%;background:#cceeff;margin:0pt;padding:0pt;">Assets for lease, net </td><td style="vertical-align:bottom;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,594</td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,643</td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"></td></tr></table>Depreciation expense amounted to $108 and $113 for the three months ended March 31, 2022 and 2021, respectively. Reduction to accumulated depreciation for returned items was $90 and $141 for the three months ended March 31, 2022 and 2021, respectively. The Company recognized a loss on disposal of assets for lease in the amount of $74 and $83 for the three months ended March 31, 2022 and 2021, respectively.

7889000

7194000

3210000

3241000

1616000

1598000

1594000

1643000

108000

113000

90000 141000

-74000

-83000

5. Property and Equipment, netCapital assets consist of the following:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.74%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.2%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;">March 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;">December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:72.74%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.2%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2022</td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2021</td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:72.74%;background:#cceeff;margin:0pt;padding:0pt;">Capital assets </td><td style="vertical-align:bottom;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"> 1,005</td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"> 882</td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:72.74%;margin:0pt;padding:0pt;">Less: accumulated depreciation </td><td style="vertical-align:bottom;width:1.2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (535)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (488)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:72.74%;background:#cceeff;margin:0pt;padding:0pt;">Capital assets, net </td><td style="vertical-align:bottom;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 470</td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 394</td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"></td></tr></table>Depreciation expense amounted to $46 and $43 for the three months ended March 31, 2022 and 2021, respectively.

<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.74%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.2%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;">March 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;">December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:72.74%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.2%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2022</td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2021</td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:72.74%;background:#cceeff;margin:0pt;padding:0pt;">Capital assets </td><td style="vertical-align:bottom;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;margin:0pt;padding:0pt;"> 1,005</td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"> 882</td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:72.74%;margin:0pt;padding:0pt;">Less: accumulated depreciation </td><td style="vertical-align:bottom;width:1.2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (535)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (488)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:72.74%;background:#cceeff;margin:0pt;padding:0pt;">Capital assets, net </td><td style="vertical-align:bottom;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 470</td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 394</td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"></td></tr></table>

1005000

882000

535000

488000

470000

394000

46000

43000

6.Long-Term InvestmentsLong term investments consist of the following for the periods presented:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;">March 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;margin:0pt;padding:0pt;">December 31, </td></tr><tr><td style="vertical-align:bottom;width:75.5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2022</td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2021</td></tr><tr><td style="vertical-align:bottom;width:75.5%;background:#cceeff;margin:0pt;padding:0pt;">Investments in SYNAPS Dx</td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;background:#cceeff;margin:0pt;padding:0pt;"> 512</td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"> 512</td></tr><tr><td style="vertical-align:bottom;width:75.5%;margin:0pt;padding:0pt;">Investments in Mellitus Health Inc.</td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 309</td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 309</td></tr><tr><td style="vertical-align:bottom;width:75.5%;background:#cceeff;margin:0pt;padding:0pt;">Total</td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 821</td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 821</td></tr></table>In September 2020, the Company acquired a promissory note from NeuroDiagnostics Inc., which is doing business as SYNAPS Dx, in the principal amount of $500. Subsequently, in December 2020, the Company agreed to convert the promissory note, together with all accrued interest thereon, into shares of preferred stock of SYNAPS Dx as repayment in full of the promissory note. The value of the note exchanged for the shares of preferred stock of SYNAPS Dx held by the Company as of March 31, 2022 and December 31, 2021 was approximately $512. In October 2020, the Company acquired from a seller a convertible promissory note previously issued by Mellitus Health Inc., (“Mellitus”) to such seller for a purchase price of $59, which represented the $50 principal amount of the note and all accrued and unpaid interest thereon.Subsequently, in October 2020, the Company purchased $250 of shares of preferred stock of Mellitus, and in connection with such transaction, the convertible promissory note, together with all accrued interest thereon, also converted pursuant to its terms into shares of preferred stock of Mellitus as repayment in full of such convertible promissory note. The value of consideration exchanged for the shares of preferred stock of Mellitus held by the Company as of March 31, 2022 and December 31, 2021 was approximately $309.In April 2021, the Company entered into an agreement with Mellitus to exclusively market and distribute its product line in the United States, including Puerto Rico, except for selected accounts. The Company is currently developing a marketing plan. Under this distribution agreement, the Company agreed to purchase $2,000 of product licenses and prepaid $2,000 for the license purchases. This prepayment is included in ‘Prepaid expenses and other current assets’ in the balance sheet. Unless terminated early in accordance with its terms, the exclusive distribution agreement will remain in full force and effect until April 1, 2026, and thereafter there is an option for this agreement to be automatically renewed for additional one-year terms. Revenue from these product licenses will be recognized in accordance with ASC 606, Revenue from Contracts with Customers. Revenue from these product licenses during the three months ended March 31, 2022 was not significant.The investments in SYNAPS Dx and Mellitus securities that were retained by the Company as of March 31, 2022 were recorded in accordance with ASC 321, Investments – equity securities, which provides that investments in equity securities in privately-held companies without readily determinable fair values are generally recorded at cost, plus or minus subsequent observable price changes in orderly transactions for identical or similar investments, less impairments. The Company elected the practical expedient permitted by ASC 321 and recorded the above investments on a cost basis. As a part of the assessment for impairment indicators, the Company considers significant deterioration in the earnings performance and overall business prospects of the investee as well as significant adverse changes in the external environment these investments operate. If qualitative assessment indicates the investments are impaired, the fair value of these equity securities would be estimated, which would involve a significant degree of judgement and subjectivity. In accordance with ASC 321, the Company assessed qualitatively for impairment and determined that there was no impairment for these investments as of March 31, 2022 and December 31, 2021.

<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;">March 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;margin:0pt;padding:0pt;">December 31, </td></tr><tr><td style="vertical-align:bottom;width:75.5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2022</td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2021</td></tr><tr><td style="vertical-align:bottom;width:75.5%;background:#cceeff;margin:0pt;padding:0pt;">Investments in SYNAPS Dx</td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;background:#cceeff;margin:0pt;padding:0pt;"> 512</td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"> 512</td></tr><tr><td style="vertical-align:bottom;width:75.5%;margin:0pt;padding:0pt;">Investments in Mellitus Health Inc.</td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 309</td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 309</td></tr><tr><td style="vertical-align:bottom;width:75.5%;background:#cceeff;margin:0pt;padding:0pt;">Total</td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 821</td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 821</td></tr></table>

512000

309000

821000

500000

512000

59000

50000

250

309000

2000000

2000000 P1Y

7. Accrued ExpensesAccrued expenses consist of the following:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.3%;margin:0pt;padding:0pt;">March 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.3%;margin:0pt;padding:0pt;">December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2022</td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2021</td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;">Compensation</td><td style="vertical-align:bottom;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"> 2,522</td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;margin:0pt;padding:0pt;"> 1,754</td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;">Accrued Taxes</td><td style="vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"> 1,339</td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"> 1,159</td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;">Miscellaneous Accruals</td><td style="vertical-align:bottom;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 522</td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 523</td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;">Total Accrued Expenses</td><td style="vertical-align:bottom;width:1.97%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 4,383</td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,436</td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"></td></tr></table>

2522000

1754000

1339000

1159000

522000

523000

4383000

3436000

8. Concentration of Credit RiskCredit risk is the risk of loss from amounts owed by the financial counterparties. Credit risk can occur at multiple levels; as a result of broad economic conditions, challenges within specific sectors of the economy, or from issues affecting individual companies. Financial instruments that potentially subject the Company to credit risk consist of cash and accounts receivable.The Company maintains cash with major financial institutions. The Company’s cash and cash equivalents consist of bank deposits and money market funds held with banks that, at times, exceed federally insured limits. The Company limits its credit risk by dealing with counterparties that are considered to be of high credit quality and by performing periodic evaluations of the relative credit standing of these financial institutions.Management periodically monitors the creditworthiness of its customers and believes that it has adequately provided for any exposure to potential credit loss. For the three months ended March 31, 2022, two customers accounted for 35.4% and 31.7% of the Company’s revenues, respectively. For the three months ended March 31, 2021, two customers accounted for 38.3% and 30.4% of the Company’s revenues. As of March 31, 2022, three customers accounted for 30.2%, 26.8%, and 22.5% of the Company’s accounts receivable, respectively. As of December 31, 2021, three customers accounted for 21.9%, 20.1%, and 16.6% of the Company’s accounts receivable, respectively. The Company’s largest customer in terms of both revenues and accounts receivable in the three months ended March 31, 2022 is a U.S. diversified healthcare company and its affiliated plans.As of March 31, 2022, three vendors accounted for 18.0%, 17.1% and 10.6% of the Company’s accounts payable, respectively. As of December 31, 2021, one vendor accounted for 14.0% of the Company’s accounts payable, respectively.

0.354

0.317

0.383

0.304

0.302

0.268

0.225

0.219

0.201

0.166

0.180

0.171

0.106

0.140

9. LeasesOn July 31, 2020, the Company entered into a 61-month lease agreement for office space to use, as necessary, for office administration, lab space and assembly and storage purposes, located in Santa Clara, California. The Company took possession of the leased office space in September 2020, and the lease is effective through September 30, 2025.As of March 31, 2022, the remaining lease term is three years and six months with no options to renew. The Company recognized facilities lease expenses of $22 and $44 for the three months ended March 31, 2022 and 2021, respectively. The following table summarizes the future minimum rental payments required under operating leases that had initial or remaining non-cancelable lease terms greater than one year as of March 31, 2022:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:86.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:86.68%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Total</td></tr><tr><td style="vertical-align:bottom;width:86.68%;background:#cceeff;margin:0pt;padding:0pt;">2022 Remaining period</td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;"> 66</td></tr><tr><td style="vertical-align:bottom;width:86.68%;margin:0pt;padding:0pt;">2023</td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"> 90</td></tr><tr><td style="vertical-align:bottom;width:86.68%;background:#cceeff;margin:0pt;padding:0pt;">2024</td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;"> 93</td></tr><tr><td style="vertical-align:bottom;width:86.68%;margin:0pt;padding:0pt;">2025</td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"> 71</td></tr><tr><td style="vertical-align:bottom;width:86.68%;background:#cceeff;margin:0pt;padding:0pt;">Thereafter</td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:86.68%;margin:0pt;padding:0pt;">Total undiscounted future minimum lease payments</td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"> 320</td></tr><tr><td style="vertical-align:bottom;width:86.68%;background:#cceeff;margin:0pt;padding:0pt;">Less: present value discount</td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (15)</td></tr><tr><td style="vertical-align:bottom;width:86.68%;margin:0pt;padding:0pt;">Total lease liabilities</td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"> 305</td></tr><tr><td style="vertical-align:bottom;width:86.68%;background:#cceeff;margin:0pt;padding:0pt;">Lease expense in excess cash payment</td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (11)</td></tr><tr><td style="vertical-align:bottom;width:86.68%;margin:0pt;padding:0pt;">Total ROU asset</td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 294</td></tr></table>As of March 31, 2022, the Company’s right-of-use (“ROU”) asset was $294, which was recorded on the Company’s balance sheet as other noncurrent assets, and the Company’s current and noncurrent lease liabilities were $81 and $224, respectively, which were recorded on the Company’s balance sheet as other short-term liabilities and other long-term liabilities, respectively. As of December 31, 2021, the Company’s ROU asset was $314, which was recorded on the Company’s balance sheet as other noncurrent assets, and the Company’s current and noncurrent lease liabilities were $80 and $245, respectively, which were recorded on the Company’s balance sheet as other short-term liabilities and other long-term liabilities, respectively.Lease ArrangementsThe Company enters into contracts with customers for the Company’s QuantaFlo product. The Company has determined these contracts meet the definition of a lease under Topic 842. The lease portfolio primarily consists of operating leases that are short-term in nature (monthly, quarterly or one year, all of which have renewal options). The Company allocates the consideration in a bundled contract with its customers based on relative standalone selling prices of the lease and non-lease components. The Company made an accounting policy election to apply the practical expedient to not separate lease and eligible non-lease components. The lease component is the predominant component and consists of fees charged for use of the equipment over the period of the arrangement. The nature of the eligible non-lease component is primarily software support. The assets associated with these leasing arrangements are separately identified in the Balance Sheet as Assets for Lease and separately disclosed in Note 4 to the Unaudited Condensed Financial Statements.

false

22000

44000

<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:86.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:86.68%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Total</td></tr><tr><td style="vertical-align:bottom;width:86.68%;background:#cceeff;margin:0pt;padding:0pt;">2022 Remaining period</td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;"> 66</td></tr><tr><td style="vertical-align:bottom;width:86.68%;margin:0pt;padding:0pt;">2023</td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"> 90</td></tr><tr><td style="vertical-align:bottom;width:86.68%;background:#cceeff;margin:0pt;padding:0pt;">2024</td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;"> 93</td></tr><tr><td style="vertical-align:bottom;width:86.68%;margin:0pt;padding:0pt;">2025</td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"> 71</td></tr><tr><td style="vertical-align:bottom;width:86.68%;background:#cceeff;margin:0pt;padding:0pt;">Thereafter</td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:86.68%;margin:0pt;padding:0pt;">Total undiscounted future minimum lease payments</td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"> 320</td></tr><tr><td style="vertical-align:bottom;width:86.68%;background:#cceeff;margin:0pt;padding:0pt;">Less: present value discount</td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (15)</td></tr><tr><td style="vertical-align:bottom;width:86.68%;margin:0pt;padding:0pt;">Total lease liabilities</td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"> 305</td></tr><tr><td style="vertical-align:bottom;width:86.68%;background:#cceeff;margin:0pt;padding:0pt;">Lease expense in excess cash payment</td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (11)</td></tr><tr><td style="vertical-align:bottom;width:86.68%;margin:0pt;padding:0pt;">Total ROU asset</td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 294</td></tr></table>

66000

90000

93000

71000

320000

15000

305000

11000

294000

81000

224000

314000

80000

245000

10. Commitments and ContingenciesFacilities LeasesOn July 31, 2020, the Company entered into a 61-month lease agreement for office space to use, as necessary, for office administration, lab space and assembly and storage purposes, located in Santa Clara, California. The Company took possession of the leased office space in September 2020, and the lease is effective through September 30, 2025. See Note 9 to the Unaudited Condensed Financial Statements for the details.Indemnification ObligationsThe Company enters into agreements with customers, partners, lenders, consultants, lessors, contractors, sales representatives and parties to certain transactions in the ordinary course of the Company’s business. These agreements may require the Company to indemnify the other party against third party claims alleging that its product infringes a patent or copyright. Certain of these agreements require the Company to indemnify the other party against losses arising from: a breach of representations or covenants, claims relating to property damage, personal injury or acts or omissions of the Company, its employees, agents or representatives. The Company has also agreed to indemnify the directors and certain of the officers and employees in accordance with the by-laws of the Company. These indemnification provisions will vary based upon the nature and terms of the agreements. In many cases, these indemnification provisions do not contain limits on the Company’s liability, and the occurrence of contingent events that will trigger payment under these indemnities is difficult to predict. As a result, the Company cannot estimate its potential liability under these indemnities. The Company believes that the likelihood of conditions arising that would trigger these indemnities is remote and, historically, the Company has not made any significant payment under such indemnification provisions. Accordingly, the Company has not recorded any liabilities relating to these agreements. In certain cases, the Company has recourse against third parties with respect to the aforesaid indemnities, and the Company believes it maintains adequate levels of insurance coverage to protect the Company with respect to potential claims arising from such agreements.401(K) PlanEffective January 1, 2022, the Company started to match 50% of employee’s 401(k) deferral up to a maximum of 6% of the employee’s eligible earnings. OtherThe Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) provides for an employee retention payroll tax credit for certain employers, which is a refundable tax credit against certain employment taxes equal to 50% of the qualified wages an eligible employer pays to employees after March 12, 2020 and before December 31, 2021. For each employee, wages (including health plan costs) up to $10,000 can be counted to determine the amount of the 50% credit. The Company started claiming this credit on its July 2020 payroll until mid-April 2021 when it determined that it no longer qualified given the change in government restrictions on travel that had impacted its sales activities. The Company’s determination that it qualified to claim the employee retention payroll tax credit is subjective and subject to audit by the Internal Revenue Service (“IRS”). If the IRS were to disagree with the Company’s tax position, it could be required to pay the retention credit claimed, along with penalties. As of December 31, 2021, the Company has claimed $1.24 million in this retention credit.LitigationFrom time to time in the normal course of business, the Company is subject to various legal matters such as threatened or pending claims or litigation. Although the results of claims and litigation cannot be predicted with certainty, the Company does not believe it is a party to any claim or litigation the outcome of which, if determined adversely to it, would individually or in the aggregate be reasonably expected to have a material adverse effect on its results of operations or financial condition.

P61M

0.50

0.06

1240000

11. Stock Incentive PlanThe Company’s stock-based compensation program is designed to attract and retain employees while also aligning employees’ interests with the interests of its stockholders. Stock options have been granted to employees under the stockholder-approved 2007 Key Person Stock Option Plan (“2007 Plan”) and stock options and restricted stock have been granted to employees under the stockholder-approved 2014 Stock Incentive Plan (“2014 Plan”). Stockholder approval of the 2014 Plan became effective in September 2014. The 2014 Plan originally provided that the aggregate number of shares of common stock that may be issued pursuant to awards granted under the 2014 Plan may not exceed 450,000 shares (the “Share Reserve”), however in October 2015, the stockholders approved a 1,500,000 increase to the Share Reserve. In addition, the Share Reserve automatically increases on January 1st of each year, for a period of not more than 10 years, beginning on January 1st of the year following the year in which the 2014 Plan became effective and ending on (and including) January 1, 2024, in an amount equal to 4% of the total number of shares of common stock outstanding on December 31st of the preceding calendar year. The Company’s Board of Directors may act prior to January 1st of a given year to provide that there will be no January 1st increase in the Share Reserve for such year or that the increase in the Share Reserve for such year will be a lesser number of shares of common stock than would otherwise occur. In the fourth quarter of 2020, the Board of Directors agreed not to increase the Share Reserve, and accordingly, the Share Reserve did not increase on January 1, 2021. On January 1, 2022, the Share Reserve increased by 270,338. The Share Reserve is currently 3,315,203 shares as of March 31, 2022.In light of stockholder approval of the 2014 Plan, the Company no longer grants equity awards under the 2007 Plan. As of March 31, 2022, there were no shares available for future stock-based compensation grants under the 2007 Plan and 1,479,103 shares of an aggregate total of 3,315,203 shares were available for future stock-based compensation grants under the 2014 Plan.Treasury Stock AcquiredOn March 14, 2022, the Company’s Board of Directors authorized a share repurchase program under which it may repurchase up to $20.0 million of its outstanding common stock. Under this program the Company may purchase shares on a discretionary basis from time to time through open market purchases, privately negotiated transactions or other means, including through Rule 10b5-1 trading plans or through the use of other techniques such as accelerated share repurchases. The timing and amount of any transactions will be subject to the discretion of the Company based upon market conditions and other opportunities that it may have for the use or investment of its cash balances. The repurchase program has no expiration date, does not require the purchase of any minimum number of shares and may be suspended, modified or discontinued at any time without prior notice. The Company purchased 2,030 shares at a cost of approximately $99 during the three months ended March 31, 2022.Stock AwardsThe Company granted fully vested stock awards of 8,406 shares of common stock to the non-employee members of the board of directors, employees and one non-employee as compensation during the three months ended March 31, 2022. Net shares issued after deducting taxes paid on these grants were 6,988. Fair value of these stock awards on grant date was $628. The Company granted fully vested stock awards of 5,400 shares of common stock to the non-employee members of the board of directors, employees and one non-employee as compensation during the three months ended March 31, 2021. Fair value of these stock awards on grant date was $537.Stock OptionsAggregate intrinsic value represents the difference between the closing market value as of March 31, 2022 of the underlying common stock and the exercise price of outstanding, in-the-money options. A summary of the Company’s stock option activity and related information for the three months ended March 31, 2022 is as follows:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.09%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:45.09%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:53.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Options Outstanding</td></tr><tr><td style="vertical-align:bottom;width:45.09%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;">Weighted</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:45.09%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;">Average</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:45.09%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;">Number of</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;margin:0pt;padding:0pt;">Weighted</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;">Remaining</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.09%;margin:0pt;padding:0pt;">Aggregate</td></tr><tr><td style="vertical-align:bottom;width:45.09%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;">Stock Options</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;margin:0pt;padding:0pt;">Average</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;">Contractual</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.09%;margin:0pt;padding:0pt;">Intrinsic Value</td></tr><tr><td style="vertical-align:bottom;width:45.09%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Outstanding</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Exercise Price</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Term (In Years)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">(In Thousands)</td></tr><tr><td style="vertical-align:bottom;width:45.09%;background:#cceeff;margin:0pt;padding:0pt;">Balance, December 31, 2021</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"> 1,356,245</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"> 3.30</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"> 3.97</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"> 119,830</td></tr><tr><td style="vertical-align:bottom;width:45.09%;margin:0pt;padding:0pt;">Options exercised</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"> (23,800)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"> 2.58</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:45.09%;background:#cceeff;margin:0pt;padding:0pt;">Balance, March 31, 2022</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"> 1,332,445</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"> 3.31</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"> 3.73</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"> 61,627</td></tr><tr><td style="vertical-align:bottom;width:45.09%;margin:0pt;padding:0pt;">Exercisable as of March 31, 2022</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"> 1,332,445</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"> 3.31</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"> 3.73</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"> 61,627</td></tr></table> There were no options granted during the three months ended March 31, 2022 or 2021. The Company has recorded an expense of $628 and $589 as it relates to stock-based compensation for the three months ended March 31, 2022 and 2021, respectively:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Three months ended March 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:61.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2022</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2021</td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:61.48%;background:#cceeff;margin:0pt;padding:0pt;">Cost of Revenues</td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;background:#cceeff;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:13.92%;background:#cceeff;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:61.48%;margin:0pt;padding:0pt;">Engineering and Product Development</td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"> 45</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.92%;margin:0pt;padding:0pt;"> 32</td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:61.48%;background:#cceeff;margin:0pt;padding:0pt;">Sales and Marketing</td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;background:#cceeff;margin:0pt;padding:0pt;"> 172</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.92%;background:#cceeff;margin:0pt;padding:0pt;"> 105</td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:61.48%;margin:0pt;padding:0pt;">General and Administrative</td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 411</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 452</td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:61.48%;background:#cceeff;margin:0pt;padding:0pt;">Total</td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 628</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:13.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 589</td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"></td></tr></table>

450000

1500000

P10Y

0.04

270338

3315203

1479103

3315203

20000000.0

2030

99000

8406

1 6988

628000

5400

537000

<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.09%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:45.09%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:53.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Options Outstanding</td></tr><tr><td style="vertical-align:bottom;width:45.09%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;">Weighted</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:45.09%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;">Average</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:45.09%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;">Number of</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;margin:0pt;padding:0pt;">Weighted</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;">Remaining</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.09%;margin:0pt;padding:0pt;">Aggregate</td></tr><tr><td style="vertical-align:bottom;width:45.09%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;">Stock Options</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;margin:0pt;padding:0pt;">Average</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;">Contractual</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.09%;margin:0pt;padding:0pt;">Intrinsic Value</td></tr><tr><td style="vertical-align:bottom;width:45.09%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Outstanding</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Exercise Price</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Term (In Years)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">(In Thousands)</td></tr><tr><td style="vertical-align:bottom;width:45.09%;background:#cceeff;margin:0pt;padding:0pt;">Balance, December 31, 2021</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"> 1,356,245</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"> 3.30</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"> 3.97</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"> 119,830</td></tr><tr><td style="vertical-align:bottom;width:45.09%;margin:0pt;padding:0pt;">Options exercised</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"> (23,800)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"> 2.58</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"> —</td></tr><tr><td style="vertical-align:bottom;width:45.09%;background:#cceeff;margin:0pt;padding:0pt;">Balance, March 31, 2022</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"> 1,332,445</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"> 3.31</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;background:#cceeff;margin:0pt;padding:0pt;"> 3.73</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"> 61,627</td></tr><tr><td style="vertical-align:bottom;width:45.09%;margin:0pt;padding:0pt;">Exercisable as of March 31, 2022</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"> 1,332,445</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"> 3.31</td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.96%;margin:0pt;padding:0pt;"> 3.73</td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"> 61,627</td></tr></table>

1356245

3.30

P3Y11M19D

119830000

23800

2.58

1332445

3.31

P3Y8M23D

61627000

1332445

3.31

P3Y8M23D

61627000

628000

589000

45000

32000

172000

105000

411000

452000

628000

589000

12. Income TaxesThe Company’s income tax provision for the three months ended March 31, 2022 and March 31, 2021 was $583 and $1,143, respectively. The income tax provision reflects its estimate of the effective tax rates expected to be applicable for the full year, adjusted for any discrete events that are recorded in the period in which they occurred. The estimates are re-evaluated each quarter based on the estimated tax expense for the full year.For uncertain tax positions that meet a “more likely than not” threshold, the Company recognizes the benefit of uncertain tax positions in the financial statements. The Company’s practice is to recognize interest and penalties, if any, related to uncertain tax positions in income tax expense in the statements of operations.The effective tax rate for the three months ended March 31, 2022 was 14.79%, compared to 18.99% for the three months ended March 31, 2021. The decrease in the effective tax rate for the three months ended March 31, 2022 is primarily related to tax benefits associated with employee share-based compensation plans and federal and state research and development credits net of reserves for uncertain tax positions related to these credits. The effective tax rate for the three months ended March 31, 2022 differed from the U.S. federal statutory rate of 21% primarily due to state income taxes (net of federal benefit) partially offset by tax benefits associated with employee share-based compensation plans and federal and state research and development (“R&D”) credit benefit. The difference between the U.S. Federal statutory rate of 21% and the Company’s effective tax rate of 18.99% for the three months ended March 31, 2021 was state income taxes (net of federal benefit) partially offset by tax benefit associated with employee share-based compensation plans and federal and state R&D credit benefit.As of March 31, 2022, and December 31, 2021, the Company had $419 and $476, respectively of unrecognized tax benefits, excluding interest and penalties. The Company’s practice is to recognize interest and penalty expenses related to uncertain tax positions in income tax expense, which was zero for the year ended December 31, 2021 and three months ended March 31, 2022.

583000

1143000

0.1479

0.1899

0.21

0.1899

419000

476000

13. Net Income Per Share, Basic and DilutedBasic earnings per share (“EPS”) represent net income attributable to common stockholders divided by the weighted average number of common shares outstanding during the measurement period. Diluted EPS represents net income attributable to common stockholders divided by the weighted average number of common shares outstanding during the measurement period while also giving effect to all potentially dilutive common shares that were outstanding during the period using the treasury stock method.Basic and diluted EPS is calculated as follows:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.37%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:38.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:38.23%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"></td><td colspan="15" style="vertical-align:bottom;white-space:nowrap;width:61.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Three months ended March 31, </td></tr><tr><td style="vertical-align:bottom;width:38.23%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:29.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2022</td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:29.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2021</td></tr><tr><td style="vertical-align:bottom;width:38.23%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Shares</td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Net Income</td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">EPS</td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Shares</td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Net Income</td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">EPS</td></tr><tr><td style="vertical-align:bottom;width:38.23%;background:#cceeff;margin:0pt;padding:0pt;">Basic </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"> 6,777,950</td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;"> 3,360</td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:5.41%;background:#cceeff;margin:0pt;padding:0pt;"> 0.50</td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"> 6,710,990</td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;"> 4,877</td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:5.43%;background:#cceeff;margin:0pt;padding:0pt;"> 0.73</td></tr><tr><td style="vertical-align:bottom;width:38.23%;margin:0pt;padding:0pt;">Common stock warrants</td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"> 71,839</td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;">—</td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.41%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"> 73,497</td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.43%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:38.23%;background:#cceeff;margin:0pt;padding:0pt;">Common stock options</td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,266,667</td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">—</td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,384,888</td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:38.23%;margin:0pt;padding:0pt;">Diluted </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 8,116,456</td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,360</td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:5.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 0.41</td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 8,169,375</td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 4,877</td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:5.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 0.60</td></tr></table>The were no weighted average shares outstanding of common stock equivalents excluded from the computation of diluted net income per share for the three months ended March 31, 2022 and 2021.

<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.37%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:38.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:38.23%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"></td><td colspan="15" style="vertical-align:bottom;white-space:nowrap;width:61.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Three months ended March 31, </td></tr><tr><td style="vertical-align:bottom;width:38.23%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:29.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2022</td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:29.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2021</td></tr><tr><td style="vertical-align:bottom;width:38.23%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Shares</td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Net Income</td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">EPS</td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Shares</td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Net Income</td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">EPS</td></tr><tr><td style="vertical-align:bottom;width:38.23%;background:#cceeff;margin:0pt;padding:0pt;">Basic </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"> 6,777,950</td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;"> 3,360</td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:5.41%;background:#cceeff;margin:0pt;padding:0pt;"> 0.50</td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;margin:0pt;padding:0pt;"> 6,710,990</td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;margin:0pt;padding:0pt;"> 4,877</td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:5.43%;background:#cceeff;margin:0pt;padding:0pt;"> 0.73</td></tr><tr><td style="vertical-align:bottom;width:38.23%;margin:0pt;padding:0pt;">Common stock warrants</td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"> 71,839</td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;">—</td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.41%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;margin:0pt;padding:0pt;"> 73,497</td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.43%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:38.23%;background:#cceeff;margin:0pt;padding:0pt;">Common stock options</td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,266,667</td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">—</td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,384,888</td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:38.23%;margin:0pt;padding:0pt;">Diluted </td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 8,116,456</td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,360</td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:5.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 0.41</td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 8,169,375</td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 4,877</td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:5.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 0.60</td></tr></table>

6777950

3360000

0.50

6710990

4877000

0.73

71839

73497

1266667

1384888

8116456

3360000

0.41

8169375

4877000

0.60

EXCEL 60 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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�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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 62 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 63 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 81 215 1 false 28 0 false 6 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://semlerscientific.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00100 - Statement - Condensed Statements of Income Sheet http://semlerscientific.com/role/StatementCondensedStatementsOfIncome Condensed Statements of Income Statements 2 false false R3.htm 00200 - Statement - Condensed Balance Sheets Sheet http://semlerscientific.com/role/StatementCondensedBalanceSheets Condensed Balance Sheets Statements 3 false false R4.htm 00205 - Statement - Condensed Balance Sheets (Parentheticals) Sheet http://semlerscientific.com/role/StatementCondensedBalanceSheetsParentheticals Condensed Balance Sheets (Parentheticals) Statements 4 false false R5.htm 00300 - Statement - Statements of Stockholders' Equity Sheet http://semlerscientific.com/role/StatementStatementsOfStockholdersEquity Statements of Stockholders' Equity Statements 5 false false R6.htm 00400 - Statement - Condensed Statements of Cash Flows Sheet http://semlerscientific.com/role/StatementCondensedStatementsOfCashFlows Condensed Statements of Cash Flows Statements 6 false false R7.htm 10101 - Disclosure - Basis of Presentation Sheet http://semlerscientific.com/role/DisclosureBasisOfPresentation Basis of Presentation Notes 7 false false R8.htm 10201 - Disclosure - Variably-Priced Revenue Sheet http://semlerscientific.com/role/DisclosureVariablyPricedRevenue Variably-Priced Revenue Notes 8 false false R9.htm 10301 - Disclosure - Inventory Sheet http://semlerscientific.com/role/DisclosureInventory Inventory Notes 9 false false R10.htm 10401 - Disclosure - Assets for Lease, net Sheet http://semlerscientific.com/role/DisclosureAssetsForLeaseNet Assets for Lease, net Notes 10 false false R11.htm 10501 - Disclosure - Property and Equipment, net Sheet http://semlerscientific.com/role/DisclosurePropertyAndEquipmentNet Property and Equipment, net Notes 11 false false R12.htm 10601 - Disclosure - Long-Term Investments Sheet http://semlerscientific.com/role/DisclosureLongTermInvestments Long-Term Investments Notes 12 false false R13.htm 10701 - Disclosure - Accrued Expenses Sheet http://semlerscientific.com/role/DisclosureAccruedExpenses Accrued Expenses Notes 13 false false R14.htm 10801 - Disclosure - Concentration of Credit Risk Sheet http://semlerscientific.com/role/DisclosureConcentrationOfCreditRisk Concentration of Credit Risk Notes 14 false false R15.htm 10901 - Disclosure - Leases Sheet http://semlerscientific.com/role/DisclosureLeases Leases Notes 15 false false R16.htm 11001 - Disclosure - Commitments and Contingencies Sheet http://semlerscientific.com/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 16 false false R17.htm 11101 - Disclosure - Stock Incentive Plan Sheet http://semlerscientific.com/role/DisclosureStockIncentivePlan Stock Incentive Plan Notes 17 false false R18.htm 11201 - Disclosure - Income Taxes Sheet http://semlerscientific.com/role/DisclosureIncomeTaxes Income Taxes Notes 18 false false R19.htm 11301 - Disclosure - Net Income Per Share, Basic and Diluted Sheet http://semlerscientific.com/role/DisclosureNetIncomePerShareBasicAndDiluted Net Income Per Share, Basic and Diluted Notes 19 false false R20.htm 20102 - Disclosure - Basis of Presentation (Policies) Sheet http://semlerscientific.com/role/DisclosureBasisOfPresentationPolicies Basis of Presentation (Policies) Policies 20 false false R21.htm 30403 - Disclosure - Assets for Lease, net (Tables) Sheet http://semlerscientific.com/role/DisclosureAssetsForLeaseNetTables Assets for Lease, net (Tables) Tables http://semlerscientific.com/role/DisclosureAssetsForLeaseNet 21 false false R22.htm 30503 - Disclosure - Property and Equipment, net (Tables) Sheet http://semlerscientific.com/role/DisclosurePropertyAndEquipmentNetTables Property and Equipment, net (Tables) Tables http://semlerscientific.com/role/DisclosurePropertyAndEquipmentNet 22 false false R23.htm 30603 - Disclosure - Long-Term Investments (Tables) Sheet http://semlerscientific.com/role/DisclosureLongTermInvestmentsTables Long-Term Investments (Tables) Tables http://semlerscientific.com/role/DisclosureLongTermInvestments 23 false false R24.htm 30703 - Disclosure - Accrued Expenses (Tables) Sheet http://semlerscientific.com/role/DisclosureAccruedExpensesTables Accrued Expenses (Tables) Tables http://semlerscientific.com/role/DisclosureAccruedExpenses 24 false false R25.htm 30903 - Disclosure - Leases (Tables) Sheet http://semlerscientific.com/role/DisclosureLeasesTables Leases (Tables) Tables http://semlerscientific.com/role/DisclosureLeases 25 false false R26.htm 31103 - Disclosure - Stock Incentive Plan (Tables) Sheet http://semlerscientific.com/role/DisclosureStockIncentivePlanTables Stock Incentive Plan (Tables) Tables http://semlerscientific.com/role/DisclosureStockIncentivePlan 26 false false R27.htm 31303 - Disclosure - Net Income Per Share, Basic and Diluted (Tables) Sheet http://semlerscientific.com/role/DisclosureNetIncomePerShareBasicAndDilutedTables Net Income Per Share, Basic and Diluted (Tables) Tables http://semlerscientific.com/role/DisclosureNetIncomePerShareBasicAndDiluted 27 false false R28.htm 40101 - Disclosure - Basis of Presentation (Details) Sheet http://semlerscientific.com/role/DisclosureBasisOfPresentationDetails Basis of Presentation (Details) Details http://semlerscientific.com/role/DisclosureBasisOfPresentationPolicies 28 false false R29.htm 40201 - Disclosure - Variably-Priced Revenue (Details) Sheet http://semlerscientific.com/role/DisclosureVariablyPricedRevenueDetails Variably-Priced Revenue (Details) Details http://semlerscientific.com/role/DisclosureVariablyPricedRevenue 29 false false R30.htm 40301 - Disclosure - Inventory (Details) Sheet http://semlerscientific.com/role/DisclosureInventoryDetails Inventory (Details) Details http://semlerscientific.com/role/DisclosureInventory 30 false false R31.htm 40401 - Disclosure - Assets for Lease, net (Details) Sheet http://semlerscientific.com/role/DisclosureAssetsForLeaseNetDetails Assets for Lease, net (Details) Details http://semlerscientific.com/role/DisclosureAssetsForLeaseNetTables 31 false false R32.htm 40402 - Disclosure - Assets for Lease, net - Additional Information (Details) Sheet http://semlerscientific.com/role/DisclosureAssetsForLeaseNetAdditionalInformationDetails Assets for Lease, net - Additional Information (Details) Details 32 false false R33.htm 40501 - Disclosure - Property and Equipment, net (Details) Sheet http://semlerscientific.com/role/DisclosurePropertyAndEquipmentNetDetails Property and Equipment, net (Details) Details http://semlerscientific.com/role/DisclosurePropertyAndEquipmentNetTables 33 false false R34.htm 40502 - Disclosure - Property and Equipment, net - Additional Information (Details) Sheet http://semlerscientific.com/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails Property and Equipment, net - Additional Information (Details) Details 34 false false R35.htm 40601 - Disclosure - Long-Term Investments (Details) Sheet http://semlerscientific.com/role/DisclosureLongTermInvestmentsDetails Long-Term Investments (Details) Details http://semlerscientific.com/role/DisclosureLongTermInvestmentsTables 35 false false R36.htm 40602 - Disclosure - Long-Term Investments - Investments in SYNAPS Dx (Details) Sheet http://semlerscientific.com/role/DisclosureLongTermInvestmentsInvestmentsInSynapsDxDetails Long-Term Investments - Investments in SYNAPS Dx (Details) Details 36 false false R37.htm 40603 - Disclosure - Long-Term Investments - Investments in Mellitus Health Inc., (Details) Sheet http://semlerscientific.com/role/DisclosureLongTermInvestmentsInvestmentsInMellitusHealthIncDetails Long-Term Investments - Investments in Mellitus Health Inc., (Details) Details 37 false false R38.htm 40701 - Disclosure - Accrued Expenses (Details) Sheet http://semlerscientific.com/role/DisclosureAccruedExpensesDetails Accrued Expenses (Details) Details http://semlerscientific.com/role/DisclosureAccruedExpensesTables 38 false false R39.htm 40801 - Disclosure - Concentration of Credit Risk (Details) Sheet http://semlerscientific.com/role/DisclosureConcentrationOfCreditRiskDetails Concentration of Credit Risk (Details) Details http://semlerscientific.com/role/DisclosureConcentrationOfCreditRisk 39 false false R40.htm 40901 - Disclosure - Leases - Future minimum rental payments (Details) Sheet http://semlerscientific.com/role/DisclosureLeasesFutureMinimumRentalPaymentsDetails Leases - Future minimum rental payments (Details) Details 40 false false R41.htm 40902 - Disclosure - Leases - Lessee Arrangements (Details) Sheet http://semlerscientific.com/role/DisclosureLeasesLesseeArrangementsDetails Leases - Lessee Arrangements (Details) Details 41 false false R42.htm 41001 - Disclosure - Commitments and Contingencies (Details) Sheet http://semlerscientific.com/role/DisclosureCommitmentsAndContingenciesDetails Commitments and Contingencies (Details) Details http://semlerscientific.com/role/DisclosureCommitmentsAndContingencies 42 false false R43.htm 41101 - Disclosure - Stock Incentive Plan - Additional information (Details) Sheet http://semlerscientific.com/role/DisclosureStockIncentivePlanAdditionalInformationDetails Stock Incentive Plan - Additional information (Details) Details 43 false false R44.htm 41102 - Disclosure - Stock Incentive Plan - Common Stock Repurchase (Details) Sheet http://semlerscientific.com/role/DisclosureStockIncentivePlanCommonStockRepurchaseDetails Stock Incentive Plan - Common Stock Repurchase (Details) Details 44 false false R45.htm 41103 - Disclosure - Stock Incentive Plan - Stock Option Activity (Details) Sheet http://semlerscientific.com/role/DisclosureStockIncentivePlanStockOptionActivityDetails Stock Incentive Plan - Stock Option Activity (Details) Details 45 false false R46.htm 41104 - Disclosure - Stock Incentive Plan - Stock-based compensation - Expenses (Details) Sheet http://semlerscientific.com/role/DisclosureStockIncentivePlanStockBasedCompensationExpensesDetails Stock Incentive Plan - Stock-based compensation - Expenses (Details) Details 46 false false R47.htm 41201 - Disclosure - Income Taxes (Details) Sheet http://semlerscientific.com/role/DisclosureIncomeTaxesDetails Income Taxes (Details) Details http://semlerscientific.com/role/DisclosureIncomeTaxes 47 false false R48.htm 41301 - Disclosure - Net Income Per Share, Basic and Diluted (Details) Sheet http://semlerscientific.com/role/DisclosureNetIncomePerShareBasicAndDilutedDetails Net Income Per Share, Basic and Diluted (Details) Details http://semlerscientific.com/role/DisclosureNetIncomePerShareBasicAndDilutedTables 48 false false R49.htm 41302 - Disclosure - Net Income Per Share, Basic and Diluted - Additional Information (Details) Sheet http://semlerscientific.com/role/DisclosureNetIncomePerShareBasicAndDilutedAdditionalInformationDetails Net Income Per Share, Basic and Diluted - Additional Information (Details) Details 49 false false All Reports Book All Reports smlr-20220331x10q.htm smlr-20220331.xsd smlr-20220331_cal.xml smlr-20220331_def.xml smlr-20220331_lab.xml smlr-20220331_pre.xml smlr-20220331ex311902d5a.htm smlr-20220331ex312490167.htm smlr-20220331ex3216095a4.htm http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021q4 true true JSON 66 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "smlr-20220331x10q.htm": { "axisCustom": 0, "axisStandard": 12, "contextCount": 81, "dts": { "calculationLink": { "local": [ "smlr-20220331_cal.xml" ] }, "definitionLink": { "local": [ "smlr-20220331_def.xml" ] }, "inline": { "local": [ "smlr-20220331x10q.htm" ] }, "labelLink": { "local": [ "smlr-20220331_lab.xml" ] }, "presentationLink": { "local": [ "smlr-20220331_pre.xml" ] }, "schema": { "local": [ "smlr-20220331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 311, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 10, "http://xbrl.sec.gov/dei/2021q4": 5, "total": 15 }, "keyCustom": 20, "keyStandard": 195, "memberCustom": 14, "memberStandard": 14, "nsprefix": "smlr", "nsuri": "http://semlerscientific.com/20220331", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_nEZB1IB9fUauPu7stShSkw", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00090 - Document - Document and Entity Information", "role": "http://semlerscientific.com/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_nEZB1IB9fUauPu7stShSkw", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_nEZB1IB9fUauPu7stShSkw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeFinanceLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10401 - Disclosure - Assets for Lease, net", "role": "http://semlerscientific.com/role/DisclosureAssetsForLeaseNet", "shortName": "Assets for Lease, net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_nEZB1IB9fUauPu7stShSkw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeFinanceLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_nEZB1IB9fUauPu7stShSkw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10501 - Disclosure - Property and Equipment, net", "role": "http://semlerscientific.com/role/DisclosurePropertyAndEquipmentNet", "shortName": "Property and Equipment, net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_nEZB1IB9fUauPu7stShSkw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_nEZB1IB9fUauPu7stShSkw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10601 - Disclosure - Long-Term Investments", "role": "http://semlerscientific.com/role/DisclosureLongTermInvestments", "shortName": "Long-Term Investments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_nEZB1IB9fUauPu7stShSkw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_nEZB1IB9fUauPu7stShSkw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10701 - Disclosure - Accrued Expenses", "role": "http://semlerscientific.com/role/DisclosureAccruedExpenses", "shortName": "Accrued Expenses", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_nEZB1IB9fUauPu7stShSkw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_nEZB1IB9fUauPu7stShSkw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10801 - Disclosure - Concentration of Credit Risk", "role": "http://semlerscientific.com/role/DisclosureConcentrationOfCreditRisk", "shortName": "Concentration of Credit Risk", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_nEZB1IB9fUauPu7stShSkw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_nEZB1IB9fUauPu7stShSkw", "decimals": null, "first": true, "lang": "en-US", "name": "smlr:LeaseDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10901 - Disclosure - Leases", "role": "http://semlerscientific.com/role/DisclosureLeases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_nEZB1IB9fUauPu7stShSkw", "decimals": null, "first": true, "lang": "en-US", "name": "smlr:LeaseDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_nEZB1IB9fUauPu7stShSkw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11001 - Disclosure - Commitments and Contingencies", "role": "http://semlerscientific.com/role/DisclosureCommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_nEZB1IB9fUauPu7stShSkw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_nEZB1IB9fUauPu7stShSkw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11101 - Disclosure - Stock Incentive Plan", "role": "http://semlerscientific.com/role/DisclosureStockIncentivePlan", "shortName": "Stock Incentive Plan", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_nEZB1IB9fUauPu7stShSkw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_nEZB1IB9fUauPu7stShSkw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11201 - Disclosure - Income Taxes", "role": "http://semlerscientific.com/role/DisclosureIncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_nEZB1IB9fUauPu7stShSkw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_nEZB1IB9fUauPu7stShSkw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11301 - Disclosure - Net Income Per Share, Basic and Diluted", "role": "http://semlerscientific.com/role/DisclosureNetIncomePerShareBasicAndDiluted", "shortName": "Net Income Per Share, Basic and Diluted", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_nEZB1IB9fUauPu7stShSkw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_nEZB1IB9fUauPu7stShSkw", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_VV8az217v0-qgjhv46r8hg", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00100 - Statement - Condensed Statements of Income", "role": "http://semlerscientific.com/role/StatementCondensedStatementsOfIncome", "shortName": "Condensed Statements of Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_nEZB1IB9fUauPu7stShSkw", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_VV8az217v0-qgjhv46r8hg", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "us-gaap:BasisOfAccounting", "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_nEZB1IB9fUauPu7stShSkw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "20102 - Disclosure - Basis of Presentation (Policies)", "role": "http://semlerscientific.com/role/DisclosureBasisOfPresentationPolicies", "shortName": "Basis of Presentation (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:BasisOfAccounting", "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_nEZB1IB9fUauPu7stShSkw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "us-gaap:LesseeFinanceLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_nEZB1IB9fUauPu7stShSkw", "decimals": null, "first": true, "lang": "en-US", "name": "smlr:ScheduleOfAssetsForLeaseTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30403 - Disclosure - Assets for Lease, net (Tables)", "role": "http://semlerscientific.com/role/DisclosureAssetsForLeaseNetTables", "shortName": "Assets for Lease, net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:LesseeFinanceLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_nEZB1IB9fUauPu7stShSkw", "decimals": null, "first": true, "lang": "en-US", "name": "smlr:ScheduleOfAssetsForLeaseTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_nEZB1IB9fUauPu7stShSkw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30503 - Disclosure - Property and Equipment, net (Tables)", "role": "http://semlerscientific.com/role/DisclosurePropertyAndEquipmentNetTables", "shortName": "Property and Equipment, net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_nEZB1IB9fUauPu7stShSkw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_nEZB1IB9fUauPu7stShSkw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30603 - Disclosure - Long-Term Investments (Tables)", "role": "http://semlerscientific.com/role/DisclosureLongTermInvestmentsTables", "shortName": "Long-Term Investments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_nEZB1IB9fUauPu7stShSkw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_nEZB1IB9fUauPu7stShSkw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30703 - Disclosure - Accrued Expenses (Tables)", "role": "http://semlerscientific.com/role/DisclosureAccruedExpensesTables", "shortName": "Accrued Expenses (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_nEZB1IB9fUauPu7stShSkw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_nEZB1IB9fUauPu7stShSkw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30903 - Disclosure - Leases (Tables)", "role": "http://semlerscientific.com/role/DisclosureLeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_nEZB1IB9fUauPu7stShSkw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_nEZB1IB9fUauPu7stShSkw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31103 - Disclosure - Stock Incentive Plan (Tables)", "role": "http://semlerscientific.com/role/DisclosureStockIncentivePlanTables", "shortName": "Stock Incentive Plan (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_nEZB1IB9fUauPu7stShSkw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_nEZB1IB9fUauPu7stShSkw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31303 - Disclosure - Net Income Per Share, Basic and Diluted (Tables)", "role": "http://semlerscientific.com/role/DisclosureNetIncomePerShareBasicAndDilutedTables", "shortName": "Net Income Per Share, Basic and Diluted (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_nEZB1IB9fUauPu7stShSkw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "p", "smlr:UnusualOrInfrequentItemsDisclosurePolicyTextBlock", "us-gaap:BasisOfAccounting", "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_nEZB1IB9fUauPu7stShSkw", "decimals": "2", "first": true, "lang": null, "name": "smlr:PercentageOfRevenueGrowth", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_t_0nmzH06kqCPeRhDilqXQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40101 - Disclosure - Basis of Presentation (Details)", "role": "http://semlerscientific.com/role/DisclosureBasisOfPresentationDetails", "shortName": "Basis of Presentation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "smlr:UnusualOrInfrequentItemsDisclosurePolicyTextBlock", "us-gaap:BasisOfAccounting", "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_nEZB1IB9fUauPu7stShSkw", "decimals": "2", "first": true, "lang": null, "name": "smlr:PercentageOfRevenueGrowth", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_t_0nmzH06kqCPeRhDilqXQ", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_nEZB1IB9fUauPu7stShSkw", "decimals": "-3", "first": true, "lang": null, "name": "smlr:RevenueRecognitionFromVariableLicenseFeeContracts", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_VV8az217v0-qgjhv46r8hg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40201 - Disclosure - Variably-Priced Revenue (Details)", "role": "http://semlerscientific.com/role/DisclosureVariablyPricedRevenueDetails", "shortName": "Variably-Priced Revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_nEZB1IB9fUauPu7stShSkw", "decimals": "-3", "first": true, "lang": null, "name": "smlr:RevenueRecognitionFromVariableLicenseFeeContracts", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_VV8az217v0-qgjhv46r8hg", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_7GlCwIXhv0ip-Trp_4c7SA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_VV8az217v0-qgjhv46r8hg", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00200 - Statement - Condensed Balance Sheets", "role": "http://semlerscientific.com/role/StatementCondensedBalanceSheets", "shortName": "Condensed Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_7GlCwIXhv0ip-Trp_4c7SA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_VV8az217v0-qgjhv46r8hg", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_7GlCwIXhv0ip-Trp_4c7SA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryNet", "reportCount": 1, "unitRef": "Unit_Standard_USD_VV8az217v0-qgjhv46r8hg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40301 - Disclosure - Inventory (Details)", "role": "http://semlerscientific.com/role/DisclosureInventoryDetails", "shortName": "Inventory (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R31": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "smlr:ScheduleOfAssetsForLeaseTableTextBlock", "us-gaap:LesseeFinanceLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_7GlCwIXhv0ip-Trp_4c7SA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_VV8az217v0-qgjhv46r8hg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40401 - Disclosure - Assets for Lease, net (Details)", "role": "http://semlerscientific.com/role/DisclosureAssetsForLeaseNetDetails", "shortName": "Assets for Lease, net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "smlr:ScheduleOfAssetsForLeaseTableTextBlock", "us-gaap:LesseeFinanceLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_7GlCwIXhv0ip-Trp_4c7SA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_VV8az217v0-qgjhv46r8hg", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:LesseeFinanceLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_nEZB1IB9fUauPu7stShSkw", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_VV8az217v0-qgjhv46r8hg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40402 - Disclosure - Assets for Lease, net - Additional Information (Details)", "role": "http://semlerscientific.com/role/DisclosureAssetsForLeaseNetAdditionalInformationDetails", "shortName": "Assets for Lease, net - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:LesseeFinanceLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_nEZB1IB9fUauPu7stShSkw", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_VV8az217v0-qgjhv46r8hg", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_7GlCwIXhv0ip-Trp_4c7SA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseBeforeAccumulatedDepreciation", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_VV8az217v0-qgjhv46r8hg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40501 - Disclosure - Property and Equipment, net (Details)", "role": "http://semlerscientific.com/role/DisclosurePropertyAndEquipmentNetDetails", "shortName": "Property and Equipment, net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_7GlCwIXhv0ip-Trp_4c7SA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseBeforeAccumulatedDepreciation", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_VV8az217v0-qgjhv46r8hg", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_nEZB1IB9fUauPu7stShSkw", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_VV8az217v0-qgjhv46r8hg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40502 - Disclosure - Property and Equipment, net - Additional Information (Details)", "role": "http://semlerscientific.com/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails", "shortName": "Property and Equipment, net - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_nEZB1IB9fUauPu7stShSkw", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_VV8az217v0-qgjhv46r8hg", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_7GlCwIXhv0ip-Trp_4c7SA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LongTermInvestments", "reportCount": 1, "unitRef": "Unit_Standard_USD_VV8az217v0-qgjhv46r8hg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40601 - Disclosure - Long-Term Investments (Details)", "role": "http://semlerscientific.com/role/DisclosureLongTermInvestmentsDetails", "shortName": "Long-Term Investments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueTableTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_us-gaap_InvestmentTypeAxis_smlr_InvestmentInPrivateCompanyTwoMember_FyYh3HJcFkumQMrnzGf4dg", "decimals": "-3", "lang": null, "name": "us-gaap:LongTermInvestments", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_VV8az217v0-qgjhv46r8hg", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "p", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_smlr_PromissoryNoteFromPrivateCompanyTwoMember_wpEHe891EEiluRk8H8hCvQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_VV8az217v0-qgjhv46r8hg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40602 - Disclosure - Long-Term Investments - Investments in SYNAPS Dx (Details)", "role": "http://semlerscientific.com/role/DisclosureLongTermInvestmentsInvestmentsInSynapsDxDetails", "shortName": "Long-Term Investments - Investments in SYNAPS Dx (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_smlr_PromissoryNoteFromPrivateCompanyTwoMember_wpEHe891EEiluRk8H8hCvQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_VV8az217v0-qgjhv46r8hg", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_nEZB1IB9fUauPu7stShSkw", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_VV8az217v0-qgjhv46r8hg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40603 - Disclosure - Long-Term Investments - Investments in Mellitus Health Inc., (Details)", "role": "http://semlerscientific.com/role/DisclosureLongTermInvestmentsInvestmentsInMellitusHealthIncDetails", "shortName": "Long-Term Investments - Investments in Mellitus Health Inc., (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_nEZB1IB9fUauPu7stShSkw", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_VV8az217v0-qgjhv46r8hg", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_7GlCwIXhv0ip-Trp_4c7SA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_VV8az217v0-qgjhv46r8hg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40701 - Disclosure - Accrued Expenses (Details)", "role": "http://semlerscientific.com/role/DisclosureAccruedExpensesDetails", "shortName": "Accrued Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_7GlCwIXhv0ip-Trp_4c7SA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_VV8az217v0-qgjhv46r8hg", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:ConcentrationRiskDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_wnoT2zx290C_nZhKeFX_eg", "decimals": "INF", "first": true, "lang": null, "name": "smlr:ConcentrationRiskNumberOfCustomers", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_customer_3-zfLvJ-z0SFwCKCvOpvVQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40801 - Disclosure - Concentration of Credit Risk (Details)", "role": "http://semlerscientific.com/role/DisclosureConcentrationOfCreditRiskDetails", "shortName": "Concentration of Credit Risk (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:ConcentrationRiskDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_wnoT2zx290C_nZhKeFX_eg", "decimals": "INF", "first": true, "lang": null, "name": "smlr:ConcentrationRiskNumberOfCustomers", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_customer_3-zfLvJ-z0SFwCKCvOpvVQ", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_7GlCwIXhv0ip-Trp_4c7SA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_VV8az217v0-qgjhv46r8hg", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00205 - Statement - Condensed Balance Sheets (Parentheticals)", "role": "http://semlerscientific.com/role/StatementCondensedBalanceSheetsParentheticals", "shortName": "Condensed Balance Sheets (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_7GlCwIXhv0ip-Trp_4c7SA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_VV8az217v0-qgjhv46r8hg", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_7GlCwIXhv0ip-Trp_4c7SA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_VV8az217v0-qgjhv46r8hg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40901 - Disclosure - Leases - Future minimum rental payments (Details)", "role": "http://semlerscientific.com/role/DisclosureLeasesFutureMinimumRentalPaymentsDetails", "shortName": "Leases - Future minimum rental payments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_7GlCwIXhv0ip-Trp_4c7SA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_VV8az217v0-qgjhv46r8hg", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "p", "smlr:LeaseDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_nEZB1IB9fUauPu7stShSkw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40902 - Disclosure - Leases - Lessee Arrangements (Details)", "role": "http://semlerscientific.com/role/DisclosureLeasesLesseeArrangementsDetails", "shortName": "Leases - Lessee Arrangements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "smlr:LeaseDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_nEZB1IB9fUauPu7stShSkw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "As_Of_12_31_2021_MwGpxQUzkEenhP5nROwSLA", "decimals": "-4", "first": true, "lang": null, "name": "smlr:IncomeTaxesReceivableCaresAct", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_VV8az217v0-qgjhv46r8hg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41001 - Disclosure - Commitments and Contingencies (Details)", "role": "http://semlerscientific.com/role/DisclosureCommitmentsAndContingenciesDetails", "shortName": "Commitments and Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "As_Of_12_31_2021_MwGpxQUzkEenhP5nROwSLA", "decimals": "-4", "first": true, "lang": null, "name": "smlr:IncomeTaxesReceivableCaresAct", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_VV8az217v0-qgjhv46r8hg", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_nEZB1IB9fUauPu7stShSkw", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "Unit_Standard_USD_VV8az217v0-qgjhv46r8hg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41101 - Disclosure - Stock Incentive Plan - Additional information (Details)", "role": "http://semlerscientific.com/role/DisclosureStockIncentivePlanAdditionalInformationDetails", "shortName": "Stock Incentive Plan - Additional information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "span", "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_nEZB1IB9fUauPu7stShSkw", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_0DcTeN77DEO1uDFRvYzzSg", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "As_Of_3_14_2022_kYUNu17D3kWL1VncjrU71A", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_VV8az217v0-qgjhv46r8hg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41102 - Disclosure - Stock Incentive Plan - Common Stock Repurchase (Details)", "role": "http://semlerscientific.com/role/DisclosureStockIncentivePlanCommonStockRepurchaseDetails", "shortName": "Stock Incentive Plan - Common Stock Repurchase (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "As_Of_3_14_2022_kYUNu17D3kWL1VncjrU71A", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_VV8az217v0-qgjhv46r8hg", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "As_Of_12_31_2021_MwGpxQUzkEenhP5nROwSLA", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Unit_Standard_shares_0DcTeN77DEO1uDFRvYzzSg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41103 - Disclosure - Stock Incentive Plan - Stock Option Activity (Details)", "role": "http://semlerscientific.com/role/DisclosureStockIncentivePlanStockOptionActivityDetails", "shortName": "Stock Incentive Plan - Stock Option Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "As_Of_3_31_2022_7GlCwIXhv0ip-Trp_4c7SA", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_0DcTeN77DEO1uDFRvYzzSg", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_nEZB1IB9fUauPu7stShSkw", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "Unit_Standard_USD_VV8az217v0-qgjhv46r8hg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41104 - Disclosure - Stock Incentive Plan - Stock-based compensation - Expenses (Details)", "role": "http://semlerscientific.com/role/DisclosureStockIncentivePlanStockBasedCompensationExpensesDetails", "shortName": "Stock Incentive Plan - Stock-based compensation - Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_us-gaap_IncomeStatementLocationAxis_smlr_EngineeringAndProductDevelopmentMember_rpsIu6QLKUaafnqa0T_WgA", "decimals": "-3", "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_VV8az217v0-qgjhv46r8hg", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_nEZB1IB9fUauPu7stShSkw", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "Unit_Standard_USD_VV8az217v0-qgjhv46r8hg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41201 - Disclosure - Income Taxes (Details)", "role": "http://semlerscientific.com/role/DisclosureIncomeTaxesDetails", "shortName": "Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_nEZB1IB9fUauPu7stShSkw", "decimals": "4", "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_t_0nmzH06kqCPeRhDilqXQ", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_nEZB1IB9fUauPu7stShSkw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic", "reportCount": 1, "unitRef": "Unit_Standard_shares_0DcTeN77DEO1uDFRvYzzSg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41301 - Disclosure - Net Income Per Share, Basic and Diluted (Details)", "role": "http://semlerscientific.com/role/DisclosureNetIncomePerShareBasicAndDilutedDetails", "shortName": "Net Income Per Share, Basic and Diluted (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_nEZB1IB9fUauPu7stShSkw", "decimals": "INF", "lang": null, "name": "us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_0DcTeN77DEO1uDFRvYzzSg", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "p", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_nEZB1IB9fUauPu7stShSkw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_0DcTeN77DEO1uDFRvYzzSg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41302 - Disclosure - Net Income Per Share, Basic and Diluted - Additional Information (Details)", "role": "http://semlerscientific.com/role/DisclosureNetIncomePerShareBasicAndDilutedAdditionalInformationDetails", "shortName": "Net Income Per Share, Basic and Diluted - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "p", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_nEZB1IB9fUauPu7stShSkw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_0DcTeN77DEO1uDFRvYzzSg", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_B2peMQVekEqvRB8a3v1vpA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_VV8az217v0-qgjhv46r8hg", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00300 - Statement - Statements of Stockholders' Equity", "role": "http://semlerscientific.com/role/StatementStatementsOfStockholdersEquity", "shortName": "Statements of Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_B2peMQVekEqvRB8a3v1vpA", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_VV8az217v0-qgjhv46r8hg", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_nEZB1IB9fUauPu7stShSkw", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_VV8az217v0-qgjhv46r8hg", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00400 - Statement - Condensed Statements of Cash Flows", "role": "http://semlerscientific.com/role/StatementCondensedStatementsOfCashFlows", "shortName": "Condensed Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_nEZB1IB9fUauPu7stShSkw", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_VV8az217v0-qgjhv46r8hg", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_nEZB1IB9fUauPu7stShSkw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccounting", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10101 - Disclosure - Basis of Presentation", "role": "http://semlerscientific.com/role/DisclosureBasisOfPresentation", "shortName": "Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_nEZB1IB9fUauPu7stShSkw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccounting", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_nEZB1IB9fUauPu7stShSkw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10201 - Disclosure - Variably-Priced Revenue", "role": "http://semlerscientific.com/role/DisclosureVariablyPricedRevenue", "shortName": "Variably-Priced Revenue", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_nEZB1IB9fUauPu7stShSkw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_nEZB1IB9fUauPu7stShSkw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10301 - Disclosure - Inventory", "role": "http://semlerscientific.com/role/DisclosureInventory", "shortName": "Inventory", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "smlr-20220331x10q.htm", "contextRef": "Duration_1_1_2022_To_3_31_2022_nEZB1IB9fUauPu7stShSkw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 28, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://semlerscientific.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://semlerscientific.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Document and Entity Information" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://semlerscientific.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://semlerscientific.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://semlerscientific.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://semlerscientific.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r397" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://semlerscientific.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r398" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://semlerscientific.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://semlerscientific.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://semlerscientific.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://semlerscientific.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://semlerscientific.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://semlerscientific.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r395" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://semlerscientific.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://semlerscientific.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://semlerscientific.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r395" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://semlerscientific.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://semlerscientific.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r395" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://semlerscientific.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://semlerscientific.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r400" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://semlerscientific.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r395" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://semlerscientific.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r395" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://semlerscientific.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r395" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://semlerscientific.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r395" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://semlerscientific.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://semlerscientific.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r394" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://semlerscientific.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r396" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://semlerscientific.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://semlerscientific.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "smlr_AccumulatedDepreciationReductionForReturnedItems": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "This element represents reduction in accumulated depreciation for returned items.", "label": "Accumulated Depreciation Reduction For Returned Items", "verboseLabel": "Reduction to accumulated depreciation for returned items" } } }, "localname": "AccumulatedDepreciationReductionForReturnedItems", "nsuri": "http://semlerscientific.com/20220331", "presentation": [ "http://semlerscientific.com/role/DisclosureAssetsForLeaseNetAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "smlr_AmountOfDilutiveSecuritiesCommonStockWarrants": { "auth_ref": [], "calculation": { "http://semlerscientific.com/role/DisclosureNetIncomePerShareBasicAndDilutedDetails": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise of stock warrants.", "label": "Amount Of Dilutive Securities Common Stock Warrants", "verboseLabel": "Net Income - Common stock warrants" } } }, "localname": "AmountOfDilutiveSecuritiesCommonStockWarrants", "nsuri": "http://semlerscientific.com/20220331", "presentation": [ "http://semlerscientific.com/role/DisclosureNetIncomePerShareBasicAndDilutedDetails" ], "xbrltype": "monetaryItemType" }, "smlr_AssetsForLeaseNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Property and Equipment, net." } } }, "localname": "AssetsForLeaseNetAbstract", "nsuri": "http://semlerscientific.com/20220331", "xbrltype": "stringItemType" }, "smlr_ConcentrationRiskNumberOfCustomers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents number of major customers in concentration risk.", "label": "Concentration Risk Number Of Customers", "verboseLabel": "Number of customers" } } }, "localname": "ConcentrationRiskNumberOfCustomers", "nsuri": "http://semlerscientific.com/20220331", "presentation": [ "http://semlerscientific.com/role/DisclosureConcentrationOfCreditRiskDetails" ], "xbrltype": "integerItemType" }, "smlr_ConcentrationRiskNumberOfVendors": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents number of major vendors in concentration risk.", "label": "Concentration Risk Number Of Vendors", "terseLabel": "Number of vendors" } } }, "localname": "ConcentrationRiskNumberOfVendors", "nsuri": "http://semlerscientific.com/20220331", "presentation": [ "http://semlerscientific.com/role/DisclosureConcentrationOfCreditRiskDetails" ], "xbrltype": "integerItemType" }, "smlr_ConvertiblePromissoryNoteOneFromPrivateCompanyThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to convertible promissory note one, from private company three.", "label": "First Promissory note from Mellitus" } } }, "localname": "ConvertiblePromissoryNoteOneFromPrivateCompanyThreeMember", "nsuri": "http://semlerscientific.com/20220331", "presentation": [ "http://semlerscientific.com/role/DisclosureLongTermInvestmentsInvestmentsInMellitusHealthIncDetails" ], "xbrltype": "domainItemType" }, "smlr_CustomerOneConcentrationRiskMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer One.", "label": "Customer one" } } }, "localname": "CustomerOneConcentrationRiskMember", "nsuri": "http://semlerscientific.com/20220331", "presentation": [ "http://semlerscientific.com/role/DisclosureConcentrationOfCreditRiskDetails" ], "xbrltype": "domainItemType" }, "smlr_CustomerThreeConcentrationRiskMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This member stands for customer three.", "label": "Customer three" } } }, "localname": "CustomerThreeConcentrationRiskMember", "nsuri": "http://semlerscientific.com/20220331", "presentation": [ "http://semlerscientific.com/role/DisclosureConcentrationOfCreditRiskDetails" ], "xbrltype": "domainItemType" }, "smlr_CustomerTwoConcentrationRiskMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer Two.", "label": "Customer two" } } }, "localname": "CustomerTwoConcentrationRiskMember", "nsuri": "http://semlerscientific.com/20220331", "presentation": [ "http://semlerscientific.com/role/DisclosureConcentrationOfCreditRiskDetails" ], "xbrltype": "domainItemType" }, "smlr_DebtInstrumentPurchasePrice": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of aggregate purchase price of convertible debt instrument received from a seller.", "label": "Debt Instrument, Purchase Price", "terseLabel": "Purchase price" } } }, "localname": "DebtInstrumentPurchasePrice", "nsuri": "http://semlerscientific.com/20220331", "presentation": [ "http://semlerscientific.com/role/DisclosureLongTermInvestmentsInvestmentsInMellitusHealthIncDetails" ], "xbrltype": "monetaryItemType" }, "smlr_EngineeringAndProductDevelopmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents engineering and product development.", "label": "Engineering and Product Development" } } }, "localname": "EngineeringAndProductDevelopmentMember", "nsuri": "http://semlerscientific.com/20220331", "presentation": [ "http://semlerscientific.com/role/DisclosureStockIncentivePlanStockBasedCompensationExpensesDetails" ], "xbrltype": "domainItemType" }, "smlr_IncomeTaxesReceivableCaresAct": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the employee retention payroll tax credit for certain employers, which is a refundable tax credit against certain employment taxes provided by the CARES Act.", "label": "Income Taxes Receivable, Cares Act" } } }, "localname": "IncomeTaxesReceivableCaresAct", "nsuri": "http://semlerscientific.com/20220331", "presentation": [ "http://semlerscientific.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "smlr_InvestmentInPrivateCompanyNumberOfSharesPurchased": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares purchased as investments during the period from the private company.", "label": "Investment in Private Company, Number of Shares Purchased", "terseLabel": "Shares purchased" } } }, "localname": "InvestmentInPrivateCompanyNumberOfSharesPurchased", "nsuri": "http://semlerscientific.com/20220331", "presentation": [ "http://semlerscientific.com/role/DisclosureLongTermInvestmentsInvestmentsInMellitusHealthIncDetails", "http://semlerscientific.com/role/DisclosureLongTermInvestmentsInvestmentsInSynapsDxDetails" ], "xbrltype": "sharesItemType" }, "smlr_InvestmentInPrivateCompanyThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to investment in private company three.", "label": "Investments in Mellitus Health Inc." } } }, "localname": "InvestmentInPrivateCompanyThreeMember", "nsuri": "http://semlerscientific.com/20220331", "presentation": [ "http://semlerscientific.com/role/DisclosureLongTermInvestmentsDetails", "http://semlerscientific.com/role/DisclosureLongTermInvestmentsInvestmentsInMellitusHealthIncDetails" ], "xbrltype": "domainItemType" }, "smlr_InvestmentInPrivateCompanyTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to investment in private company two.", "label": "Investments in SYNAPS Dx" } } }, "localname": "InvestmentInPrivateCompanyTwoMember", "nsuri": "http://semlerscientific.com/20220331", "presentation": [ "http://semlerscientific.com/role/DisclosureLongTermInvestmentsDetails" ], "xbrltype": "domainItemType" }, "smlr_KeyPersonStockOptionPlan2007Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information related to 2007 Key Person Stock Option Plan (\"2007 Plan\").", "label": "2007 Key Person Stock Option Plan" } } }, "localname": "KeyPersonStockOptionPlan2007Member", "nsuri": "http://semlerscientific.com/20220331", "presentation": [ "http://semlerscientific.com/role/DisclosureStockIncentivePlanAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "smlr_LeaseDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of information about leases.", "label": "Lease Disclosure [Text Block]", "terseLabel": "Leases" } } }, "localname": "LeaseDisclosureTextBlock", "nsuri": "http://semlerscientific.com/20220331", "presentation": [ "http://semlerscientific.com/role/DisclosureLeases" ], "xbrltype": "textBlockItemType" }, "smlr_OperatingLeaseExpensesInExcessOfCashPayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of lease expense in excess of cash payments during the period.", "label": "Operating Lease Expenses in Excess of Cash Payments", "negatedLabel": "Lease expense in excess cash payment" } } }, "localname": "OperatingLeaseExpensesInExcessOfCashPayments", "nsuri": "http://semlerscientific.com/20220331", "presentation": [ "http://semlerscientific.com/role/DisclosureLeasesFutureMinimumRentalPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "smlr_PercentageOfRevenueGrowth": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of Revenue Growth.", "label": "Percentage of Revenue Growth", "terseLabel": "Percentage of Revenue Growth" } } }, "localname": "PercentageOfRevenueGrowth", "nsuri": "http://semlerscientific.com/20220331", "presentation": [ "http://semlerscientific.com/role/DisclosureBasisOfPresentationDetails" ], "xbrltype": "percentItemType" }, "smlr_PercentageOfSharesReserveIncrease": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents percentage of shares reserve to total number of shares of common stock outstanding.", "label": "Percentage Of Shares Reserve Increase", "verboseLabel": "Percentage of shares reserve increased" } } }, "localname": "PercentageOfSharesReserveIncrease", "nsuri": "http://semlerscientific.com/20220331", "presentation": [ "http://semlerscientific.com/role/DisclosureStockIncentivePlanAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "smlr_PrepaidLicensePurchases": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration paid in advance for license purchases.", "label": "Prepaid License Purchases", "terseLabel": "Prepaid license purchases" } } }, "localname": "PrepaidLicensePurchases", "nsuri": "http://semlerscientific.com/20220331", "presentation": [ "http://semlerscientific.com/role/DisclosureLongTermInvestmentsInvestmentsInMellitusHealthIncDetails" ], "xbrltype": "monetaryItemType" }, "smlr_PrivateCompanyThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to private company #3.", "label": "Mellitus" } } }, "localname": "PrivateCompanyThreeMember", "nsuri": "http://semlerscientific.com/20220331", "presentation": [ "http://semlerscientific.com/role/DisclosureLongTermInvestmentsInvestmentsInMellitusHealthIncDetails" ], "xbrltype": "domainItemType" }, "smlr_PromissoryNoteFromPrivateCompanyTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to promissory note from private company two.", "label": "Promissory note from SYNAPS Dx" } } }, "localname": "PromissoryNoteFromPrivateCompanyTwoMember", "nsuri": "http://semlerscientific.com/20220331", "presentation": [ "http://semlerscientific.com/role/DisclosureLongTermInvestmentsInvestmentsInSynapsDxDetails" ], "xbrltype": "domainItemType" }, "smlr_PurchaseAgreementRenewalTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term of renewal of the purchase agreement.", "label": "Purchase Agreement Renewal Term", "terseLabel": "Renewal term of purchase agreement (in years)" } } }, "localname": "PurchaseAgreementRenewalTerm", "nsuri": "http://semlerscientific.com/20220331", "presentation": [ "http://semlerscientific.com/role/DisclosureLongTermInvestmentsInvestmentsInMellitusHealthIncDetails" ], "xbrltype": "durationItemType" }, "smlr_RevenueRecognitionFromSalesOfHardwareAndEquipmentAccessories": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "It represents as a revenue recognition from sales of hardware and equipment accessories.", "label": "Revenue Recognition From Sales of Hardware and Equipment Accessories", "verboseLabel": "Revenue from sales of hardware and equipment accessories" } } }, "localname": "RevenueRecognitionFromSalesOfHardwareAndEquipmentAccessories", "nsuri": "http://semlerscientific.com/20220331", "presentation": [ "http://semlerscientific.com/role/DisclosureVariablyPricedRevenueDetails" ], "xbrltype": "monetaryItemType" }, "smlr_RevenueRecognitionFromVariableLicenseFeeContracts": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "It represents as a revenue recognition from variable license fee contracts.", "label": "Revenue Recognition From Variable License Fee Contracts", "terseLabel": "Revenue from variable-fee licenses" } } }, "localname": "RevenueRecognitionFromVariableLicenseFeeContracts", "nsuri": "http://semlerscientific.com/20220331", "presentation": [ "http://semlerscientific.com/role/DisclosureVariablyPricedRevenueDetails" ], "xbrltype": "monetaryItemType" }, "smlr_ScheduleOfAssetsForLeaseTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets for lease.", "label": "Schedule of Assets for Lease [Table Text Block]", "terseLabel": "Schedule of assets for lease" } } }, "localname": "ScheduleOfAssetsForLeaseTableTextBlock", "nsuri": "http://semlerscientific.com/20220331", "presentation": [ "http://semlerscientific.com/role/DisclosureAssetsForLeaseNetTables" ], "xbrltype": "textBlockItemType" }, "smlr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfNonEmployees": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of non-employees to whom the Company granted stock awards.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Non-employees", "terseLabel": "Number of non-employees" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfNonEmployees", "nsuri": "http://semlerscientific.com/20220331", "presentation": [ "http://semlerscientific.com/role/DisclosureStockIncentivePlanAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "smlr_ShareBasedPaymentArrangementSharesIssuedNetOfSharesForTaxWithholdings": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number, after shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share Based Payment Arrangement, Shares Issued, Net Of Shares For Tax Withholdings", "terseLabel": "Net shares issued after deducting taxes paid on granted shares" } } }, "localname": "ShareBasedPaymentArrangementSharesIssuedNetOfSharesForTaxWithholdings", "nsuri": "http://semlerscientific.com/20220331", "presentation": [ "http://semlerscientific.com/role/DisclosureStockIncentivePlanAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "smlr_StockIncentivePlan2014Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information related to 2014 Stock Incentive Plan (\"2014 Plan\").", "label": "2014 Stock Incentive Plan" } } }, "localname": "StockIncentivePlan2014Member", "nsuri": "http://semlerscientific.com/20220331", "presentation": [ "http://semlerscientific.com/role/DisclosureStockIncentivePlanAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "smlr_TaxesPaidRelatedToNetShareSettlementOfEquityAwardsShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares impact from taxes paid related to net share settlement of equity awards.", "label": "Taxes Paid related to Net Share Settlement of Equity Awards, Shares", "terseLabel": "Taxes paid related to net share settlement of equity awards, shares" } } }, "localname": "TaxesPaidRelatedToNetShareSettlementOfEquityAwardsShares", "nsuri": "http://semlerscientific.com/20220331", "presentation": [ "http://semlerscientific.com/role/StatementStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "smlr_UnusualOrInfrequentItemsDisclosurePolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of the policy for an event or transaction that is unusual in nature or infrequent in occurrence, or both.", "label": "Unusual or Infrequent Items Disclosure [Policy Text Block]", "terseLabel": "COVID-19" } } }, "localname": "UnusualOrInfrequentItemsDisclosurePolicyTextBlock", "nsuri": "http://semlerscientific.com/20220331", "presentation": [ "http://semlerscientific.com/role/DisclosureBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "smlr_VendorOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Vendor one", "label": "Vendor one" } } }, "localname": "VendorOneMember", "nsuri": "http://semlerscientific.com/20220331", "presentation": [ "http://semlerscientific.com/role/DisclosureConcentrationOfCreditRiskDetails" ], "xbrltype": "domainItemType" }, "smlr_VendorThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Vendor three.", "label": "Vendor three" } } }, "localname": "VendorThreeMember", "nsuri": "http://semlerscientific.com/20220331", "presentation": [ "http://semlerscientific.com/role/DisclosureConcentrationOfCreditRiskDetails" ], "xbrltype": "domainItemType" }, "smlr_VendorTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Vendor two", "label": "Vendor two" } } }, "localname": "VendorTwoMember", "nsuri": "http://semlerscientific.com/20220331", "presentation": [ "http://semlerscientific.com/role/DisclosureConcentrationOfCreditRiskDetails" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r46", "r48", "r83", "r84", "r187", "r205" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureLongTermInvestmentsInvestmentsInMellitusHealthIncDetails" ], "xbrltype": "stringItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r145", "r220", "r223", "r363" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureConcentrationOfCreditRiskDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r186", "r204", "r227", "r228", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r362", "r364", "r392", "r393" ], "lang": { "en-us": { "role": { "label": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r145", "r220", "r223", "r363" ], "lang": { "en-us": { "role": { "label": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureConcentrationOfCreditRiskDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r186", "r204", "r225", "r227", "r228", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r362", "r364", "r392", "r393" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r186", "r204", "r225", "r227", "r228", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r362", "r364", "r392", "r393" ], "lang": { "en-us": { "role": { "label": "Range [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r47", "r48", "r83", "r84", "r187", "r205" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureLongTermInvestmentsInvestmentsInMellitusHealthIncDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies and Estimates" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r35" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accrued Liabilities Disclosure [Text Block]", "verboseLabel": "Accrued Expenses" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureAccruedExpenses" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r34", "r328" ], "calculation": { "http://semlerscientific.com/role/StatementCondensedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "verboseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableMember": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Obligations incurred and payable to vendors for goods and services received.", "label": "Accounts payable" } } }, "localname": "AccountsPayableMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureConcentrationOfCreditRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [ "r387" ], "lang": { "en-us": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts receivable" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureConcentrationOfCreditRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r4", "r22", "r146", "r147" ], "calculation": { "http://semlerscientific.com/role/StatementCondensedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, Net, Current", "verboseLabel": "Trade accounts receivable, net of allowance for doubtful accounts of $71 and $61, respectively" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxesCurrent": { "auth_ref": [ "r17", "r342", "r354" ], "calculation": { "http://semlerscientific.com/role/DisclosureAccruedExpensesDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.", "label": "Accrued Income Taxes, Current", "verboseLabel": "Accrued Taxes" } } }, "localname": "AccruedIncomeTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r36" ], "calculation": { "http://semlerscientific.com/role/DisclosureAccruedExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://semlerscientific.com/role/StatementCondensedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses", "totalLabel": "Total Accrued Expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureAccruedExpensesDetails", "http://semlerscientific.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accrued Expenses" } } }, "localname": "AccruedLiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r23", "r254", "r328" ], "calculation": { "http://semlerscientific.com/role/StatementCondensedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r87", "r88", "r89", "r251", "r252", "r253", "r295" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/StatementStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in additional paid in capital (APIC) resulting from a tax benefit (deficiency) associated with an share-based compensation plan other than an employee stock ownership plan (ESOP).", "label": "Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net", "verboseLabel": "Taxes paid related to net share settlement of equity awards" } } }, "localname": "AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/StatementStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r229", "r231", "r256", "r257" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition", "terseLabel": "Stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/StatementStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Reconciliation of Net Income to Net Cash Provided by Operating Activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r231", "r248", "r255" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Allocated Share-based Compensation Expense", "verboseLabel": "Stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureStockIncentivePlanAdditionalInformationDetails", "http://semlerscientific.com/role/DisclosureStockIncentivePlanStockBasedCompensationExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r28", "r148", "r156" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Allowance for Doubtful Accounts Receivable, Current", "verboseLabel": "Allowance for doubtful accounts on trade accounts receivable (in dollars)" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/StatementCondensedBalanceSheetsParentheticals" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits": { "auth_ref": [ "r116" ], "calculation": { "http://semlerscientific.com/role/DisclosureNetIncomePerShareBasicAndDilutedDetails": { "order": 3.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise of stock options or restrictive stock units (RSUs).", "label": "Dilutive Securities, Effect on Basic Earnings Per Share, Options and Restrictive Stock Units", "verboseLabel": "Net Income - Common stock options" } } }, "localname": "AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureNetIncomePerShareBasicAndDilutedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r117" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Weighted average shares outstanding excluded from the computation of diluted net income per share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureNetIncomePerShareBasicAndDilutedAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_Assets": { "auth_ref": [ "r79", "r133", "r136", "r141", "r154", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r285", "r289", "r301", "r326", "r328", "r340", "r353" ], "calculation": { "http://semlerscientific.com/role/StatementCondensedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "verboseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r5", "r6", "r45", "r79", "r154", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r285", "r289", "r301", "r326", "r328" ], "calculation": { "http://semlerscientific.com/role/StatementCondensedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current Assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r232", "r249" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureStockIncentivePlanAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureLongTermInvestmentsInvestmentsInMellitusHealthIncDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r293", "r294" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureLongTermInvestmentsInvestmentsInMellitusHealthIncDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccounting": { "auth_ref": [ "r86" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting [Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccounting", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureBasisOfPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "verboseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r2", "r31", "r74" ], "calculation": { "http://semlerscientific.com/role/StatementCondensedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "verboseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r69", "r74", "r77" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "CASH AND CASH EQUIVALENTS, END OF PERIOD", "periodStartLabel": "CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r69", "r302" ], "calculation": { "http://semlerscientific.com/role/StatementCondensedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "INCREASE IN CASH" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r40", "r170", "r345", "r357" ], "calculation": { "http://semlerscientific.com/role/StatementCondensedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Note 10)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies." } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r167", "r168", "r169", "r171", "r388" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "verboseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureCommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r41" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Number of shares increase in Share Reserve" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureStockIncentivePlanAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r87", "r88", "r295" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/StatementStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "verboseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/StatementCondensedBalanceSheetsParentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "verboseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/StatementCondensedBalanceSheetsParentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "verboseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/StatementCondensedBalanceSheetsParentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r21", "r206" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "verboseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/StatementCondensedBalanceSheetsParentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r21", "r328" ], "calculation": { "http://semlerscientific.com/role/StatementCondensedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.001 par value; 50,000,000 shares authorized; 6,855,168, and 6,824,380 shares issued, and 6,787,216 and 6,758,458 shares outstanding (treasury shares of 67,952 and 65,922, respectively)" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r126", "r127", "r145", "r298", "r299", "r387" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureConcentrationOfCreditRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r126", "r127", "r145", "r298", "r299", "r370", "r387" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureConcentrationOfCreditRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r126", "r127", "r145", "r298", "r299", "r370", "r387" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureConcentrationOfCreditRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskDisclosureTextBlock": { "auth_ref": [ "r129" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.", "label": "Concentration Risk Disclosure [Text Block]", "terseLabel": "Concentration of Credit Risk" } } }, "localname": "ConcentrationRiskDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureConcentrationOfCreditRisk" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Concentration Risk [Line Items]", "terseLabel": "Concentration of Credit Risk" } } }, "localname": "ConcentrationRiskLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureConcentrationOfCreditRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r126", "r127", "r145", "r298", "r299" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "verboseLabel": "Concentration risk percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureConcentrationOfCreditRiskDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTable": { "auth_ref": [ "r124", "r126", "r127", "r128", "r298", "r300", "r387" ], "lang": { "en-us": { "role": { "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Concentration Risk [Table]" } } }, "localname": "ConcentrationRiskTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureConcentrationOfCreditRiskDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r126", "r127", "r145", "r298", "r299", "r387" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureConcentrationOfCreditRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r209", "r210", "r221" ], "calculation": { "http://semlerscientific.com/role/StatementCondensedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Deferred Revenue, Current", "verboseLabel": "Deferred revenue" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r61", "r79", "r154", "r172", "r173", "r174", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r301" ], "calculation": { "http://semlerscientific.com/role/StatementCondensedStatementsOfIncome": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "Cost of Revenue", "terseLabel": "Cost of revenues" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/StatementCondensedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r60" ], "calculation": { "http://semlerscientific.com/role/StatementCondensedStatementsOfIncome": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/StatementCondensedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r125", "r145" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer concentration risk" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureConcentrationOfCreditRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtConversionConvertedInstrumentAmount1": { "auth_ref": [ "r75", "r76" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt Conversion, Converted Instrument, Amount", "terseLabel": "Conversion value" } } }, "localname": "DebtConversionConvertedInstrumentAmount1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureLongTermInvestmentsInvestmentsInMellitusHealthIncDetails", "http://semlerscientific.com/role/DisclosureLongTermInvestmentsInvestmentsInSynapsDxDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r16", "r17", "r18", "r78", "r85", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r310", "r341", "r343", "r352" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureLongTermInvestmentsInvestmentsInMellitusHealthIncDetails", "http://semlerscientific.com/role/DisclosureLongTermInvestmentsInvestmentsInSynapsDxDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r183", "r200", "r201", "r309", "r310", "r311" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Principal amount", "verboseLabel": "Principal amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureLongTermInvestmentsInvestmentsInMellitusHealthIncDetails", "http://semlerscientific.com/role/DisclosureLongTermInvestmentsInvestmentsInSynapsDxDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r38", "r78", "r85", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r310" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureLongTermInvestmentsInvestmentsInMellitusHealthIncDetails", "http://semlerscientific.com/role/DisclosureLongTermInvestmentsInvestmentsInSynapsDxDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredIncomeTaxAssetsNet": { "auth_ref": [ "r261", "r262" ], "calculation": { "http://semlerscientific.com/role/StatementCondensedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.", "label": "Deferred Income Tax Assets, Net", "verboseLabel": "Long-term deferred tax assets" } } }, "localname": "DeferredIncomeTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r72", "r80", "r270", "r275", "r276", "r277" ], "calculation": { "http://semlerscientific.com/role/StatementCondensedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "terseLabel": "Deferred tax expense" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanDisclosureLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Defined Contribution Plan Disclosure [Line Items]" } } }, "localname": "DefinedContributionPlanDisclosureLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.", "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay", "terseLabel": "Maximum contribution of percentage of employee's eligible earnings" } } }, "localname": "DefinedContributionPlanEmployerMatchingContributionPercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage employer matches of the employee's percentage contribution matched.", "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match", "terseLabel": "Employer matching contribution" } } }, "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedContributionPlanTable": { "auth_ref": [ "r226" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about defined contribution pension plans or defined contribution other postretirement plans, separately for pension plans and other postretirement benefit plans.", "label": "Defined Contribution Plan [Table]" } } }, "localname": "DefinedContributionPlanTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r72", "r160" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r72", "r160" ], "calculation": { "http://semlerscientific.com/role/StatementCondensedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation, Depletion and Amortization, Nonproduction", "terseLabel": "Depreciation" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationNonproduction": { "auth_ref": [ "r72", "r160" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The expense recognized in the current period that allocates the cost of nonproduction tangible assets over their useful lives.", "label": "Depreciation, Nonproduction", "terseLabel": "Depreciation expense" } } }, "localname": "DepreciationNonproduction", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureAssetsForLeaseNetAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r259" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]", "terseLabel": "Stock Option Plan" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureStockIncentivePlan" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Option Plan" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Income Per Share, Basic and Diluted" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r57", "r92", "r93", "r94", "r95", "r96", "r100", "r103", "r114", "r115", "r116", "r120", "r121", "r296", "r297", "r348", "r359" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Net income per share, basic", "verboseLabel": "Basic EPS (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureNetIncomePerShareBasicAndDilutedDetails", "http://semlerscientific.com/role/StatementCondensedStatementsOfIncome" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r57", "r92", "r93", "r94", "r95", "r96", "r103", "r114", "r115", "r116", "r120", "r121", "r296", "r297", "r348", "r359" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Net income per share, diluted", "verboseLabel": "Diluted EPS (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureNetIncomePerShareBasicAndDilutedDetails", "http://semlerscientific.com/role/StatementCondensedStatementsOfIncome" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r117", "r118", "r119", "r122" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "verboseLabel": "Net Income Per Share, Basic and Diluted" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureNetIncomePerShareBasicAndDiluted" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r264" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective income tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureIncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r81", "r264", "r278" ], "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "verboseLabel": "Federal statutory rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureIncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r36" ], "calculation": { "http://semlerscientific.com/role/DisclosureAccruedExpensesDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "verboseLabel": "Compensation" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r246" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Stock options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureStockIncentivePlanAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r51", "r52", "r53", "r87", "r88", "r89", "r91", "r97", "r99", "r123", "r155", "r206", "r207", "r251", "r252", "r253", "r271", "r272", "r295", "r303", "r304", "r305", "r306", "r307", "r308", "r365", "r366", "r367", "r401" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/StatementStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount": { "auth_ref": [ "r152" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of impairment loss on investment in equity security without readily determinable fair value.", "label": "Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount", "terseLabel": "Impairment" } } }, "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureLongTermInvestmentsInvestmentsInMellitusHealthIncDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Equity Securities without Readily Determinable Fair Value [Line Items]" } } }, "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureLongTermInvestmentsDetails", "http://semlerscientific.com/role/DisclosureLongTermInvestmentsInvestmentsInMellitusHealthIncDetails", "http://semlerscientific.com/role/DisclosureLongTermInvestmentsInvestmentsInSynapsDxDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueTable": { "auth_ref": [ "r151", "r152", "r153" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment in equity security without readily determinable fair value.", "label": "Equity Securities without Readily Determinable Fair Value [Table]" } } }, "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureLongTermInvestmentsDetails", "http://semlerscientific.com/role/DisclosureLongTermInvestmentsInvestmentsInMellitusHealthIncDetails", "http://semlerscientific.com/role/DisclosureLongTermInvestmentsInvestmentsInSynapsDxDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueTableTextBlock": { "auth_ref": [ "r151", "r152", "r153" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of investment in equity security without readily determinable fair value.", "label": "Equity Securities without Readily Determinable Fair Value [Table Text Block]", "terseLabel": "Schedule of long term investments" } } }, "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureLongTermInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinanceLeaseRightOfUseAsset": { "auth_ref": [ "r314" ], "calculation": { "http://semlerscientific.com/role/DisclosureAssetsForLeaseNetDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization", "totalLabel": "Assets for lease, net" } } }, "localname": "FinanceLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureAssetsForLeaseNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization": { "auth_ref": [ "r317", "r320" ], "calculation": { "http://semlerscientific.com/role/DisclosureAssetsForLeaseNetDetails": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseRightOfUseAsset", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated amortization of right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, Accumulated Amortization", "negatedLabel": "Less: accumulated depreciation" } } }, "localname": "FinanceLeaseRightOfUseAssetAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureAssetsForLeaseNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetAfterAccumulatedAmortizationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets for Lease, net" } } }, "localname": "FinanceLeaseRightOfUseAssetAfterAccumulatedAmortizationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization": { "auth_ref": [ "r314" ], "calculation": { "http://semlerscientific.com/role/DisclosureAssetsForLeaseNetDetails": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseRightOfUseAsset", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before accumulated amortization, of right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, before Accumulated Amortization", "verboseLabel": "Assets for lease" } } }, "localname": "FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureAssetsForLeaseNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnSaleOfLeasedAssetsNetOperatingLeases": { "auth_ref": [ "r159", "r313" ], "calculation": { "http://semlerscientific.com/role/StatementCondensedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net gain (loss) arising from the lessor's sale of assets held- or available-for-lease under contractual arrangements classified as operating leases.", "label": "Gain (Loss) on Sale of Leased Assets, Net, Operating Leases", "negatedLabel": "Loss on disposal of assets for lease", "verboseLabel": "Loss on disposal of assets for lease" } } }, "localname": "GainLossOnSaleOfLeasedAssetsNetOperatingLeases", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureAssetsForLeaseNetAdditionalInformationDetails", "http://semlerscientific.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r62" ], "calculation": { "http://semlerscientific.com/role/StatementCondensedStatementsOfIncome": { "order": 4.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "verboseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/StatementCondensedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r58" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureStockIncentivePlanStockBasedCompensationExpensesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r55", "r133", "r135", "r137", "r140", "r142", "r338", "r346", "r350", "r360" ], "calculation": { "http://semlerscientific.com/role/StatementCondensedStatementsOfIncome": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Pre-tax net income" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/StatementCondensedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Statements of Income" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r164", "r166" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureStockIncentivePlanStockBasedCompensationExpensesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r166" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureStockIncentivePlanStockBasedCompensationExpensesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r81", "r265", "r268", "r269", "r273", "r279", "r281", "r282", "r283" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "verboseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureIncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r82", "r98", "r99", "r132", "r263", "r274", "r280", "r361" ], "calculation": { "http://semlerscientific.com/role/StatementCondensedStatementsOfIncome": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Income tax provision" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureIncomeTaxesDetails", "http://semlerscientific.com/role/StatementCondensedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r71" ], "calculation": { "http://semlerscientific.com/role/StatementCondensedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "verboseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r71" ], "calculation": { "http://semlerscientific.com/role/StatementCondensedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Trade accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r71" ], "calculation": { "http://semlerscientific.com/role/StatementCondensedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "verboseLabel": "Accrued expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r71", "r336" ], "calculation": { "http://semlerscientific.com/role/StatementCondensedStatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Contract with Customer, Liability", "verboseLabel": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r71" ], "calculation": { "http://semlerscientific.com/role/StatementCondensedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventory" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "verboseLabel": "Changes in Operating Assets and Liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "auth_ref": [ "r71" ], "calculation": { "http://semlerscientific.com/role/StatementCondensedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.", "label": "Increase (Decrease) in Other Noncurrent Assets", "negatedLabel": "Other non-current assets" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "auth_ref": [ "r71" ], "calculation": { "http://semlerscientific.com/role/StatementCondensedStatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Liabilities", "verboseLabel": "Other current and non-current liabilities" } } }, "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r71" ], "calculation": { "http://semlerscientific.com/role/StatementCondensedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/StatementStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants": { "auth_ref": [ "r104", "r105", "r106", "r116" ], "calculation": { "http://semlerscientific.com/role/DisclosureNetIncomePerShareBasicAndDilutedDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants", "verboseLabel": "Common stock warrants (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToCallOptionsAndWarrants", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureNetIncomePerShareBasicAndDilutedDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r104", "r105", "r107", "r116" ], "calculation": { "http://semlerscientific.com/role/DisclosureNetIncomePerShareBasicAndDilutedDetails": { "order": 3.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements", "verboseLabel": "Common stock options (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureNetIncomePerShareBasicAndDilutedDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_InterestIncomeExpenseNet": { "auth_ref": [ "r349" ], "calculation": { "http://semlerscientific.com/role/StatementCondensedStatementsOfIncome": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of operating interest income (expense).", "label": "Interest Income (Expense), Net", "terseLabel": "Interest income" } } }, "localname": "InterestIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/StatementCondensedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r158" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "verboseLabel": "Inventory" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureInventory" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r3", "r44", "r328" ], "calculation": { "http://semlerscientific.com/role/StatementCondensedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventory", "verboseLabel": "Inventory balance" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureInventoryDetails", "http://semlerscientific.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385" ], "lang": { "en-us": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureLongTermInvestmentsDetails", "http://semlerscientific.com/role/DisclosureLongTermInvestmentsInvestmentsInMellitusHealthIncDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385" ], "lang": { "en-us": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investments [Domain]" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureLongTermInvestmentsDetails", "http://semlerscientific.com/role/DisclosureLongTermInvestmentsInvestmentsInMellitusHealthIncDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long-Term Investments." } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "auth_ref": [ "r150", "r339", "r351", "r386", "r399" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investments in certain debt and equity securities.", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "terseLabel": "Long-Term Investments" } } }, "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureLongTermInvestments" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_LesseeFinanceLeasesTextBlock": { "auth_ref": [ "r324" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.", "label": "Lessee, Finance Leases [Text Block]", "verboseLabel": "Assets for Lease, net" } } }, "localname": "LesseeFinanceLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureAssetsForLeaseNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": { "auth_ref": [ "r319" ], "lang": { "en-us": { "role": { "documentation": "Indicates (true false) whether lessee has option to extend operating lease.", "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]", "terseLabel": "Options to renew" } } }, "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureLeasesLesseeArrangementsDetails" ], "xbrltype": "booleanItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r322" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "verboseLabel": "Schedule of future minimum rental payments required under operating leases" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r322" ], "calculation": { "http://semlerscientific.com/role/DisclosureLeasesFutureMinimumRentalPaymentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://semlerscientific.com/role/DisclosureLeasesFutureMinimumRentalPaymentsDetailsCalc2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total undiscounted future minimum lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureLeasesFutureMinimumRentalPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r322" ], "calculation": { "http://semlerscientific.com/role/DisclosureLeasesFutureMinimumRentalPaymentsDetailsCalc2": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureLeasesFutureMinimumRentalPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r322" ], "calculation": { "http://semlerscientific.com/role/DisclosureLeasesFutureMinimumRentalPaymentsDetailsCalc2": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "verboseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureLeasesFutureMinimumRentalPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r322" ], "calculation": { "http://semlerscientific.com/role/DisclosureLeasesFutureMinimumRentalPaymentsDetailsCalc2": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two", "verboseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureLeasesFutureMinimumRentalPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r322" ], "calculation": { "http://semlerscientific.com/role/DisclosureLeasesFutureMinimumRentalPaymentsDetailsCalc2": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "2022 Remaining period" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureLeasesFutureMinimumRentalPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r322" ], "calculation": { "http://semlerscientific.com/role/DisclosureLeasesFutureMinimumRentalPaymentsDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedTerseLabel": "Less: present value discount" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureLeasesFutureMinimumRentalPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": { "auth_ref": [ "r318" ], "lang": { "en-us": { "role": { "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee Operating Lease, Remaining Lease Term", "terseLabel": "Remaining lease term" } } }, "localname": "LesseeOperatingLeaseRemainingLeaseTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureLeasesLesseeArrangementsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r319" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Lease agreement term" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://semlerscientific.com/role/DisclosureLeasesLesseeArrangementsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r27", "r79", "r154", "r301", "r328", "r344", "r356" ], "calculation": { "http://semlerscientific.com/role/StatementCondensedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "verboseLabel": "Liabilities and Stockholders' Equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r37", "r79", "r154", "r172", "r173", "r174", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r286", "r289", "r290", "r301", "r326", "r327", "r328" ], "calculation": { "http://semlerscientific.com/role/StatementCondensedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrent": { "auth_ref": [ "r12", "r13", "r14", "r18", "r19", "r79", "r154", "r172", "r173", "r174", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r286", "r289", "r290", "r301", "r326", "r327" ], "calculation": { "http://semlerscientific.com/role/StatementCondensedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.", "label": "Liabilities, Noncurrent", "totalLabel": "Total long-term liabilities" } } }, "localname": "LiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Noncurrent [Abstract]", "terseLabel": "Long-term liabilities:" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermInvestments": { "auth_ref": [ "r32" ], "calculation": { "http://semlerscientific.com/role/StatementCondensedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).", "label": "Long-term Investments", "terseLabel": "Long-term investments" } } }, "localname": "LongTermInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureLongTermInvestmentsDetails", "http://semlerscientific.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r69" ], "calculation": { "http://semlerscientific.com/role/StatementCondensedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net Cash (Used in) Provided by Financing Activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "verboseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r69" ], "calculation": { "http://semlerscientific.com/role/StatementCondensedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net Cash Used in Investing Activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r69", "r70", "r73" ], "calculation": { "http://semlerscientific.com/role/StatementCondensedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net Cash Provided by Operating Activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r49", "r50", "r53", "r56", "r73", "r79", "r90", "r92", "r93", "r94", "r95", "r98", "r99", "r112", "r133", "r135", "r137", "r140", "r142", "r154", "r172", "r173", "r174", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r297", "r301", "r347", "r358" ], "calculation": { "http://semlerscientific.com/role/StatementCondensedStatementsOfIncome": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net income", "totalLabel": "Net income" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/StatementCondensedStatementsOfIncome", "http://semlerscientific.com/role/StatementStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r92", "r93", "r94", "r95", "r100", "r101", "r113", "r116", "r133", "r135", "r137", "r140", "r142" ], "calculation": { "http://semlerscientific.com/role/DisclosureNetIncomePerShareBasicAndDilutedDetails": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "terseLabel": "Net Income - Basic EPS" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureNetIncomePerShareBasicAndDilutedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "auth_ref": [ "r102", "r108", "r109", "r110", "r111", "r113", "r116" ], "calculation": { "http://semlerscientific.com/role/DisclosureNetIncomePerShareBasicAndDilutedDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "totalLabel": "Net Income - Diluted EPS" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureNetIncomePerShareBasicAndDilutedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "verboseLabel": "Recently Issued Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r63" ], "calculation": { "http://semlerscientific.com/role/StatementCondensedStatementsOfIncome": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Other income" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/StatementCondensedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingCostsAndExpenses": { "auth_ref": [], "calculation": { "http://semlerscientific.com/role/StatementCondensedStatementsOfIncome": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.", "label": "Operating Expenses", "verboseLabel": "Engineering and product development" } } }, "localname": "OperatingCostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/StatementCondensedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "verboseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/StatementCondensedStatementsOfIncome" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r133", "r135", "r137", "r140", "r142" ], "calculation": { "http://semlerscientific.com/role/StatementCondensedStatementsOfIncome": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Income from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/StatementCondensedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r321", "r323" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Lease expenses" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureLeasesLesseeArrangementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r315" ], "calculation": { "http://semlerscientific.com/role/DisclosureLeasesFutureMinimumRentalPaymentsDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Total lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureLeasesFutureMinimumRentalPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r315" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "verboseLabel": "Current lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureLeasesLesseeArrangementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r316" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.", "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]" } } }, "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureLeasesLesseeArrangementsDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r315" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "verboseLabel": "Noncurrent lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureLeasesLesseeArrangementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r316" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability.", "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]" } } }, "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureLeasesLesseeArrangementsDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r314" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Total ROU asset", "verboseLabel": "ROU asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureLeasesFutureMinimumRentalPaymentsDetails", "http://semlerscientific.com/role/DisclosureLeasesLesseeArrangementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r316" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset.", "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]" } } }, "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureLeasesLesseeArrangementsDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r8", "r9", "r10", "r36" ], "calculation": { "http://semlerscientific.com/role/DisclosureAccruedExpensesDetails": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "verboseLabel": "Miscellaneous Accruals" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r33" ], "calculation": { "http://semlerscientific.com/role/StatementCondensedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "verboseLabel": "Other non-current assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r7", "r8", "r36", "r328" ], "calculation": { "http://semlerscientific.com/role/StatementCondensedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Other short-term liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r39" ], "calculation": { "http://semlerscientific.com/role/StatementCondensedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "verboseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r64" ], "calculation": { "http://semlerscientific.com/role/StatementCondensedStatementsOfIncome": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other expenses" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/StatementCondensedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r67" ], "calculation": { "http://semlerscientific.com/role/StatementCondensedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedLabel": "Treasury stock acquired", "terseLabel": "Cost of share repurchased" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureStockIncentivePlanCommonStockRepurchaseDetails", "http://semlerscientific.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r67" ], "calculation": { "http://semlerscientific.com/role/StatementCondensedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payment, Tax Withholding, Share-based Payment Arrangement", "negatedLabel": "Taxes paid related to net settlement of equity awards", "terseLabel": "Taxes paid on stock awards" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureStockIncentivePlanAdditionalInformationDetails", "http://semlerscientific.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireEquipmentOnLease": { "auth_ref": [ "r65" ], "calculation": { "http://semlerscientific.com/role/StatementCondensedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for payments to acquire rented equipment which is recorded as an asset.", "label": "Payments to Acquire Equipment on Lease", "negatedLabel": "Purchase of assets for lease" } } }, "localname": "PaymentsToAcquireEquipmentOnLease", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r65" ], "calculation": { "http://semlerscientific.com/role/StatementCondensedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Additions to property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r232", "r249" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureStockIncentivePlanAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureStockIncentivePlanAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r5", "r29", "r30" ], "calculation": { "http://semlerscientific.com/role/StatementCondensedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "verboseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.", "label": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpensesAndOtherCurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureLongTermInvestmentsInvestmentsInMellitusHealthIncDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r66", "r250" ], "calculation": { "http://semlerscientific.com/role/StatementCondensedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "verboseLabel": "Proceeds from exercise of stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r1", "r49", "r50", "r53", "r68", "r79", "r90", "r98", "r99", "r133", "r135", "r137", "r140", "r142", "r154", "r172", "r173", "r174", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r284", "r287", "r288", "r291", "r292", "r297", "r301", "r350" ], "calculation": { "http://semlerscientific.com/role/StatementCondensedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net income" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property and Equipment, net" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r165", "r389", "r390", "r391" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "verboseLabel": "Property and Equipment, net" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosurePropertyAndEquipmentNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAccumulatedDepreciation": { "auth_ref": [ "r162", "r325" ], "calculation": { "http://semlerscientific.com/role/DisclosurePropertyAndEquipmentNetDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAfterAccumulatedDepreciation", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding lessor's underlying asset for which right to use has been conveyed to lessee under operating lease, of accumulated amortization, depreciation, depletion for physical asset used in normal conduct of business to create and distribute product and service.", "label": "Property, Plant, and Equipment, Excluding Lessor Asset under Operating Lease, Accumulated Depreciation", "negatedLabel": "Less: accumulated depreciation" } } }, "localname": "PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAccumulatedDepreciation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosurePropertyAndEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAfterAccumulatedDepreciation": { "auth_ref": [ "r163", "r325" ], "calculation": { "http://semlerscientific.com/role/DisclosurePropertyAndEquipmentNetDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://semlerscientific.com/role/StatementCondensedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated depreciation and excluding lessor's underlying asset for which right to use has been conveyed to lessee under operating lease, of physical asset used in normal conduct of business to create and distribute product and service.", "label": "Property, Plant, and Equipment, Excluding Lessor Asset under Operating Lease, after Accumulated Depreciation", "terseLabel": "Property and equipment, net", "totalLabel": "Capital assets, net" } } }, "localname": "PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAfterAccumulatedDepreciation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosurePropertyAndEquipmentNetDetails", "http://semlerscientific.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseBeforeAccumulatedDepreciation": { "auth_ref": [ "r161", "r325" ], "calculation": { "http://semlerscientific.com/role/DisclosurePropertyAndEquipmentNetDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAfterAccumulatedDepreciation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before accumulated depreciation and excluding lessor's underlying asset for which right to use has been conveyed to lessee under operating lease, of physical asset used in normal conduct of business to create and distribute product and service.", "label": "Property, Plant, and Equipment, Excluding Lessor Asset under Operating Lease, before Accumulated Depreciation", "terseLabel": "Capital assets" } } }, "localname": "PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseBeforeAccumulatedDepreciation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosurePropertyAndEquipmentNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r15", "r163" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "verboseLabel": "Schedule of capital assets" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosurePropertyAndEquipmentNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNet": { "auth_ref": [ "r163", "r312", "r325" ], "calculation": { "http://semlerscientific.com/role/StatementCondensedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated depreciation, of lessor's underlying asset for which right to use has been conveyed to lessee under operating lease.", "label": "Property, Plant, and Equipment, Lessor Asset under Operating Lease, after Accumulated Depreciation", "verboseLabel": "Assets for lease, net" } } }, "localname": "PropertySubjectToOrAvailableForOperatingLeaseNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r59", "r157" ], "calculation": { "http://semlerscientific.com/role/StatementCondensedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "Provision for Doubtful Accounts", "verboseLabel": "Allowance for doubtful accounts" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PurchaseObligation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.", "label": "Purchase Obligation", "verboseLabel": "Purchase of product licenses" } } }, "localname": "PurchaseObligation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureLongTermInvestmentsInvestmentsInMellitusHealthIncDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r24", "r207", "r254", "r328", "r355", "r368", "r369" ], "calculation": { "http://semlerscientific.com/role/StatementCondensedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r87", "r88", "r89", "r91", "r97", "r99", "r155", "r251", "r252", "r253", "r271", "r272", "r295", "r365", "r367" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/StatementStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Variably-Priced Revenue" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r130", "r131", "r134", "r138", "r139", "r143", "r144", "r145", "r219", "r220", "r337" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Lease revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureAssetsForLeaseNetAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerMember": { "auth_ref": [ "r126", "r145" ], "lang": { "en-us": { "role": { "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureConcentrationOfCreditRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r222", "r224" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Variably-Priced Revenue" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureVariablyPricedRevenue" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r54", "r79", "r130", "r131", "r134", "r138", "r139", "r143", "r144", "r145", "r154", "r172", "r173", "r174", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r301", "r350" ], "calculation": { "http://semlerscientific.com/role/StatementCondensedStatementsOfIncome": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "terseLabel": "Revenues" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/StatementCondensedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_RisksAndUncertaintiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Concentration of Credit Risk" } } }, "localname": "RisksAndUncertaintiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "verboseLabel": "Schedule of accrued expenses" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureAccruedExpensesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": { "auth_ref": [ "r247" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.", "label": "Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block]", "verboseLabel": "Schedule of stock-based compensation expense" } } }, "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureStockIncentivePlanTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r116" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of basic and diluted EPS" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureNetIncomePerShareBasicAndDilutedTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r232", "r249" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureStockIncentivePlanAdditionalInformationDetails", "http://semlerscientific.com/role/DisclosureStockIncentivePlanStockBasedCompensationExpensesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r236", "r242", "r244" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]", "verboseLabel": "Schedule of stock option activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureStockIncentivePlanTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingAndMarketingExpense": { "auth_ref": [], "calculation": { "http://semlerscientific.com/role/StatementCondensedStatementsOfIncome": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.", "label": "Selling and Marketing Expense", "verboseLabel": "Sales and marketing" } } }, "localname": "SellingAndMarketingExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/StatementCondensedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingAndMarketingExpenseMember": { "auth_ref": [ "r58" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling and marketing expense.", "label": "Sales and Marketing" } } }, "localname": "SellingAndMarketingExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureStockIncentivePlanStockBasedCompensationExpensesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r71" ], "calculation": { "http://semlerscientific.com/role/StatementCondensedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Compensation", "verboseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r241" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "terseLabel": "Aggregate of shares granted fully vested stock awards" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureStockIncentivePlanAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "auth_ref": [ "r243" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value", "terseLabel": "Fair value of stock awards on grant date" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureStockIncentivePlanAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureStockIncentivePlanAdditionalInformationDetails", "http://semlerscientific.com/role/DisclosureStockIncentivePlanStockBasedCompensationExpensesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized", "verboseLabel": "Number of share reserve approved" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureStockIncentivePlanAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r234" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "verboseLabel": "Maximum number of shares issued pursuant to awards granted under plan" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureStockIncentivePlanAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r249" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "verboseLabel": "Number of shares available for future stock-based compensation grants" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureStockIncentivePlanAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r239" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "verboseLabel": "Exercisable, Ending" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureStockIncentivePlanStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r239" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "verboseLabel": "Exercisable, Ending" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureStockIncentivePlanStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Number of stock option granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureStockIncentivePlanAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r249" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "verboseLabel": "Aggregate Intrinsic Value, Options Outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureStockIncentivePlanStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r238", "r249" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Balance, Ending", "periodStartLabel": "Balance, Beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureStockIncentivePlanStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "verboseLabel": "Number of Stock Options Outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureStockIncentivePlanStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r237" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Balance, Ending", "periodStartLabel": "Balance, Beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureStockIncentivePlanStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "verboseLabel": "Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureStockIncentivePlanStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r230", "r235" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Equity Award [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureStockIncentivePlanAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "verboseLabel": "Options exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureStockIncentivePlanStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r233" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period", "verboseLabel": "Maximum term of stock option grants" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureStockIncentivePlanAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r249" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value", "verboseLabel": "Aggregate Intrinsic Value, Options Exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureStockIncentivePlanStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r249" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "verboseLabel": "Weighted Average Remaining Contractual Term, Options Exercisable (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureStockIncentivePlanStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of non-vested options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares", "verboseLabel": "Total number of unvested shares" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureStockIncentivePlanAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r245" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "verboseLabel": "Weighted Average Remaining Contractual Term, Options Outstanding (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureStockIncentivePlanStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r206" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Shares, Issued", "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/StatementStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r43", "r51", "r52", "r53", "r87", "r88", "r89", "r91", "r97", "r99", "r123", "r155", "r206", "r207", "r251", "r252", "r253", "r271", "r272", "r295", "r303", "r304", "r305", "r306", "r307", "r308", "r365", "r366", "r367", "r401" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/StatementStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/StatementStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Statements of Cash Flows" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Balance Sheets" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statements of Stockholders' Equity" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r87", "r88", "r89", "r123", "r337" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/StatementStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan": { "auth_ref": [ "r20", "r21", "r206", "r207", "r258" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of capital stock issued (purchased by employees) in connection with an employee stock ownership plan.", "label": "Stock Issued During Period, Shares, Employee Stock Ownership Plan", "terseLabel": "Employee stock grants (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/StatementStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r20", "r21", "r206", "r207", "r240" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedLabel": "Options exercised", "verboseLabel": "Stock option exercises (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureStockIncentivePlanStockOptionActivityDetails", "http://semlerscientific.com/role/StatementStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan": { "auth_ref": [ "r20", "r21", "r206", "r207", "r258" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate value of stock issued during the period as a result of employee stock ownership plan (ESOP).", "label": "Stock Issued During Period, Value, Employee Stock Ownership Plan", "terseLabel": "Employee stock grants" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/StatementStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r43", "r206", "r207" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Stock option exercises" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/StatementStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stock repurchase plan authorized.", "label": "Stock Repurchase Program, Authorized Amount", "terseLabel": "Shares authorized under Share Repurchase Program" } } }, "localname": "StockRepurchaseProgramAuthorizedAmount1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureStockIncentivePlanCommonStockRepurchaseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchasedDuringPeriodShares": { "auth_ref": [ "r20", "r21", "r206", "r207" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Shares", "negatedLabel": "Treasury stock acquired (Shares)", "terseLabel": "Number of share repurchased" } } }, "localname": "StockRepurchasedDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureStockIncentivePlanCommonStockRepurchaseDetails", "http://semlerscientific.com/role/StatementStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchasedDuringPeriodValue": { "auth_ref": [ "r20", "r21", "r206", "r207" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Value", "negatedLabel": "Treasury stock acquired" } } }, "localname": "StockRepurchasedDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/StatementStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r21", "r25", "r26", "r79", "r149", "r154", "r301", "r328" ], "calculation": { "http://semlerscientific.com/role/StatementCondensedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/StatementCondensedBalanceSheets", "http://semlerscientific.com/role/StatementStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders' equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_SupplierConcentrationRiskMember": { "auth_ref": [ "r125" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that purchases in the period from one or more significant suppliers is to cost of goods or services, as defined by the entity, such as total cost of sales or services, product line cost of sales or services, segment cost of sales or services. Risk is the materially adverse effects of loss of a material supplier or a supplier of critically needed goods or services.", "label": "Vendor concentration risk" } } }, "localname": "SupplierConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureConcentrationOfCreditRiskDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r42", "r208" ], "lang": { "en-us": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/StatementStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockShares": { "auth_ref": [ "r42", "r208" ], "lang": { "en-us": { "role": { "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.", "label": "Treasury Stock, Shares", "terseLabel": "Treasury stock, shares" } } }, "localname": "TreasuryStockShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/StatementCondensedBalanceSheetsParentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r260", "r267" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "terseLabel": "Unrecognized tax benefits" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": { "auth_ref": [ "r266" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense", "terseLabel": "Interest and penalty expenses related to uncertain tax positions" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r102", "r116" ], "calculation": { "http://semlerscientific.com/role/DisclosureNetIncomePerShareBasicAndDilutedDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted average number of shares used in computing diluted income per share", "totalLabel": "Diluted shares (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureNetIncomePerShareBasicAndDilutedDetails", "http://semlerscientific.com/role/StatementCondensedStatementsOfIncome" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r100", "r116" ], "calculation": { "http://semlerscientific.com/role/DisclosureNetIncomePerShareBasicAndDilutedDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average number of shares used in computing basic income per share", "verboseLabel": "Basic shares (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://semlerscientific.com/role/DisclosureNetIncomePerShareBasicAndDilutedDetails", "http://semlerscientific.com/role/StatementCondensedStatementsOfIncome" ], "xbrltype": "sharesItemType" } }, "unitCount": 6 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1707-109256" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1757-109256" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1828-109256" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1500-109256" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(19)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258" }, "r122": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592" }, "r129": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(25))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(26))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r158": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "40", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=124072958&loc=SL51729484-110225" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r165": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r169": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r171": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(23))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r224": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "25", "SubTopic": "40", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109244457&loc=d3e16649-113920" }, "r259": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r283": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=123405975&loc=d3e41551-112718" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "40", "SubTopic": "30", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=123393937&loc=d3e44908-112734" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r324": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=124258985&loc=SL77919398-209981" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953" }, "r339": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "940", "URI": "http://asc.fasb.org/subtopic&trid=2176304" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.10)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r351": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/subtopic&trid=2209399" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r386": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "946", "URI": "http://asc.fasb.org/subtopic&trid=2324412" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r394": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r395": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r396": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r397": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r398": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r399": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1403" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r86": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" } }, "version": "2.1" } ZIP 67 0001554859-22-000014-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001554859-22-000014-xbrl.zip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�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